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Neurotuberculosis is the most severe form of extra-pulmonary tuberculosis, characterised 
by the formation of rich foci a brain form of granulomas, and tuberculous meningitis. Granulomas 
contain mycobacteria by recruitment of immune cells that surround the bacteria. The cytokine 
tumour necrosis factor has been found to be involved in the recruitment of the immune cells and 
structure maintenance of granulomas. Tumour necrosis factor is a multifunctional proinflammatory 
cytokine which play a critical role in the initial and long-term host immune protection against 
Mycobacterium tuberculosis (M. tuberculosis) infection. This cytokine is synthesised by several cell 
types of hematopoetic origin, such as microglia/macrophages, neutrophils, dendritic cells and 
lymphocytes, and non-hematopoetic origin such as astrocytes and neurons. During 
neurotuberculosis, excess of tumour necrosis factor has been implicated in persisting 
hyperinflammation, however, deficiency of tumour necrosis factor lead to uncontrolled bacterial 
growth; both phenomena causing necrotic lysis. Thus, a need exists to investigate the contribution 
of tumour necrosis factor by specific cell types in the control of cerebral M. tuberculosis infection 
and its protective immune response. In this study, we investigated the role of tumour necrosis 
factor derived from neurons, microglia/macrophages, neutrophils, CD4+ and CD8+ T cells in host 
immunity against M. tuberculosis; using an experimental murine model with cell type-specific gene 
targeting. We found that mice deficient for tumour necrosis factor in neurons (NsTNF-/-), as well as 
from microglia/macrophages and neutrophils (M-TNF-/-) are not susceptible to M. tuberculosis 
infection with a phenotype similar to wild type mice. Interestingly, mice with ablation of tumour 
necrosis factor in myeloid (microglia/macrophages, neutrophils) and CD4+ and CD8+ T cells (MT-
TNF-/-) were highly susceptible to M. tuberculosis infection with a phenotype similar to that of 
complete deficient tumour necrosis factor (TNF-/-) mice, which succumbed by 21 days post-
infection. Thus, it seems that the resistance observed in M-TNF-/- mice may be caused by the 
compensation of T cell-derived TNF whose function appeared as non-redundant. Impaired 
protective immunity observed in MT-TNF-/- and TNF-/- mice were related to alteration of cytokines 
and chemokines, and also to reduce antigen response and B cells IgM secretion. Our data suggest 
that neurons as well as microglia/macrophages and neutrophils derived tumor necrosis factor have 
a very limited role in protective cerebral immune responses. In MT-TNF-/- mice, TNF mediated 
protective immunity against cerebral M. tuberculosis infection requires primarily T cell-derived TNF 
as opposed to macrophage/neutrophil derived TNF. These findings may inform the development of 
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1.1 Mycobacterium tuberculosis complex 
1.1.1 Morphology and physiology 
Mycobacterium tuberculosis (M. tuberculosis), previously known as the tubercle bacillus, 
was first discovered by Robert Koch on 24th March 1882. M. tuberculosis is an intracellular rod 
shaped bacteria. This gram-positive bacterial species is found in the genus Mycobacterium and 
demonstrates the acid-fast staining characteristic. It is the causative agent of most cases of 
human tuberculosis, including neurotuberculosis (Springer et al., 2001). Tuberculosis is a 
primary infectious disease caused by the members of M. tuberculosis complex (Mycobacterium 
africanum, Dassie bacillus, Oryx bacillus, Seal bacillus, Mycobacterium microti, Mycobacterium 
caprae and Mycobacterium bovis). Mycobacterium bovis, is the causal agent of TB in cattle, 
while the Mycobacterium africanum cause human pulmonary tuberculosis in West and Central 
Africa, and has been prevalent since ancient times (Girard et al., 2005 and Demers et al., 
2010). Mycobacterium tuberculosis is nonmotile, obligate aerobe that does not form spores. 
The cell wall of M. tuberculosis contains peptidoglycan similar to that of other Gram-positive 
organisms, to which many branched-chain polysaccharides, proteins, and lipids are attached 
(Ryan et al., 2010). Porins and other proteins are found through the cell wall (Kartmann, 1999). 
Of particular importance is the presence of long-chain fatty acids called mycolic acids (for which 
the mycobacteria are named) and arabinogalactan, a lipid polysaccharide complex extending 
from the plasma membrane to the surface. These elements give the mycobacteria a cell wall 
with unusually high lipid content (more than 60% of the total cell wall mass), which accounts for 
many of their biological characteristics (Ryan et al., 2010). A schematic representation of the M. 
tuberculosis cell wall is illustrated in Figure 1.1. The acid-fast staining characteristic is the most 
frequently observed of these features. It does not retain any bacteriological stain due to high 












The M. tuberculosis bacillus divides approximately every 15-20 hours, This is extremely 
slow compared to other bacteria, which tend to have division times measured in minutes (such 
as Escherichia coli, which can divide every 20 minutes). Their slow growth is due to the fact 
that they have a hydrophobic cell surface, which causes them to clump and limits permeability 
of nutrients into the cell (Ryan et al., 2010). When in the lungs, M. tuberculosis are taken up by 
the alveolar macrophages. These, after activation, produce effector molecules such as TNF 
and NO which restricts the growth of M. tuberculosis. Despite the antimicrobial effects 
produced by the host (macrophage), in most cases, they are unable to digest M. tuberculosis. 
Nitrate can be produced by oxidation of nitric oxide and has been found to be the source of 
nitrogen for bacteria within the human host  (Niederweis, 2008). Nitrate reduction by M. 
tuberculosis is regulated by controlling the transport of nitrate into the cell by the NarK2 gene 
(Niederweis, 2008). It is therefore proposed that the NarK2 gene senses the redox state of the 
cell, probably by monitoring the flow of electrons to cytochrome oxidase, and adjusts its activity 
so that nitrate is transported under reducing form, but not under oxidizing (Sohaskey, 2003). 






It also has been suggested that the fusion of the phagosome with a lysosome may be 
prevented by the M. tuberculosis cell wall, which blocks the bridging of endosomal and 
phagosomal membrane-tethering molecule, called early endosomal autoantigen 1 (Fratti et al., 
2001 and  Fratti et al., 2003). However, this blockage does not prevent the fusion of vesicles 
filed with nutrients. As a consequence, the M. tuberculosis multiplies unchecked inside the 
macrophage (Li et al., 2010). M. tuberculosis carries the UreC gene, which prevents the 
phagosome from acidifying (Reyrat et al., 1995). It produces an enzyme called alkyl 
hydroperoxide reductase, which is believed to be involved in protecting the organism against 
the oxidative stress induced by reactive oxygen species and reactive nitrogen species, 
encountered within the infected macrophage (Springer et al., 2001). In addition, M. tuberculosis 
secrete early secretory antigenic target (ESAT-6) (Tsolaki et al., 2013), which helps the 
mycobacterium to escape from the phagosome into cytosol. Also, it may inhibit the activation of 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) through preventing 
interaction between MyD88 (myeloid differentiation primary response gene 88) and the 
downstream kinase of interleukin-1 receptor-associated kinase 4 (Pathak et al., 2007 and Yu & 
Xie, 2012). 
 
1.1.2 Mycobacterium tuberculosis genotype 
 
The genome sequences of two virulent strains, M. tuberculosis H37Rv (a commonly used 
laboratory strain which has been subjected to in vitro passage) and the clinical strains such as 
CDC 1551, Beijing clinical isolates (CCDC5180 and CCDC5079) and Colombian clinical isolate 
UT205 are now publicly available (Cole et al., 1998; Valway et al., 1998; Zhang et al., 2011 and 
Isaza et al., 2012). One study has shown that the M. tuberculosis genotype influences the 
clinical disease phenotype, and that a significant interaction exists between host and 
mycobacterial genotypes for the development of tuberculosis disease (Nahid et al., 2010). The 
M. tuberculosis CDC 1551 strain was clinical isolated, and was responsible for an outbreak of 
TB in a rural area of the USA in 1995 (Valway et al., 1998). The Beijing clinical isolates 
CCDC5180 and CCDC5079, and the recently isolated Colombian clinical isolate UT205 are 
associated with drug resistant-TB (Zhang et al., 2011 and Saza et al., 2012). The M. 
tuberculosis H37Rv strain was first isolated in 1905, and is used as reference strain. It is 
currently the most used strain in tuberculosis research. In addition, research has shown that 





(the M. tuberculosis clinical strains and M. tuberculosis H37Rv strain) show 99% identity at the 
nucleotide level, but the strains display phenotypic differences which might be explained by 
changes at the protein expression level (Delcher et al., 1999). The strain size of the genome 
H37Rv comprises 4,411,529 base pairs, with 3959 genes of high guanine and cytosine content 
that is reflected in the biased amino-acid content of the proteins (Cole et al., 1998). The 
difference between M. tuberculosis and other bacteria are in a large portion of coding capacity 
found in M. tuberculosis, which are dedicated to the production of enzymes that usually 
participate in lipolysis and lipogenesis and also to the newly found two families of glycine-rich 
proteins (Cole et al., 1998).   
 
1.1.3 Epidemiology of tuberculosis and neurotuberculosis 
Neurotuberculosis will exist as long as the primary pulmonary infection exists and it is 
imperative to consider the epidemiology of TB. Global control of tuberculosis is far from 
complete (Lönnroth et al., 2010). Important to consider is that TB also exists in a latent form, 
latent TB infection (LTBI) is the presence of M. tuberculosis in an individual without clinical, 
imaging, or microbiologic evidence of active disease (Sharma et al., 2012). This burden is 
distributed largely among under-resourced countries (Sharma et al., 2012). Latent TB 
prevalence rates have been noted for up to 79%, with an annual risk of developing TB infection 
ranging from 0.5% to 14.3% among healthcare workers in resource limited countries (WHO, 
2012). In the general population, the lifetime risk of progression from LTBI to active disease is 
about 5% to 10%; in the immunocompromised individuals (e.g. those with HIV), this rises to 
30% (annual risk, 10%) (Selwyn et al., 1989). The pathogenic state of bacterial infection and 
probability of reactivation depend on the balance between host immunity (Sharma et al., 2012). 
Research has shown that primates, mouse, rabbit and guinea pig are also susceptible to M. 
tuberculosis infection (Lurie et al., 1952; Riley, 1957; Riley et al., 1959; Rhoades et al., 1997; 
Flynn et al., 2003 and Dannenberg, 2006). Research  has also shown that Mycobacterium 
bovis (M. bovis) may cause bovine tuberculosis, a highly infectious disease in cattle, and one of 
the biggest challenges facing the cattle farming industry today (O’Reilly & Daborn, 1995). M. 
bovis may also infect and cause TB in goats, pigs, deer, badgers, camelids (llamas and 
alpacas), dogs and cats, as well as many other mammals (O’Reilly & Daborn, 1995; Smith et 
al., 2009 and Brooks-Pollock et al. 2013). Transmission of infection within and between species 





Study has also shown that other form bacterium Mycobacterium such as Mycobacterium 
bovis (M. bovis) may cause Bovine tuberculosis, which is an highly infectious disease of cattle, 
and one of the biggest challenges facing the cattle farming industry today (O’Reilly & 
Daborn,1995). M. bovis may also infect and cause TB in goats, pigs, deer, badgers, camelids 
(llamas and alpacas), dogs and cats, as well as many other mammals (O’Reilly & Daborn 1995; 
Smith et al., 2009 and Brooks-Pollock et al. 2013). Transmission of infection within and 
between species is mainly by the airborne route (O’Reilly & Daborn 1995).  
The ambiguity about the eradication of the burden of TB is supported by an analysis of 
predictors of TB case notification trends during the past few years (Dye, 2006). This analysis 
suggests that the variation in TB trends is more strongly associated with social, economic and 
biological factors. Social determinants of TB, such as food insecurity and malnutrition, poor 
housing and environmental conditions, and financial, geographic, and cultural barriers to health 
care access (Hargreaves et al., 2011) are factor that increases susceptibility to TB. For 
example, poor ventilation and overcrowding in homes, workplaces, and communities increase 
the likelihood of uninfected individuals being exposed to TB infection (Hill et al., 2006; Baker et 
al., 2008 and Boccia et al., 2009); poverty, malnutrition, and hunger may increase susceptibility 
to infection (Boccia et al., 2009), disease (Pakasi et al., 2009), and severity of clinical outcome 
(Van Lettow et al., 2004). 
Although rates of prevalence and death are falling globally, the rate of decline is not fast 
enough to meet the millennium development goal estimated targets to cut in half, TB 
prevalence and death rates by 2015 compared to 1990 levels (WHO, 2009; Lönnroth et al., 
2010). The World Health Organization (WHO), has reported the highest estimated incidence 
rate (356 per 100 000 population per year), but the majority of patients with tuberculosis live in 
the most populous countries of Asia such as Bangladesh, China, India, Indonesia, and 
Pakistan; which together account for almost half (48%) of the new cases that arise every year 
(Lönnroth et al., 2010).  
In the year 2007, South Africa was classified as the world’s highest prevalence of human 
immunodeficiency virus (HIV) in incident TB cases (73%) and the second-highest prevalence of 
TB with 692/100,000 (WHO, 2009). In 2008, around 9.4 million new cases of tuberculosis have 
been reported, amongst these, 1.2 million of MDR-TB, and HIV continues to reinforce the 
epidemic, especially in Africa (Corbett et al., 2003; Cheng, 2009; WHO, 2009 and Wright et al., 
2009). However, the long-term elimination target to reduce incidence of TB to less than one 





et al., 2010). Recently, the emergence and spread of totally drug-resistant TB was reported in 
South Africa (Klopper et al., 2013). 
Some of these important factors are poor living and working conditions. These could be 
associated with high risk of TB transmission. In addition, other factors that are included in the 
host’s defence impairment against TB infection are HIV infection, malnutrition, diabetes, 
smoking, indoor air pollution and alcohol abuse (Lönnroth et al., 2009). Despite the 2.2% 
decrease reported in previous years, in 2011, approximately 8.7 million cases of new 
pulmonary TB cases were reported globally (Figure: 1.2) (WHO, 2012). In 2009, the Centres for 
Disease Control (CDC), USA, recorded that 4.7% of all TB were meningeal (CDC, 2010). 
Phypers et al., (2006) reported that 1% of Canadian TB patients will develop neurotuberculosis. 
In Taiwan 1.5% of TB deaths were reported due to neurotuberculosis (Lu et al., 2005). In 
countries with high TB prevalence children are most at risk of developing neurotuberculosis, 
however, in countries with low TB prevalence, it is immigrants from high prevalence areas who 











In 2009, 53 411 new cases were reported, and the South African Department of Health 
reported that tuberculosis meningitis (TBM) had the highest number of cases among all 
extrapulmonary TB cases (Department: Health, Republic of South Africa: “National tuberculosis 
management guidelines 2009” and http://www.doh.gov.za/docs/stats/2011/ SouthAfrican 
Tuberculosis Profile 2011 WHO.pdf). A recent study from Cameroon showed that 8% of patients 
with HIV infection developed neurotuberculosis, and 80% of these patients died (Luma et al., 
2013). Neurotuberculosis occurs in 1 to 10% of all cases of TB (Rock et al., 2004 and Nelson & 
Zunt, 2011). Accurate figures for incidence and prevalence of neurotuberculosis are difficult to 




Neurotuberculosis is extrapulmonary tuberculosis caused by M. tuberculosis. 
Neurotuberculosis occurs when the immune response is weakened, mycobacteria disseminate 
from the primary site of infection, with continuous enlargement of the caseating granulomas in 
the lymph nodes. This phenomenon is referred to as progressive primary tuberculosis (TB) 
(Davis & Ramakrishnan, 2009). However, the enlarging nodes spread the infection 
progressively in two different ways: (i) Bronchus: occurs when there is creation of tuberculous 
bronchopneumonia, due to the erosion on an infected lymph node into a bronchus. Infection can 
spread by passing the bacilli from the bronchi of one lung into the opposite lung. This condition 
is known as galloping consumption. (ii) Blood vessel: occurs when the erosion of an infected 
lymph node into a blood vessel leads to lympho-heamatogenous spread of mycobacteria into 
many parts of the mammalian body, including the central nervous system (CNS) and leading to 
neurotuberculosis. 
Neurotuberculosis is a devastating complication of disease caused by M. tuberculosis, it 
carries a high mortality with a high distressing level of neurological morbidity. It 
disproportionately affects children, especially in the developing world and immunocompromised 
individuals (Rock et al., 2008). The mortality rate of neurotuberculosis is ~50%, and the majority 
of the survivors suffer permanent neurologic sequelae (Girgis et al., 1991; Joosten et al., 2000; 
Hosoglu et al., 2002; Thwaites & Hien, 2005; Gijs et al., 2009; Anderson et al., 2010;  Donald, 
2010 and Pan et al., 2012). Neurotuberculosis continues to exert a disturbing toll in developed 
and developing countries, despite the availability of anti-tuberculosis treatment (Thwaites & 





an initial 2-month treatment period, followed by a two-drug regimen for 10 months. The total 
duration of treatment for neurotuberculosis is 12 months, which makes it more difficult for 
patients to adhere. In sub-Saharan African countries, due to the effects of HIV, tuberculosis is 
now the most common form of bacterial meningitis (Vinnard & Macgregor, 2009). However, in 
countries where a high incidence of tuberculosis is declared, tuberculosis meningitis is usually a 
disease of young children that develops three to six months after primary pulmonary infection 
with M. tuberculosis (Thwaites & Hien, 2005).  
 
 
1.2.1 Pathogenesis of neurotuberculosis  
 
Neurotuberculosis results from a rupture of subpial or subependymal foci which has 
been deposited earlier following lympho-hematogenous dissemination of M. tuberculosis from 
the primary pulmonary infection (Gijs et al., 2009 and Misra et al., 2010), or rupture of an 
adjacent parenchymal focus as suggested by Leonard & Des Prez (1990). It is now believed 
that the dissemination to the CNS is directly related to the pattern of blood flow, which usually 
spreads to the basal ganglia and cerebral hemispheres in adults, and to the cerebellum in 
children (Harris & Morris, 2007). The widely accepted hypothesis of Rich & McCordock (1933) 
reported that bacilli reach the CNS by a haematogenous route secondary to disease elsewhere 
in the body. Since the brain parenchyma and the meninges are physiologically and anatomically 
protected from the systemic circulation system by the blood brain barrier (BBB), the 
mechanisms by which the bacilli initially invade this barrier are not clear. It is believed that M. 
tuberculosis can cross the BBB as a free organism or via infected peripheral myeloid cells. 
However the latter hypothesis seems controversial, as myeloid cellular traffic is severely 
restricted into the CNS prior to invasion by the offending pathogen (Ransohoff et al., 2003), 
however according to the proposed statement by Kivisäkk et al., (2003) and Krumbholz et al., 
(2007) lymphoid cells can in physiological state bypass the BBB by entering the subarachnoid 
space via the meningeal veins or the choroid plexus. The BBB poses a challenge for the 
treatment of neurotuberculosis. Isoniazid, the bactericidal agent easily crosses the BBB and 
achieves concentrations in the CSF similar to those in serum (Shin et al., 1990). Although 
pyrazinamide can cross the BBB, its role in neurotuberculosis is uncertain given its 
bacteriostatic activity, is thought to be directed against older, resting bacilli (Phuapradit et al., 
1990). However, many other drugs such as rifampicin, ethambutol, and streptomycin cross the 





Rich & McCordock, (1933) proposed that CNS tuberculosis develops in two stages, at 
first, small tuberculous lesions (Rich’s foci) develop in the CNS, either during the stage of 
bacteremia of the primary tuberculous infection or shortly afterwards. These initial tuberculous 
lesions localise either in the meninges, the subpial or subependymal surface of the brain or the 
spinal cord and may remain dormant for years after initial infection (Cambrea et al., 2009). 
Second, rupture or growth of one or more of these small tuberculous lesions produces the 
development of various types of CNS tuberculosis (Dastur et al., 1995 and Berger et al., 1996). 
However, the specific incentive for rupture or the growth of Rich’s foci is not yet well understood. 
It is suggested that immunological mechanisms also play a significant role (Cambrea et al., 
2009). Yet the type and size of lesions that result from the discharge of tuberculous bacilli into 
the cerebro-spinal fluid (CSF) depend on the number and virulence of the bacilli, as well as the 
immune response of the host (Garg, 1999). Studies have suggested that with a considerable 
inoculation or in the absence of an adequate cell-mediated immune response, the parenchymal 
cerebral tuberculous foci may develop into tuberculoma or tuberculous brain abscess (Dastur et 
al., 1995). The parenchymal cerebral tuberculous foci, may lead to various pathogenesis, 
including hydrocephalus (Figure: 1.3). Which usually occur as a consequence of the obstruction 
of the basal cisterns, outflow of the fourth ventricle, or occlusion of the cerebral aqueduct. 
Hydrocephalus may lead to atrophy of the brain parenchyma (Trivedi et al., 2009). 
Neurotuberculosis is mainly characterized as a meningoencephalitis, as it affects both 
the meninges and the brain parenchyma together with its vasculature. Granulomatous 
inflammatory reaction in CNS caused by M. tuberculosis may involve the meninges, brain, 
spinal cord, and the bones covering the brain and spinal cord, and may manifest clinically 
depending on the specific location of the disease process as shown in Table: 1.1 (Trivedi et al., 
2009). During neurotuberculosis, there is a presence of thick, gelatinous exudates around the 
Sylvian fissures, basal cisterns, brainstem, and cerebellum. The basal gelatinous exudates of 
neurotuberculosis are more severe in the vicinity of the circle of Willis, and usually produce a 
vasculitis-like syndrome (Garg, 1999). These gelatinous exudates may contain leukocytes such 
as infiltrating macrophages, dendritic cells and lymphocytes, and also some erythrocytes. As the 





































































   Table 1.1: Variable presentation of neurotuberculosis (adapted from Bano et al., 2012) 
Tubercular meningitis (TBM) & its complications 
 Hydrocephalus  
 Vasculitis causing infarction 
 Cranial neuropathies 
Pachymeningitis 
Granulomatous basal meningitis 
Parenchymal tuberculosis 
 Parenchymal tuberculomas  
 Tubercular abscesses  
 Miliary tuberculomas  
 Tubercular encephalopathy  
 Focal tubercular cerebritis  
 Tuberculoma en plaque 
Spinal tuberculosis 
 Tubercular Spondylitis (Pott’s spine)  
 Non-osseous spinal tuberculomas 
 Tubercular arachnoiditis (myeloradiculopathy) 
 Tubercular myelitis 
CNS tuberculosis in HIV patients 
Tubercular hypophysitis 
Tuberculosis of calvarium and base of skull 
Orbital tuberculosis 
Tubercular otitis media & temporal bone tuberculosis 
 
 
          1.2.2 Immunobiology of neurotuberculosis 
 
          The majority of individuals in the general population who come in contact with M. 
tuberculosis never develop clinical disease (Comstock, 1982). This shows that the innate and 
adaptive immune response of the host in controlling M. tuberculosis infection is effective. 
Neuroturbeculosis often affects children and immunocompromised individuals due to the 
weakness of immune response in these individuals. The CNS was previously known as 
immunoprivileged. This vital system has a structure and function that is unique but, in common 





inflammation/infection. Failure to control these immune responses in the CNS can result in 
immunopathological disorders (Ransohoff & Engelhardt, 2012). Microglia cells are the resident 
myeloid cells of the CNS (Saijo & Glass, 2011). They constitute 5-20% of total glial cells in 
rodents, depending on the specific region of the CNS (Lawson et al., 1990 and Perry et al., 
1991), In the human brain, microglia constitute 20% of all glial cells which  comprises 
approximately 10% of all brain cells (Lawson et al., 1990). Human microglial cells are effectively 
infected with M. tuberculosis and are possibly the principal cells target in the CNS (Peterson et 
al., 1995 and Curto et al., 2004). They are thought to be the first line of defence during 
neurotuberculosis (Curto et al., 2004 and Rock et al., 2004). The innate immune cells during M. 
tuberculosis infection expresses pattern recognition receptors (PRRs) that recognize various 
pathogens-associated molecular patterns (PAMPS) found on mycobacteria (Kleinnijenhuis et 
al., 2011). Antigen presenting cells (APCs), including microglia as well as other myeloid cells, 
express these PRRs (Kratky et al., 2011; Saijo & Glass, 2011 and Saijo et al., 2013). Upon 
activation, they acquire an amoeboid-like morphologic condition (Kozlowski & Weimer, 2012). 
Following the recognition of PAMPs by microglia, PRR-mediated signalling induces the 
production of antimicrobial peptides (such as cathelicidin-related antimicrobial peptide 
(CRAMP)), cytokines (such as TNF and interleukin-1β (IL-1β)), chemokines (such as CCL2 also 
referred to as monocyte chemotactic protein-1 (MCP-1) that recruits cells of the immune 
response to the site of mycobacterial infection (Möller & Hoal, 2010), CCL3 also referred to as 
macrophage inflammatory protein 1 alpha (MIP-1 alpha) and CCL5 also referred to as regulated 
on activation, normal T cell expressed and secreted (RANTES)) and the production of reactive 
oxygen/nitrogen species (Male, 1996; Hasan et al., 2005; Korbel et al., 2008; Liu & Modlin, 2008 
and  Saijo & Glass, 2011). These molecules play key roles in innate immunity. Chemokines 
expressed by resident CNS cells during infection, enhance leukocyte trafficking into the CNS 
(Nygårdas et al., 2000; Cardona et al., 2003; Wilson et al., 2010 and Ransohoff & Brown, 2012). 
Like peripheral antigen presenting cells (macrophages/neutrophils or DCs), activated microglia 
also up-regulate the expression of major histocompatibility class II (MHCII) molecules, to enable 
them to present antigens to T cells through the T cell receptor (TCR) (Rock et al., 2004). In 
addition, activated microglia produce proinflammatory cytokines (such as IL-12) (Becher et al., 
1996; Park & Shin, 1996; Aloisi et al., 1997 and Stalder et al., 1997) to skew CD4+ T cells into T 
helper 1 (Th1) cell. During this synapse, APCs (including microglia) produces various molecular 
markers of antigen presentation and activation such as MHCII as well as co-stimulatory 
molecules CD80 and CD86, also known as B7-1 and B7-2 respectively, and T cells upregulate 





Benveniste, 1996). The above mentioned markers may also have both neurodegenerative and 
neuroprotective effects, through interactions with other cell types, including lymphocytes, 
astrocytes, and neurons (Rock et al., 2004, 2008). Like other APCs, classically activated 
microglia contributes to both innate and adaptive immunity during neurotuberculosis.  
The cytokine TNF has been shown to be critical in the neuropathogenesis of M. 
tuberculosis (Mardh et al., 1983; Mastroianni et al., 1997; Tsenova et al., 1999; Curto et al., 
2004 and Tobin et al., 2012). It also has been shown that TNF plays a major role in granuloma 
formation and the containment of mycobacterial infections (Kindler et al., 1989 and Flynn et al., 
1995). The production of this pivotal cytokine in the CNS has been found to alter the BBB 
permeability and CSF leukocytosis in experimental bacterial meningitis (Ramilo et al., 1990; 
Saez-Llorens et al., 1990 and Saukkonen et al., 1990). In addition, it has been implicated in 
fostering the progression of neurotuberculosis in a murine model (Tsenova et al., 1999). 
However, Tobin et al., (2012) show that TNF deficiency or TNF excess can both cause 
macrophage lysis, therefore placing M. tuberculosis in a permissive extracellular niche. It is 
therefore urgent and important to identify the cellular sources of TNF that contribute to the 
immunopathology, and the mechanisms by which TNF produces necrosis of infected cells or 










Figure 1.4: Lymphoid, myeloid and neuronal lineage. T cells, B cells and NK cells comprise lymphoid 
lineage. Only T cells and B cells are involved in adaptive immunity. Cells of the other progenitors take 






1.3 Tumour necrosis factor  
TNF is a pleiotropic cytokine that has been found to play a critical but incompletely 
understood role in immune response against intracellular bacterial pathogens including M. 
tuberculosis (Miller & Ernst, 2009). There are two types of TNF, alpha (α) and beta (β), but since 
the 1998 TNF congress, the names of TNF-α and TNF-β were changed to TNF and 
Lymphotoxin-α respectively (Tracey et al., 2008 and Watanabe et al., 2010). However, the 
nomenclature of TNF-α is still widely used and is synonymous with the term TNF used in this 
thesis. TNF occurs in two forms: (i) a type II transmembrane protein (tmTNF) and (ii) a soluble 





biology of tmTNF and sTNF is shown in Figure 1.5. The tmTNF is a precursor form of soluble 
TNF, and is initially expressed as a homotrimer of 26-kDa monomers tmTNF (Horiuchi et al., 
2010). Cleavage of the membrane form of TNF by the metalloproteinase TNF-alpha converting 
enzyme (TACE) (Itai et al., 2001 and Mohan et al., 2002), and by the protease cathepsin B 
(Guicciardi et al., 2000 and Foghsgaard et al., 2001) results in the generation of soluble TNF. 
Thus, both mTNF and sTNF are biologically active (Horiuchi et al., 2010). However, the 
relative amounts of each protein are collectively determined by the cell types involved, the 
inducing stimuli, the amounts of active TACE, the activation status of the cells, and the 
amounts of natural TACE inhibitors (Smookler et al., 2006). The remaining tmTNF after 
cleavage with the metalloproteinase TACE is then, further processed by signal peptide 
peptidase-like 2B (SPPL2B), thereafter the intracellular domain is translocated into the nucleus 










1.3.1 Tumour necrosis factor cell signalling in the CNS 
Although this cytokine is mainly produced by macrophages, TNF is also produced by 
other cell types including adipose tissue, cardiac myocytes, endothelial cells, fibroblasts, 
neutrophils, dendritic cells, lymphoid cells, mast cells, and CNS cells (Ware et al., 1992; Zhou & 
Tedder, 1995; Tracey et al., 2008 and Chatzidakis & Mamalaki, 2010). In the CNS, the levels of 
TNF are approximately 100 pM (Santello et al., 2011), and are thought to depend on local 
production mainly by microglia, astrocytes and neurons cells (Lee et al.,1993; Tchelingerian et 
al., 1996; Bezzi et al., 2001; Bailey et al., 2006; Stellwagen et al., 2006 and Ransohoff & 
Cardona, 2010). However in pathological conditions, these cells undergo complex changes and 
significantly increase their capacity to synthesize proinflammatory TNF cytokines (Lue et al., 
2001 and Vezzani et al., 2002). With the increased presence of infiltrating leukocytes in the 
CNS, the levels of TNF (tmTNF and sTNF) are further enhanced (Gregersen et al., 2000). So 
far, the biological functions of tmTNF elicited by an outside-to-inside (reverse) signal have not 
completely been understood (Pattacini et al., 2010). However, it has been proposed that 
outside-to-inside signalling mediated by tmTNF may have a great contribution to the pleiotropy 
of this proinflammatory cytokine and its enhancement of immune response (Eissner et al, 
2004).  
Currently, two types of TNF receptors (TNFRs) have been cloned and characterised, TNF 
receptor type 1 (TNFR1; CD120a; p55/60) and TNF receptor type 2 (TNFR2; CD120b; p75/80) 
with molecular weights of 55 kDa and 75 kDa respectively (Jacobsen et al., 1994 and Ryan & 
Aksentijevich, 2009). These TNFRs are belonging to the TNF super family of receptors, they 
are structurally related and are present on the surface of numerous cells (Cubillas et al., 2010). 
TNF acts via either the low-affinity TNFR1 or high-affinity TNFR2 (Tartaglia & Goeddel, 
1992). Binding of TNF to its two receptors, TNFR1 and TNFR2, results in recruitment of signal 
transducers that activate at least three distinct effectors. Via the complex signaling cascades 
and networks, these effectors lead to the activation of caspases and two transcription factors, 
activation Protein-1 and NF-KappaB (Nuclear Factor-Kappa B) (Baud & Karin, 2001). For 
TNFR 1, TRADD (TNFR-Associated Death Domain) protein, binds to TNFR1 and recruits 
FADD (Fas-Associated Death Domain), RAIDD (RIP-Associated ICH-1/CED-3-homologous 
protein with a Death Domain), MADD (MAPK Activating Death Domain) and RIP (Receptor-
Interacting Protein) (Haider & Knöfler, 2009). The binding of TRADD and FADD to TNFR1 may 
lead to the recruitment, oligomerization, and activation of caspase 8. Activated caspase 8 





and ultimately induces apoptosis. Caspase 8 also cleaves BID (BH3 Interacting Death 
Domain). The tBID (Truncated BID) disrupts the outer mitochondrial membrane to cause 
release of the pro-apoptotic factors CytoC (Cytochrome-C). CytoC that is released from the 
intermembrane space binds to APAF1 (Apoptotic Protease Activating Factor-1), which recruits 
caspase 9 and in turn can proteolytically activate caspase 3. The protein kinase RIP2 is related 
to RIP that is a component of TNFR1 which mediates the recruitment of caspase death 
proteases. It has been also found that TRAF2 (TNF Receptor-Associated Factor-2) is 
implicated in the activation of two distinct pathways that leads to the activation of activation 
protein-1 via the JNK (Jun NH2-terminal Kinase), MEKK (MEK Kinase), p38 and, together with 
RIP, NF-KappaB activation, via the NIK (NF-Kappa B-Inducing Kinase) (Baud et al., 2001; 
Micheau et al., 2003; Varfolomeev et al., 2004 and Blackwell et al., 2009). TNF has been 
shown to activate MAPKs (Mitogen Activated Protein Kinases). The TNF superfamily receptors 
typically induce both NF-κB and JNK activation by recruiting the TRAF2 signal transduction 
protein to their cytoplasmic domain (Adrian et al., 2005). TNFR2 however, is a poor activator of 
these signaling pathways despite its high TRAF2 binding capability (Adrian et al., 2005). 
Although, TNFR2 does not have a death domain (DD), it can mediate signalling through 
TRAFs, by sharing its signal effects with activated c-Jun N-terminal kinase (JNKs) molecules 
(Haider & Knöfler, 2009). TNFR2 expression is highly regulated and primarily found on cells of 
the immune system,nonetheless it is also expressed on endothelial and neurological tissues 
(Beltinger et al., 1996 and Richter et al., 2012). TNFR2 is efficiently activated only by mTNF, 
despite binding sTNF with high affinity (Grell et al., 1995 and Brambilla et al., 2011). Thus, 
mTNF-mediated signaling occurs in a juxtacrine fashion through intercellular signaling, typical 
of TNF responses such as cytotoxicity (Perez et al., 1990) or lymphoïd T cell activation (Aversa 
et al., 1993), while sTNF is able of promoting paracrine and systemic functions through TNFR1 
(Grell et al., 1995; Brambilla et al., 2011 and Richter et al., 2012).  
TNFR1 is a large polypeptide with an extracellular domain, expressed on the cell surface 
of most cells and tissues. It consists of 4 cysteine-rich domains, an intracellular DD, and a 
transmembrane domain (Ryan & Aksentijevich, 2009). When, TNF binds to TNFR1, the 
receptor death domain recruits numerous adaptor proteins that form a signaling complex 
(Wang et al., 2000). This signaling complex may then result in the activation of various 
transcription factors, such as c- Jun or nuclear factor kappaB (NF-kB), as well as expression of 
genes that are critical for physiological processes such as cell growth, apoptosis, and 
immunopathology (Santello & Volterra, 2012). The activation of each of these processes may 





molecules that are expressed in a given cell, which in turn may depend on the cell history and 
metabolic state (Shen et al., 2006 and Zhang et al., 2009). The signalling may be amplified or 
dampened by many complex feedback mechanisms (Wajant et al., 2003). One may like to limit 
the TNFR1 signalling by proteolytically cleaving its extracellular domain with TACE, thereafter 
releasing a soluble fragment of TNFR1 (Ryan & Aksentijevich, 2009). TNFR1 and TNFR2, both 
have proteolytic effects (Ware et al., 1995). Although, TNFR1 and TNFR2 do not share 
significant homology in their intracytoplasmic domains, they are characterised by four repeated 
cysteine-rich motifs, with significant intersubunit sequence homology (Tartaglia & Goeddel, 
1992 and Wallach et al., 1999). Signalling of TNF through TNFR1 either results in the formation 
of complex I and activation of NFkB (pathway 1) promoting inflammation, survival and 
differentiation or provokes cell death through complex II and activation of caspases (pathway 2) 
(Haider & Knöfler, 2009). Recruitment of the apoptosis signal-regulating kinase 1 (ASK-1) 
(pathway 3) induces JNK and activator protein 1 (AP-1) which in turn may initiate apoptosis or 
survival (Haider & Knöfler, 2009). TNFR2-dependent signalling may also promote cell death or 
survival through pathways 1 and 2 respectively, but also activate phosphatidylinositol-3-
kinase/AKT (PI3K/AKT), suppressing apoptosis and promoting proliferation, migration and 
survival (Haider & Knöfler, 2009). The TNF signaling pathway through TNFR1 and TNFR2 is 
shown in Figure 1.6. 
It is important to note that TNF action is more complex than previously thought and can 
produce reverse effects, protective or deleterious, depending on several factors, including: (i) 
the type of cells or organ in which the process of activation is taking place; (ii) the type of 
receptor predominantly activated by TNF; (iii) the concentration at which the cytokine acts (iv) 







   Figure 1.6: TNF-dependent signalling pathways mediated via TNFR1 and TNFR2 (Adapted from 
Haider & Knöfler, 2009). 
 
 
1.3.2 Tumour necrosis factor involvement in neurotuberculosis 
The cytokine TNF plays four major actions during TB: (i) It is involved in the activation of 
macrophages, affecting their phagocytic and killing abilities; (ii) participate in the recruitment of 
many inflammatory cells (key to proper granuloma formation); (iii) regulate the induction of 
cytokine and chemokine production; and (iv) induction of apoptosis of macrophages and T cells 
(Marino et al., 2012). TNF plays a critical role in response to M. tuberculosis during 
neurotuberculosis (Buonsenso et al., 2010). The effects triggered by TNF are not only 
quantitatively, but also qualitatively distinct from those exerted at normal levels.  Studies have 
shown that excess TNF production can lead to neuronal and oligodendrocyte cell death 





intercellular adhesion molecule-1 (ICAM-1), leukocyte adhesion molecule-1 (LAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1) via astrocyte-microglia interaction (Hurwitz et al., 
1992; Kyrkanides et al., 1999 and Tang et al., 2011). TNF is involved in activation of the 
hypothalamus pituitary–adrenal axis, induction of a fever response, and triggers the release of 
other proinflammatory cytokines (Ramilo et al., 1990; Saukkonen et al., 1990; Hashimoto et al., 
1991 and De Vries et al., 1997). TNF also influences the trafficking of compounds into the brain 
by affecting the BBB permeability (De Vries et al., 1997). In patients with neurotuberculosis, 
high TNF levels in the CSF correlate with increased levels of IL-6 and protein, as well as low 
glucose levels (Low et al., 1995). In addition, TNF and IL-1β levels are associated with 
prolonged fever, seizures, spasticity, and death (Low et al., 1995 and Sharief et al., 1992). Due 
to the pleiotropic mode of action of these cytokines, they can potentially influence an immense 
variety of CNS signals and processes (Carpentier & Palmerv, 2009). During CNS infection, 
specific attention has been attributed to the proinflammatory cytokines such as IL-1β, IL-6, IL-
12 and TNF (Santello & Volterra, 2012). Cytokine such as TNF and IL-12, and chemokines with 
their receptors are secreted by various M. tuberculosis infected antigen presenting cells 
(Henderson et al., 1997; Kim et al., 1999; Giacomini et al., 2001 and Hickman et al., 2002). The 
detrimental effects of TNF in the CNS may also depend on the presence of other cytokines 
produced by either resident populations of CNS cells or infiltrating leukocytes, such as T cells. 
T cells have the ability to produce TNF along with interferon-γ (IFN-γ) that acts in both innate 
and specific cell-mediated immunities (Moser & Murphy, 2000). The effects produced by these 
cytokines may induce macrophage antimicrobicidal actions such as the production of nitric 
oxide (NO) and reactive nitrogen intermediates (RNI) mediated by nitric oxide sythase (NOS2) 
(Nathan, 1997 and Cooper et al., 2002). Babu et al., (2008) confirmed that TNF, IFN-γ and NO 
are involved in the immunopathology of neurotuberculosis. The combined effects of both TNF 
and IFN-γ may be harmful to neuronal elements (Babu et al., 2008).  
 
1.4 Genetically modified mice 
All disease pathology, be they inherited, infectious or environmentally induced, is 
affected or influenced directly or indirectly by an individual genome. The use of genetic modified 
mice may help us to understand these fundamental interactions. Sequencing of the mouse and 
human genomes has revealed outstanding similarities. Most human genes have a related 





similarities and to the practical considerations (mice breed rapidly, and methods of genetic 
modification are more effective, when compared with other mammals), the mouse model is 
widely used as a tool, for research in investigating immune mechanisms to unravel biological 
systems, and in the development of new drug therapies. Neurotuberculosis is a complicated 
disease, until today, the immunopathologly of this devastating disease is still not well 
understood. Previous studies using mice infected with laboratory or clinical mycobacterial 
strains, using different infection routes have shown mice to develop CNS pathology similar to 
human  (Thwaites et al., 2003 and van Well et al., 2007).  
Gene targeting manipulation has been used widely. The method can be used to 
remove exons, add a gene, delete a gene of interest and introduce point mutations. Targeted 
gene mutations have allowed the generation of specific gene knockout mice where a specific 
gene of interest is rendered non-functional. Typically, mutations have been designed to 
eliminate gene function, resulting in the generation of null mutant or knockout mice. The first 
consists of the cloning of the specific gene of interest and modification by removing some 
sequences from the specific gene (Mak et al., 2001). A targeting construct is then produced in 
which an exon of the gene of interest is replaced by a neomycin resistance cassette (Neo). A 
thymidine kinase (TK) cassette is included for negative selection. Homologous recombination 
results in the incorporation of the engineered mutation into the endogenous gene locus. Beside 
the above conditional mentioned approach, many approaches are routinely used for 
manipulating the mouse genome and generating new genetically modified mice; some of them 
are based on the Cre/loxP recombination system (Kuhn & Schwenk, 1997 and Bergqvist et al., 
1998). 
Since 1998, at the workshop for “Conditional Genome Alterations” in Cold Spring 
Harbor; where it was announced by Rossant & McMahon, (1999) that “Cre (cyclisation 
recombination) works”. After several years of investigations, scientists are now certain that the 
Cre recombinase of the P1 bacteriophage efficiently catalyzes recombination between two of its 
consensus 34 base pair DNA recognition sites (loxP sites) in any cellular environment and on 
any kind of DNA (Nagy, 2000). The Cre/loxP recombination system is a site-specific 
recombinase technology widely used to elegantly carry out insertions, translocations, deletions 
and inversions in the DNA of cells. The system allows for organs/tissue or cell specific deletion 
of the gene of interest and can be expressed under the control of a tissue or cell specific 
promoter (Mak et al., 2001 and Zhu et al., 2001). Elimination of the gene by the Cre/loxP 
recombination system removes the problem of early embryonic fatality of mice, especially when 





enzyme originates from the bacteriophage P1 and is a site specific recombinase that 
recombines DNA fragments only at loxP sites (Kuhn & Schwenk, 1997 and Mak et al., 2001). 
The Cre recombinase of the P1 bacteriophage is a member of the integrase family of site-
specific recombinases. It is a 38 kD protein that catalyzes the recombination between two of its 
recognition sites, called loxP (Hamilton & Abremski, 1984). This is a 34 bp consensus 
sequence, consisting of a core spacer sequence of 8 bp and two 13 bp palindromic flanking 
sequences. First, a pair of loxP sites repeats  flanks the target DNA to be deleted (Figure 1.7). 
Thereafter, the mouse expressing Cre enzyme (under the control of an inducible promoter in the 
transgenic mice, so that it can delete the target DNA inside the selected cells) is generated. One 
loxP site is left behind and the two flanking fragments of DNA are spliced together. In a cell 
type-specific manner, the target DNA is excised and degraded. While other cell types, where the 
Cre enzyme is not directed still have their intact genes. Mating of these two lines will result in 
Cre-mediated deletion of the gene of interest only in the cells or tissue expressing Cre 
recombinase. Thereafter the strains are screened for homologous recombination by PCR or 
Southern blot analysis. One of the advantages of the Cre/loxP recombination system is that 
there is no need for additional sequence elements or co-factors for efficient recombination 
regardless of the cellular environment (Nagy, 2000). Concerning the molecular mechanism of 
recombination, a single recombinase molecule binds to each palindromic half of a loxP site, 
then the recombinase molecules form a tetramer, thus bringing two loxP sites together 
(Voziyanov et al., 1999).  
Many studies using mouse models of complete TNF deletion have demonstrated that 
TNF has numerous effects and functions during pulmonary tuberculosis (Flynn et al., 1995; 
Botha et al., 2003; Allie et al., 2008 and Allie et al., 2010). These studies demonstrated that TNF 
is involved in immune cell trafficking into the site of infection, controlling bacterial replication and 













Figure 1.7: Cre/loxP mediated gene targeting only in the cells or tissue expressing Cre 
recombinase. The targeted gene is flanked by two loxP sites (floxed gene). The foxed gene is 
























  1.5 Aims and objectives of the study 
To our knowledge, no study has yet investigated the immunopathology of 
neurotuberculosis using complete TNF deficient or cell type-specific TNF deficient mice. In this 
thesis, we independently investigated the role of neurons as a basic functional cell of the brain, 
the myeloid (microglia-macrophages and neutrophils) cell subset, and lymphoid (CD4+- and 
CD8+) T cell subsets as cellular sources of TNF in protective immunity against cerebral M. 
tuberculosis infection. In this study we aimed: (i) to investigate the contribution of neuronal, 
microglia/macrophage, neutrophil, CD4+- and CD8+ T cell-derived TNF in the host’s immune 
function against cerebral M. tuberculosis infection, and (ii) to assess the relative roles of each 
cell type and potential co-operativity in immune function during cerebral M. tuberculosis 
infection. 
To achieve our aim we have designed the following objectives: (i) to evaluate the 
recruitment of immune cells such as antigen presenting cells, and T and B lymphoid cells into 
the central nervous system during M. tuberculosis infection as a function of TNF; (ii) to evaluate 
the activation status of recruiting immune cells in protective immunity against cerebral M. 
tuberculosis infection;   (iii) to evaluate the mortality, bacilli burden as the primary indicator of 
TNF mediated immune protection and organ pathology in response to cerebral M. tuberculosis 
infection; (iv) to examine whether lymphocytic infiltration of the brain is regulated by neuronal, 
myeloid or lymphoid cell-derived TNF; (v) to assess whether the role of brain neuronal cell, as 
well as immune cells subsets such as microglia, macrophages, neutrophils, CD4+ and CD8+ T 
cell-derived TNF influence the expression of cytokine and chemokine levels during experimental 
neurotuberculosis, and (vi) to investigate whether TNF synthesised by neurons, microglia, 
macrophages, neutrophils or T cells regulate TNF cytokine and chemokine expression during 
experimental neurotuberculosis. 
We therefore hypothesised that neuronal derived TNF, as well as myeloid or T cell-
derived TNF is required to generate host protective immune responses against cerebral M. 










            
 
 









           CHAPTER  II 


















2.1 Animals and development of conditional NsTNF-/- mice 
            Mice 8-12 week-old male or female (all on a C57BL/6 genetic background) were used in 
experiments. All mice were bred and maintained under specific pathogen free (SPF) conditions 
in the Research Animal Facility at the University of Cape Town. Experimental mice were housed 
in an individually ventilated cage (IVC) system and supplied with sterile water and food ad 
libitum. Tail biopsies of experimental mice were obtained to extract genomic DNA and confirm 
strain genotypes. All experimental procedures were performed in a biocontainment level 3 
facility. Mouse strains used and generated in this study were: (i) Knockin transgenic Syn1-Cre 
mice obtained from Jackson Laboratories (Bar Harbor, Maine, USA), in which Cre expression is 
controlled by the rat Synapsin I promoter, and has been shown to drive transgene expression 
specifically in neuronal cells (Hoesche et al., 1993 and Zhu et al., 2001). (ii) The knockin TNF 
floxed mice (TNFf/f, wild type (WT) used as control positive) in which the TNF gene was modified 
by the insertion of synthetic loxP sites flanking the coding region of interest. Briefly, three loxP 
sites were introduced into the targeting vector; where two loxP sites were flanked by the neo 
selection cassette and then placed approximately 1kb downstream of the TNF gene, and then 
the third loxP site was inserted into the third intron (Grivennikov et al., 2005). (iii) In order to 
generate novel mice with specific deletion of the TNF gene in neurons (NsTNF-/- mice), we 
crossed the TNFf/f mice with Syn1-Cre mice. (iv) Microglia/macrophages and neutrophils 
specific TNF deficient mice (M-TNF-/- mice) generated by Grivennikov et al., (2005). (v) Myeloid 
(microglia/macrophage and neutrophils) and lymphoid (CD4+- and CD8+ T cells) cell type-
specific TNF deficient mice (MT-TNF-/- mice) were generated by Allie et al., (2013), by cross 
breeding the M-TNF-/-  mice with the CD4/CD8TNF-/- mice (T-TNF-/-) (Grivennikov et al., 2005). 
(vi) and the complete TNF deficiency mice (TNF-/-) were previously generated by Kuprash et al., 
(2005). Our TNF-/- strain was originally generated from TNFf/f mice, we therefore opted to use 
this strain as our negative control for the entire study. All studies and procedures were approved 
by the University of Cape Town, Animal Ethics Committee (HSFAEC No: 010/018). 
 
 
 2.1.1 Genotyping of mice 
The mice used in all experiments were first genotypes and phenotypes of matting, 
breeding stocks and litters used were confirmed by polymerase chain reaction (PCR). Mice 
were genotyped for the presence of either Cre or TNF using a Peltier Thermal Cycler (model 
PTC-200) from MJ research (Biozym, Hessissch Olderdorf, Germany). Primers were purchased 




from The Department of Biochemistry, Faculty of Science, University of Cape Town.  
 
 
  2.1.1.1 Extraction of genomic DNA and PCR analysis 
 
Mice tail tip biopsies (approximately 1 cm) were obtained under anaesthetic. Genomic 
DNA was extracted by lysing tails overnight with rotation at 56°C in lysing buffer containing 
50mM Tris-HCl pH 8, 100mM EDTA pH 8, 100mM NaCl, 1% SDS and 0.5mg/ml Proteinase K 
(Sigma, St. Louis, MO). A volume of 250µl of saturated NaCl was added and the solution was 
vortexed for ± 15 seconds, before centrifugation for 10 minutes at 10,000 rpm. 750μl of 
supernatant was transferred to a tube containing 450μl of ice-cold isopropanol. DNA was 
precipitated by gently inverting the tube. The solution was then centrifuged for 5 minutes at 
13000 rpm to sediment the DNA. The DNA was then washed with 70% ethanol, sedimented 
again by centrifugation and the pellet dried at 37°C using a Digital Dry Bath (Labnet 
international, inc Woodbridge, NJ 07095). The dried DNA pellet was resuspended in 200μl of 
distilled water for 3 hours at room temperature, and a volume of 2μl of DNA solution was used 
per PCR reaction. The standard PCR reaction mix (Table 2.1) was used in all PCR analysis, 











10 x PCR buffer 5 µl 1 x PCR Buffer 
MgCL (25mM) 3 µl 1.5mM 
dNTNP (10 µl) 1 µl 0.2mM 
Primer 1 (10 µl) 1 µl 0.2mM 
Primer 2 (10 µl) 1 µl 0.2mM 
Taq (5U/µl) 0.125 µl 0.625U 
DNA sample  2 µl  
H2O 36.875 µl  
Total volume 50 µl  





2.1.1.2 Primer sequences used for screening of Syn1-Cre and TNF genes 
  
 Amplification of Syn1-Cre and TNF genes were performed by PCR, according to the 
conditions set out in tables 1, 2, 3 and 4. Magnesium chloride, 10x PCR buffer and Taq 
polymerase were purchased from Vector Laboratories, (UK) and the dNTP stocks were 
obtained from Promega, Madison, United states. 
 
2.1.1.2.1 Primers used for screening Syn1-Cre and NsTNF-/- mice were as follows:  
 
              IMR1084:  5’ GCG GTC TGG CAG TAA AAA CTA TC 3’  
              IMR1085:  5’ GTG AAA CAG CAT TGC TGT CAC TT 3’ 
              IMR7338:  5’ CTA GGC CAC AGA ATT GAA AGA TCT 3’ 
              IMR7339:  5’ GTA GGT GGA AAT TCT AGC ATC ATC C 3’ 
 
      Table 2.2: Amplification conditions for the Syn1-Cre gene 







1. Initial denaturation   94    180  
2. Denaturation  94    30   
3. Primer annealing  51.7    60  
4. Extension   72    60  
5. Final extension  72  120  
Steps 2-4 was repeated for 35 cycles     
 
      Amplification products:  
                             Wild type gene: 324bp (IMR7338 and IMR7339) 










2.1.1.2.2 Primer sequences used for screening TNFf/f mice were as follows: 
 
               KO41: 5’ TGA GTC TGT CTT AAC TAA CC 3’ 
               KO42: 5’ CCC TTC ATT CTC AAG GCA CA 3’ 
 
         Table 2.3: Amplification conditions for the TNF floxed gene 







1. Initial denaturation   94    120  
2. Denaturation  94    40   
3. Primer annealing  55    45  
4. Extension   72    60  
5. Final extension  72  300 
Steps 2-4 was repeated for 35 cycles     
 
         Amplification products:  
                            Wild type TNF gene: 350bp 
                            Floxed TNF gene: 400bp 
 
2.1.1.2.3 Primer sequences used for screening of M-TNF-/- mice were as follows: 
 
             Mlys1:  5' CTT GGG CTG CCA GAA TTT CTC 3’ 
             Mlys2:  5' TTA CAG TCG GCC AGG CTG AC 3 
             Cre8:    5' CCC AGA AAT GCC AGA TTA CG 3’ 
 
         Table 2.4: Amplification conditions for the Mlys Cre gene 







1. Initial denaturation   94    300 
2. Denaturation  94    30   
3. Primer annealing  55    30  
4. Extension   72    90  
5. Final extension  72  420 
Steps 2-4 was repeated for 34 cycles     
 
      Amplification products:   
                             Mlys gene (WT):      350bp (Mlys1 and Mlys2) 
                             Mlys Cre transgene: ∼700bp (primers Cre8 and Mlys1) 




2.1.1.2.4 Primer sequences used for screening of MT-TNF-/- mice were as follows: 
 
             Mlys 1:  5' CTT GGG CTG CCA GAA TTT CTC 3’ 
              Mlys 2:  5' TTA CAG TCG GCC AGG CTG AC 3 
              Cre 8:    5' CCC AGA AAT GCC AGA TTA CG 3’ 
 
         Table 2.5: Amplification conditions for the Mlys Cre gene 







1. Initial denaturation   94    300 
2. Denaturation  94    30   
3. Primer annealing  55    30  
4. Extension   72    90  
5. Final extension  72  420 
Steps 2-4 was repeated for 34 cycles     
 
      Amplification products:   
                             Mlys gene (WT):      350bp (Mlys1 and Mlys2) 
                             Mlys Cre transgene: ∼700bp (primers Cre8 and Mlys1) 
 
          
 
 
             CD4 Cre1: 5' ATC AAG GTC CTG AGG AAG AG 3’ 
             CD4 Cre2: 5' ACC TCA TCA CTC GTT GCA TC 3’ 
             CD4 Cre3: 5' CTA GGA GTT GTG CTG CAC AG 3’ 
 
         Table 2.6: Amplification conditions for the CD4 Cre gene  







1. Initial denaturation   94    600 
2. Denaturation  94    30   
3. Primer annealing  55    60  
4. Extension   72  120  
5. Final extension  72  300 
Steps 2-4 was repeated for 35 cycles     
 
       Amplification products:   
                              CD4 gene (WT):       350bp (CD4 Cre1 and CD4 Cre3) 
                              CD4 Cre transgene: 242bp (CD4 Cre1 and CD4 Cre2) 




2.1.1.2.5 Primer sequences used for screening TNF-/- mice were as follows: 
 
             KO 41:               5’ TGA GTC TGT CTT AAC TAA CC 3’ 
              KO 49:               5’ CTC TTA AGA CCC ACT TGC TC 3’ 
              MTNFRTP 81:   5’ GTC TAC TTT GGA GTC ATT GC 3’ 
              MTNFRTP 82:   5’ GAC ATT CGA GGC TCC AGT 3’ 
 
 
         Table 2.7: Amplification conditions for the TNF-/- gene 







1. Initial denaturation   94    180  
2. Denaturation  94    30   
3. Primer annealing  56    60  
4. Extension   72  120  
5. Final extension  72  300 
Steps 2-4 was repeated for 35 cycles     
 
      Amplification products:  
                              TNF gene: 350bp (MTNFRTP81 and MTNFRTP82) 




Amplification reaction products were electrophoresed on 1.5% agarose gels (Appendix A) 
with ethidium bromide at 160 volts for 90 minutes using 0.5 x Tris borate ethylene diamino tetra 
acetic acid (TBE) (Appendix A) as the electrophoresis buffer. A 1.5kb DNA ladder (Promega, 









 2.1.2 Characterisation of Neuron specific TNF Knockout mice 
 
TNFf/f, NsTNF-/- and TNF-/- mice were intracerebraly stimulated with 5µg/ml of LPS, for 90 
minutes. Mice were transcardially perfused with 4% paraformaldehyde in PBS. Brains were 
collected in 1xPBS and kept on ice. Brain cells were harvested by passing brain through a 70 
µm cell strainer (Beckton Dickinson (BD) Biosciences Discovery Labware, Bedford, MA, USA) to 
generate a single cell suspension. Harvested single cells were fixed with fixation buffer and 
thereafter incubated in permeabilisation buffer containing saponin before being intracellularly 
labelled with neuron-specific Beta III Tubulin antibody (unlabelled), as well as PE-conjugated 
secondary IgG and TNF-specific (TNF-Alexa Fluor 647) markers (Table 2.8). Samples were 
then resuspended in fixation assay buffer overnight before analysis on a multi-colour FACSAria 
flow cytometer (BD Biosciences, Erembodegem Belgium). Unstained as well as IgG-PE and 
IgG-Alexa Fluor 647 stained controls were used to set Beta-tubulin+ and TNF+ gates. Reagent 
preparation is further detailed in appendix E.  
 
  Table 2.8: Antibodies used for flow cytometry analysis of intracellular cytokine staining  
 





Neuron specific Beta III Tubulin     1:50       - abcam® 





anti-mouse TNF:Alexa Fluor 647  1:50 MP6-XT22 BD PharmingenTM 
 
 
 2.2 M. tuberculosis strain 
The M. tuberculosis H37Rv strain was obtained from the Trudeau Mycobacterial Culture 
Collection (Trudeau Institute, Saranac Lake, NY), and grown at 37°C until mid log phase in 
Middlebrook 7H9 broth (Difco™ BD Becton, Dickinson and Company, Sparks, MD 21152, USA) 
containing 0.5% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC) (BBLTM 
Becton Dickinson and Company Sparks, MD 21152, USA), culture aliquots were stored at -80°C 
in 2ml cryovials (Nalge Nunc International, Naperville, IL, USA) after adding 10% (v/v)glycerol 




(Sigma, St Louis, MO). Colony forming units per milliliter were determined by passing the 
mycobacterial suspension 30x through a 29,5G needle fitted with a 1 ml syringe (Omnican®, 
B.Braun, Melsungen, Germany) to disperse clumps and plating 100μl of 10 fold serial dilutions 
on Middlebrook 7H10 agar (Difco™ BD Becton, Dickinson and Company, Sparks, MD 21152, 
USA) supplemented with 10% (v/v) OADC and 0.5% (v/v) glycerol. Plates were sealed in a 
plastic bag and incubated at 37°C for 18-21 days, thereafter colonies were counted using a 




  2.3 Mycobacterial preparation for infection 
A 1ml aliquot of M. tuberculosis H37Rv was thawed at room temperature and clumps 
were disrupted by aspirating the mycobacterial suspension 30 times through a 29,5G needle 
fitted with a 1ml syringe (Omnican®, B.Braun, Melsungen, AG, Germany). An inoculum volume 
of 2.5 ml at a concentration of 1 x 105 cfu/ml was prepared, thereafter 10-fold serial dilutions of 
inoculums were plated on Middlebrook 7H10 agar (Difco™ BD Becton, Dickinson and 
Company, Sparks, MD 21152, USA) supplemented with 10% (v/v) OADC (BBL™ BD 
Microbiology systems, and Company, Sparks,MD 21152, USA) and 0.5% (v/v) glycerol in 90mm 
compartmentalized plates (Sterilin, Bibby Sterilin Ltd., Stone, Staffs, UK). The culture plates 
were sealed in a plastic bag and incubated at 37°C for 18-21 days. The colonies were then 
counted using a colony counter (MRC Model 570, MRC Ltd, Israel) and the concentration of 
mycobacteria calculated. Middlebrook 7H10 agar preparation is detailed in appendix B. 
 
         2.4 Stereotaxic infection 
         Intracranial infection was performed using stereotaxic frame. Mice were anaesthetised by 
intraperitoneal injection with appropriate doses of ketamine hydrochloride (100mg/kg Bayer Pty 
Ltd, Germany) and Xylazine (10mg/kg Intervet, Zurich-Switzerland). After the animal has 
reached full anaesthesia, furs were removed from the top of the skull with the shaver. The 
anaesthetised mice were mounted to the stereotaxic frame. Mouse's ears were locked firmly 
with ear bars into ear sockets of the stereotactic frame, and slide the incisor bar into place and 
tighten nose clamp firmly on the bridge of the nose. The scalp was disinfected with 70% 




ethanol, and an incision was made along a midline and extended forward to the back of the 
eyes and backward to between the ears, avoiding damage to the muscles. Animals were 
stereotaxically injected with a dose of 1x105 CFU M. tuberculosis. Using single needle insertion 
(coordinates: +0.2 mm relative to bregma, 2.0mm from midline) to a depth of 2.0mm into the 
cortex. The solution was injected with a Hamilton syringe (Gastight no.1701, Hamilton, 
Bonaduz, Switzerland) at a rate of 0.1µl per minute and delivered in 3μl of saline keeping the  
needle in place for 10 minutes in order to allow absorption of the solution. The hole was sealed 
with bone wax, the incision was sutured and the animal was removed from the stereotaxic 
frame. Animals received subcutaneous analgesic Meloxicam (1 mg/kg; Boehringer Ingelheim 
Pharmaceuticals, Germany) as a prophylactic pain killer at the time of infection, followed by 
subsequent administration at 24h intervals for a two day period thereafter. The animals were 
kept warm during the recovery. Mice were monitored twice daily and sacrificed a various 
predetermined time points by either inhalation with 0.01% halothane (Safeline Pharmaceuticals 
Pty Ltd, South Africa) or overdose with ketamine/xylazine cocktail. Specific anaesthetic doses 
preparation is detailed in appendix C. 
 
2.5 Clinical severity scoring system for mice  
To evaluate the clinical course of neurotuberculosis in mice, we adapted the previously 
described scoring system according to the clinical manifestations presented in our animals 
(Tsenova et al., 2005). Animals were intracerebrally infected with M. tuberculosis at a dose of 
1x105 cfu/brain. Mice were scored daily for neurologic manifestations during the course of 
infection as follows: Normal (no detectable signs) = 0; head tilt = 1; motility or decrease activity 
= 2; behaviour depression = 3; and moribund state = 4.  
 
2.6 Colony forming units 
Animals were euthanised by acute exposure to halothane (2-bromo-2-chloro-1,1,1-
trifluoro-ethane) 0.01%. The abdomen and the thoracic cavity were opened and brain, lung, 
spleen and liver were aseptically collected, weighed and then put in 1ml 0.9% NaCl/ 0.04% 
(v/v) Tween 80 solution. Organs were homogenised using a glass tissue Grinder-homogeniser 
(Kimix - Chemicals and Laboratory Suppliers, Cape Town - South Africa), and 100μl solution of 




ten-fold serial dilutions of organ homogenates were plated in duplicate onto Middlebrook 7H10 
agar (Difco™ BD and Company, Sparks, MD 21152, USA) supplemented with10% OADC (v/v) 
(BBL™ Beckton Dickinson Microbiology systems, BD and Company, Sparks, MD 21152, USA) 
and 0.5% (v/v) glycerol in 90mm compartmentalised plates (Bibby Sterilin Ltd, Stone, Staffs, 
UK). Culture plates were sealed in plastic bags and incubated at 37°C for 18-21 days. 
Mycobacterial colonies were counted using a colony counter (MRC Model 570, MRC Ltd, 
Israel) and the final cerebral, pulmonary and splenic dose calculated. Cerebral, pulmonary and 




2.7 Organs and tissue preparation for histology  
Brains, lungs and spleens were collected from euthanised mice at defined time points 
and immersed in a volume of 10% formalin (10% formaldehyde in PBS pH 7.4) at least 10x that 
of the tissue. Organs were processed and embedded in paraffin wax overnight (Histosec 
Pastilles, Merck). All fixed tissues were dehydrated in an automated tissue processor (Shandon 
Elliot, Shandon Southern Instruments, Ltd, Camberly, Surrey, UK) for paraffin wax embedding. 
Dehydration was completed after immersing the tissues in 1 x 70% ethanol for 2hrs, thereafter 
in 2 x in 96% ethanol for 2hrs each, following in 4 x 2hrs in absolute alcohol and 2 x 2hrs in 
Xylol. Sections 4 µm thick were cut from the paraffin blocks using a microtone (Leica, model 
RM-2125, Wetzlar, Germany), and labelled for haematoxylin and eosin (H&E), Ziehl Neelsen, or 
inducible-nitric oxide synthase (iNOS) and thereafter mounted on aminopropyltriethoxysilane 
(APES 99%) coated slides. Sections for H&E was used to reveal brain morphology and 
pathology, Ziehl Neelsen was to assess the presence of acid fast bacilli, and the  inducible-nitric 
oxide synthase was used to assess the activation of antigen presenting cells.  
 
 
2.7.1 Haematoxilin and eosin staining  
 
 After dewaxing tissues sections at 56°C overnight, each brain section was washed twice 
with absolute ethanol for 1 minute, twice in 96% alcohol for 1 minute, followed by 1 minute in 
70% alcohol and rinsed in tap H20. Sections were incubated for 8 minutes in haemotoxylin and 
rinsed with water. Thereafter they were washed for 30 - 60 minutes with water and directly 




counter stained for 2 minutes in 1% eosin solution. Tissue sections were washed again with 
water, dehydrated in different alcohol concentrations (70% and 96% alcohol), and then Xylol 
and mounted with Canada Balsam (Sigma-Aldrich, Kempton Park, South Africa). Reagent 
preparation is further described in appendix D. 
 
 
2.7.2 Ziehl-Neelsen staining 
 
Following dewaxing tissues sections at 56°C overnight, slide sections were covered with 
a filtered carbol fuchsin solution and heated gently until fumes appeared. Slides were allowed to 
stand for 5 minutes, and then rinsed gently under a stream of running tap water. Excess stain 
was removed by rinsing in 1% acid alcohol containing 1% HCl in 70% alcohol. This procedure 
was followed by covering the slides with 20% sulphuric acid for 20 minutes. Thereafter, slides 
were rinsed gently under a stream of running tap water for 10 minutes. Sections were covered 
with drops of Loeffler's methylene blue for 1 minute. Slide sections were washed prior to 
dehydration with alcohol (70%, 90%, and 96%, absolute). All slides were dipped in xylol for a 
minute and mounted in Entellan (Merck, Darmstadt, Germany). Reagent preparation is further 
described in appendix D. 
 
 
 2.7.3 Brain inducible nitric oxide synthase staining 
 
 The inducible-nitric oxide synthase (iNOS) staining was used to assess the activation of 
antigen presenting cells. Formalin-fixed paraffin-embedded brain sections were deparaffinised 
and rehydrated followed by staining with rabbit anti-mouse specific inducible nitric oxide 












           2.8 Flow cytometry analysis 
2.8.1 Brain single cells staining for flow cytometric analysis  
 
Animals were euthanised with a lethal dose of Ketamine/xylazine. Thereafter, mice were 
disinfected with Ethanol (70%). The thoracic cavities of mice under aneasthesia were opened 
for transcardial perfusion with 10ml of 1x PBS. After the perfusion, the heads of the mice were 
removed and the brain aseptically collected into a tube containing 2ml of 1x PBS and kept on 
ice.  
Brains were passed through a 70µm cell strainer (BD Biosciences Discovery Labware, 
Bedford, MA, USA) to generate a single cell suspension. Cells (1x108 cells/brain) were pelleted 
by centrifugation at 2000 rpm for 5 minutes.  
 
  2.8.2 Cell surface staining for flow cytometry analysis 
           
Individual mice whole brain tissues were harvested at 0 (naïve), 1, 2 and 3 weeks post 
infection to generate single cell suspensions. For surface marker staining, 1 x 106 cells were 
used and non-specific binding to cells was prevented through incubation in 25µl of blocking 
solution containing αFcγRIII (1mg/ml of rat α-mouse CD32/16c in normal rat serum (heat 
inactivated) and normal mouse serum (heat inactivated), and diluted in 141.56µl FACS buffer 
(containing 0.1% (v/v) BSA and 0.01% (v/v) NaN3 in PBS, pH 7.4) for 20 minutes at 4°C. The 
brain cells were thereafter washed by adding 1ml FACS buffer and then centrifuged at 2000 rpm 
for 5 minutes at 4°C. Diluted antibody combinations (25μl of each diluted antibody) at a final 
concentration of 2μg/ml were added to the cells and incubated for 20 minutes at 4°C in the dark. 
After washing the cells, a volume of 200μl of fixation buffer (2% paraformaldehyde (PFA) and 
0.4% NaOH in PBS, pH 7.2) was added into each well and the cells fixed overnight at 4°C. Flow 
cytometric analysis was done on multi-colour FACS LSRFortesa cell analyser (BD Biosciences, 
San Jose, California, USA) using Flowjo software. 
To identify the CD11b, CD11c and CD45 expression, isolated single cells were labelled 
with specific markers (CD11b:PerCP-Cy5-5, CD11c:Alexa 700 and CD45:APC)  for flow 
cytometric analysis to examine CD11b, CD11c and CD45 expression. We confirmed the 
CD11c+CD45high population by measuring CD11c expression after gating the CD11blowCD45high 
population. Cell body or live cells were identified and gated according to the previously 




published strategy (Guez-Barber et al., 2012), and its application in these studies is shown in 
Figure 2.1. Microglia phenotype was defined as CD11b+ and CD45low as previously reported 
(Sedgwick et al., 1991; Ford et al., 1995 and Nikodemova & Watters, 2012). In addition, the 
macrophage population was also identified as CD11b+ cells, but showed to express CD45high 
(Sedgwick et al., 1991 and Ford et al., 1995). Distinct population was displayed, expressing 
CD45high cells, but expressed CD11blow which we referred to as dendritic cells (DCs), this 
population was later confirmed for the CD11c+ in mice, expression of  CD11c+ determines DCs 
phenotype (Wildenberg et al., 2009 and Fischer & Reichmann, 2001). The antibodies and initial 
concentrations used are listed in Table 2.9, and the gating strategy as described by Ford et al., 
(1995); Carson et al (1998); Campanella et al., (2002); Kruglov et al., (2011) and Nimer et al., 
(2013) was used. 
To identify the Follicular B cells population, isolated single cells were labelled with 
specific B-cell markers (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5 and B200:Horizon V500), and 
Figure 2.2 shows the gating strategy used to identify the CD1dlowB220+AA4.1- (Follicular B cells) 
population. The follicular B cells were gated and identified according to Castillo-Méndez et al., 
(2007) previously described method, and antibodies and initial concentrations used are 
described in Table 2.10.   
In order to identify the plasmablast and plasma cells, isolated single cells were labelled 
with specific B-cell (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5-A, CD138:APC and B200:Horizon 
V500) markers. Figure 2.3 shows the gating strategy used to identify the plasmablast and 
plasma cell populations. Plasmablast and plasma cells were identified and analysed using 
antibodies and their initial concentrations in Table 2.10 (Radwanska et al., 2008).  
The CD4+- and CD8+ T cells were identified and analysed after the isolated single cells 
were labelled with specific T cells (CD3е: Pacific Blue, CD4:Alexa 700 and CD8:PerCP-Cy5.5) 
for analysis of CD4+- and CD8+ T cell populations by flow cytometry (Figure 2.4). The antibodies 
and initial concentrations used ared described in Table 2.11, and the previously described 
gating strategy (Friberg et al., 2011 and Schmetterer et al., 2011). Reagents preparation is 
further described in appendix E. 
 
 
  2.8.3 Total cell number or absolute number calculation  
 
The absolute numbers of each population gated were calculated using the following 
fomula: 




Total cell number = Total cell count for the organ  X  Percentage of total cells which are positive. 
 
   
 
Figure 2.1: Gating strategy of myeloid derived APCs used during neurotuberculosis. TNFf/f, NsTNF-
/- and TNF-/- mice were intracerebrally infected with M. tuberculosis (1x105 cfu/brain). Brains were 
collected at week 0 (naïve), 1, 2 and 3 post-infection, and immediately harvested. To identify microglia 
and infiltrating myeloid populations, isolated cells labelled with CD11b:PerCP-Cy5-5, CD11c:Alexa 700 
and CD45:APC as myeloid antigen presenting cell markers and analysed by flow cytometry. Live brain 
cells were first gated on a forward scatter/side scatter (FSC-A/SSC-A) dot plot showing distinct clusters 
for debris and live cells, using unstained, naïve and infected samples (1), and brain live cells were gated 
on FSC-A/FSC-H to generate singlets (2). Cells were thereafter labelled with CD11b:PerCP-Cy5-5 or 
CD11c:Alexa 700 and CD45:APC to gate for APCs. Microglia (CD11b+CD45low) (population 3), 
macrophages (CD11b+CD45high) (population 4), DCs (CD11blowCD45high) (population 5), were identified. 
To confirm the dendritic cell population (CD11c+CD45high) phenotype, we evaluated SSC-A/CD11c:Alexa 
700 marker (6) expression after gating on CD11blowCD45high population. Flow cytometry data of controls 
(wild type and TNF-/-) used in result section 1 were the same data used as control in result section 2. 
 





                                      
Figure 2.2: Fo B cells gating strategy used during neurotuberculosis. TNFf/f, NsTNF-/- and TNF-/- 
mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells labelled and analysed using the 
BD LSRFortessa flow cytometer analyzer. In order to identify Fo B cells population, isolated single brain 
cells were labelled with CD1d:PE-A, CD93(AA4.1):PerCP-Cy5-5-A and B220:V500-A markers. Brain live 
cells are first gated on a FSC-A/SSC-A dot plot using naïve and infected (1). The gate 1 event is 
visualised using an FSC-A/SSC-A dot plot and the singlets (single cells) were gated on FSC-A/FSC-H (2). 
Cells on gate 2 were simultaneously displayed on both CD93(AA4.1):PerCP-Cy5-5-A/B220:V500-A in 
order to discriminate the immature cells, and yielded to AA4.1+B220+ population and (3). The AA4.1-
B220+ population were then gated using CD1d:PE-A versus B220:Horizon V500-A markers to 
discriminate the marginal zone cells (4) and Fo B cells detected as CD1dlowB220+AA4.1- cells (5) were 
mapped in a CD1d:PE/B220:V500 dot plots using gate 3. Flow cytometry data of controls (wild type and 










     
Figure 2.3: Flow cytometry gating strategy for plasmablast and plasma cells. Brains were harvested 
at week 0 (naïve), 1, 2 and 3 post-infection, and cells isolated from naïve and the intracerebrally infected 
TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Isolated single cells 
were labelled with CD1d:PE-A, AA4.1:PerCP-Cy5-5-A, CD138:APC-A and CD45R/B220:V500-A. From 
top left: Brain live cells are gated on FSC-A/SSC-A using naïve and infected samples (1), and singlets 
were gated on FSC-A/FSC-H (2). Thereafter gated with CD138:APC-A and B220 V500-A. Two B-cell 
subsets are identified: the plasma cells (B220lowCD138+) (3), and plasmablast cells (4). The identified 
plasmablast population in 4, was further gated for B220 V500-A with CD1d:PE-A to discriminate the 
CD1dlow cells, and the plasmablasts population yield as CD1dhighB220highCD138- (5). Flow cytometry data 















Figure 2.4: Gating strategy for effector T cells using naïve and infected mice. Brains were collected 
and directly harvested at week 0 (naïve), 1, 2 and 3 post-infection, and cells were isolated from naïve and 
intracerebrally infected TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. 
Following the previously described gating strategy, CD4+ and CD8+ cells were analysed by multi-channel 
BD LSRFortessa flow cytometer analyser using T cell and activation markers (CD3е: Pacific Blue, 
CD4:Alexa 700, CD8:PerCP-Cy5.5 and CD44:PE). The leftmost panel shows, brain cells were gated with 
forward scatter versus side scatter to map live cells (1). The CD4+ T cells were gated based on CD3+CD4+ 
(2), while the CD8+ T cells were gated based on CD3+CD8+ T cells (3). Flow cytometry data of controls 






























































































Rat-anti-mouse CD93 (AA4.1):  































































2.9 Organs homogenate preparations 
Brain, lung and spleen were collected aseptically in 10 ml tubes.  Whole organs were 
removed from infected mice at specific time points, weighed and homogenised in 1 ml 0.04% 
Tween 80 saline containing protease inhibitor (Lasec, South Africa). Samples were centrifuged 
at 2000 rpm for 4 minutes at 4°C and supernatants were collected. Samples were aliquoted and 
frozen at -80°C until assayed. Reagent preparation is further detailed in appendix F. 
 
 
2.9.1 Cytokines and chemokines measurement  
 
Supernatants from organ homogenates (Brain) were used to measure cytokines and 
chemokines concentrations by sandwich enzyme-linked immunosorbent assay (ELISA). The 
following cytokines and chemokines were measured using the commercially available ELISA 
reagents for cytokines IL-1β, IL-2, IL-6, IL-12p70, TNF and IFN-γ; and chemokines MCP-1, MIP-
1α and RANTES (R&D Systems, Germany) according to the manufacturer’s instructions, using 
a commercially (R&D) available antibodies kits and protocol, in ELISA multiplate reader with 
integrated SoftMax Pro 4.3.1 LS software (Table 2.12 and Table 2.13). Briefly, Nunc-Maxisorp 
96-well microtiter plate (Nalge, Nunc International, Naperville, USA) were coated with 50 μl/well 
of either a cytokine or chemokine capture antibody diluted (0.4 – 4 μg/ml) in coating buffer 




containing 0.02% NaN3 in 1xPBS (pH 7.4) and incubated overnight at room temperature. All 
wells were washed for a total of three times with wash buffer containing 0.05% Tween 20 and 
0.01% NaN3 in 1xPBS. Non-specific binding was blocked with blocking buffer containing 4% 
BSA (bovine serum albumin fraction 5) (Roche, Roche Diagnostics GmbH, Mannheim, 
Germany), 10% of NaN3 in PBS and incubated for a minimum of 1 hour at room temperature. In 
a different 96-well microtiter plate, the appropriate standards were diluted in Two-fold dilution 
series with an initial starting concentration of 250ρg/ml - 4000ρg/ml in dilution buffer (1% BSA in 
1xPBS, pH7.4) (see Tables 2.12 and 2.13 for initial concentrations and sensitivity). Thereafter, a 
volume of 50μl/well of standards and samples were added to the coated 96-well microtiter 
plates respectively and incubated for 2 hours at room temperature. Thereafter, all wells were 
washed as described above, and then 50μl/well of the biotinylated (detection) antibody (0.2-
50μg/ml) dissolved in dilution buffer was added and incubated for 2 hours at room temperature. 
50μl/well of alkaline phosphatase labelled streptavidin diluted (1 in 1000) with dilution buffer 
were added to each well, and incubated for 20 minutes at room temperature. Wells were 
washed again as described above, and 50μl/well of P-Nitrophenol-Phosphate (PNPP) (1mg/ml) 
dissolved in substrate buffer (containing 0.3g NaN3, 97 ml Diethanolamine and 0.8g 
MgCl2.6H2O) were added to each well.  The optimal density of each well was determined within 
30 minutes at 405nm (reference 492nm) using microplate spectrophotometer (Molecular 
Devices, Spectra MAXGemini, California, USA) with SoftMax Pro 4.3.1LS software. Reagent 














IL-1β 4 µg/ml 2000 ρg/ml 400 ng/ml 
IL-2 2 µg/ml 2000 ρg/ml 400 ng/ml 
IL-6 2 µg/ml 1000 ρg/ml 400 ng/ml 
IL-10 2 µg/ml 4000 ρg/ml 200 ng/ml 
IL-12p70 4 µg/ml 2500 ρg/ml 400 ng/ml 
IFN-γ 2 µg/ml 2000 ρg/ml 400 ng/ml 
TNF 0.4 µg/ml 1000 ρg/ml 200 ng/ml 
 
 














CCL2/MCP-1 500 µg/ml 250 ρg/ml 18 µg/µml 
CCL3 /MIP-1α 250 µg/ml 500 ρg/ml 50 µg/ml 




2.10 Statistical analysis 
Data were analysed by comparing of TNFf/f wild type and gene-deficient mice (cell-type 
specific TNF: NsTNF-/-, M-TNF-/- and MT-TNF-/- or global TNF-/- mice) at specific time points, and 
expressed as mean ± SD. All data were analysed using Prism 4 software (GraphPad), where 
the statistical analysis was performed by student t-Test and one-way or two-way analysis of 
variance (ANOVA), followed by Turkey’s test for correction of multiple comparisons for all body 
weights, organ weights, clinical scores, CFU, all absolute cell numbers and activation data. One 
way ANOVA was used to compare three or more groups (time points), while the two way 
ANOVA was used to compares the differences among the mouse strains as function of time. 
For survival studies, statistical analysis was performed using the log-rank test. Data with a value 
of p < 0.05 was considered statistically significant. Each experiment was performed at least 

















        CHAPTER  III 























Neuronal derived tumour necrosis factor is redundant for protective 
immunity against neurotuberculosis 
 
R1.1 Generation of NsTNF-/- mice  by cross breeding 
To generate mice with specific deletion of TNF gene in neurons, we utilised the Cre/loxP 
recombination system and a knockin/transgenic approach. The genotypes of the original Syn1-
Cre mice (lanes 1-4, from the left hand) were confirmed by PCR analysis using IMR1084, 
IMR1085, IMR7338 and IMR7339 which yielded an amplification product of 100bp, to confirm 
the presence of the Cre gene and a 324bp amplification product which represented Syn1-
Crewt/wt wild type allele (Figure 3.1.1A). Neuronal cell type-specific TNF deficient mice were 
generated by mating the Syn1-CreCre/wt mice with the knockin TNFf/f mice. Prior to mating, the 
genotype of TNFf/f mice was confirmed using PCR specific primers, KO41 and KO42 to yield an 
amplification product of 400bp, to confirm the presence of TNF floxed gene (Figure 3.1.1B). The 
wild type C57BL/6J mouse strain is represented by a 350bp amplification product (Figure 
3.1.1B). The mating of Syn1-CreCre/wt mice and TNFf/f mice resulted in a Syn1-CreCre/wt TNFf/wt 
heterozygote mouse strain after verifying by PCR analysis using both TNF flox primers and 
Syn1-Cre primers. We named this strain as NsTNF+/- mice (Figure 3.1.2A). The NsTNF+/- mice 
(lanes 3-5, from the left hand) showed that both WT and flox bands are present when using TNF 
flox primers (Figure 3.1.2A). The results indicate the presence of the WT 350bp band in 
C57BL/6 mice and flox 400bp band in floxed TNFf/f mice. However, genotyping using Syn1-Cre 
primers showed the presence of 324bp band indicative of WT mice and 100bp (Cre gene) band 
in NsTNF+/- mice (lanes 3-5) thus confirming the genotypes of mutant and Cre expression mice 
(Figure 3.1.2B).  
In order to generate the homozygote neuronal cell type-specific TNF mice, we mated the 
above generated NsTNF+/- mice with TNFf/f mice and analysed offspring by tail biopsy analysis 
(Figure 3.1.3). The PCR amplification product in NsTNF-/- mice (lanes 4-6, from the left hand) 
showed that only 400bp flox bands are present when using TNF flox primers (Figure 3.1.3A). 
The results indicate the presence of the WT 350bp band in C57BL/6 mice, and flox 400bp band 
in TNFf/f mice and in NsTNF+/- (Figure 3.1.3A). However, genotyping using Syn1-Cre primers 
showed the presence of 324bp band indicative of WT mice and 100bp (Cre gene) band in the 
control NsTNF+/- and NsTNF-/- mice. Thus, confirming the genotypes of mutant and Cre 














Figure 3.1.1: Genotyping of Syn1-Cre
cre/wt
 mice and TNF
f/f 
mice. PCR analysis was performed using 
genomic DNA extracted from tail biopsies using Syn 1-Cre specific primers IMR1084, IMR1085, IMR7338 
and IMR7339. WT (C57BL/6J) and TNFf/f mice were used as positive controls and water (-) as a negative 
control. An amplification product of 324bp confirmed the presence of the WT gene in C57BL/6J (control 
mice). The presence of the Cre gene in mice (lanes 1 - 4, from the left hand are the original Syn1-Crecre/wt 
mice) yielded an amplification product of 100bp (A). The PCR analysis of DNA extracted from tail biopsies 
of TNFf/f mice using KO41 and KO42 primers yielded an amplification product of 400bp to confirm the 
presence of the TNF floxed gene in TNFf/f mice. The unfloxed gene in C57BL/6J yielded an amplification 









Figure 3.1.2: Genotyping of NsTNF
+/-
 mice. Genotyping of NsTNF+/- mice strain was carried out by PCR 
analysis. WT (C57BL/6J) and TNFf/f mice were used as positive controls and water as a negative control 
(-). The results indicate the presence of the WT 350bp band in C57BL/6J mice and flox 400bp band in 
floxed TNFf/f mice. However, in NsTNF+/-, both WT and flox bands are present when using flox TNF 
primers (Figure 3.1.2A). Genotyping using Syn1-Cre primers showed the 324bp amplification product 
indicative of WT mice and a 100bp (Cre gene) amplification product in heterozygous NsTNF+/- mice, thus 
confirming the genotypes of mutant and Cre expression mice (Figure 3.1.2B). 
 
 
Figure 3.1.3: Genotyping of NsTNF
-/- 
mice. PCR analysis of DNA from tail biopsies was performed 
using a WT (C57BL/6J), TNFf/f and NsTN+/- mice as controls, and water as a negative control (-). The 
results indicate the presence of the WT 350bp amplification product in C57BL/6 mice or NsTNF+/- mice 
(lanes 1, 3, 7 and 9, from the left hand) while TNFf/f or NsTNF-/- mice only expressed the 400bp 
amplification product when using flox primers (Figure 3.1.3A). Genotyping using Syn1-Cre primers 
showed the 324bp amplification product indicative of WT mice, and 100bp amplification product (Cre 






R1.1.1 Genotype confirmation of complete TNF-/- mice  
 
Complete TNF deficient mice used in this study were generated by Cre/loxP 
recombination system (Kuprash et al., 2005). Mice were genotyped for the confirmation of 
complete TNF gene ablation using KO41 and KO49 as primers to yield an amplification product 
of 450bp. However, primers MTNFRTP81 and MTNFRTP82 were used for the amplification of 




Figure 3.1.4: Genotyping of mutant mouse strains was carried out by PCR analysis of DNA from tail 
biopsies using WT (C57BL/6J) and TNFf/f as positive control samples and water as a negative control (- 
lane). The primers KO41, KO49, MTNFRTP81 and MTNFRTP82 were used to confirm the absence of the 
TNF gene in the global TNF-/- mice (450bp amplification product) and the presence of the TNF gene 
(350bp amplification product) in the TNFf/f mice. The unfloxed TNF gene is present in the normal 
C57BL/6J mice.  
 
 
R1.2 Neuronal cells in NsTNF-/- mice do not synthesise TNF  
NsTNF-/- mice were characterised by confirmation of neuronal specific TNF ablation 
using flow cytometry. TNFf/f, NsTNF-/- and TNF-/- mice were stimulated by intracerebral injection 
with 5µg/ml of LPS for 90 minutes. Brain cells were harvested and single cells labelled using 
neurons-specific Beta III Tubulin, PE-conjugated secondary IgG and TNF-specific (TNF-Alexa 
Fluor 647) markers. Studies have reported the expression of TNF in neuron cells in different 
parts of the brain (Liu et al., 1994 and Gahring et al., 1994), however, no study have have 
shown the proportion of neuron expressing TNF in full brain. Our flow cytometric analysis shows 
the expression of TNF in naïve neurons of full brain to be ~8.03% (Appendix I). Flow cytometric 




expression in complete TNF-/- mice, which as expected showed complete abrogation of TNF 
expression (Figure 3.1.5A-B). Complete deletion from neurons was verified by the negative shift 
evident in the histogram overlay (Figure 3.1.5C). 
 
 
                           
Figure 3.1.5: Efficiency of TNF ablation in NsTNF
-/-
 mice following intracerebal stimulation with 
LPS. Representative FACS plots of Beta III Tubulin/IgG-PE versus TNF-Alexa Fluor 647; numbers 
represent the percentage of gated cells (A). Percentage of TNF+ Neuron+ cells are shown as mean ± SD 
of five mice per group, *p < 0.01 (B). A histogram overlay showing the TNF expression in TNFf/f (green), 
NsTNF-/- (blue) and TNF-/- mice (red) following the intracerebral stimulation with 5µg/ml of LPS for 90 
minutes (C). Gates were drawn on unstimulated cells. The data represent one of at least three 






R1.3 Protection of NsTNF-/- mice and clinical course during cerebral M. 
tuberculosis infection 
Previous studies have demonstrated the role of TNF in pulmonary tuberculosis (Flynn et 
al., 1995; Bean et al., 1999; Kaneko et al., 1999; Fremond et al., 2005 and Allie et al., 2008), 
neurotuberculosis (Tsenova et al., 1999; Tobin et al., 2010, Tobin et al., 2012 and El-Kebir et 
al., 2013) as well as in other cerebral infectious diseases (Wollebo et al., 2011 and Kramer et 
al., 2012). In order to define the role of neuronal derived TNF during neurotuberculosis, we 
intracerebrally infected TNFf/f, NsTNF-/- and TNF-/- mice with 1x105 cfu/brain of M. tuberculosis. 
The survival rate of mice was monitored; mice body weights measured, clinical scores recorded 
and organs weights measured.  
Our data showed that TNFf/f mice survived the cerebral M. tuberculosis infection and 
gained weight. The finding is in line with the previous studies in which long term survival in wild 
type mice after CNS M. tuberculosis infection was demonstrated (van Well et al., 2007; Be et 
al., 2008 and Lee et al., 2009).  Complete TNF-/- mice were highly susceptible to cerebral M. 
tuberculosis with an average body weight loss of > 20% and succumbed by day 21. In contrast, 
the newly generated NsTNF-/- mice showed high survival rates and exhibited increasing body 
weights similar to TNFf/f mice (Figure 3.1.6A-B). The postsurgery decreased body weight 
observed between day 1 and day 5 post M. tuberculosis infection is due to surgical intervention, 
as it has been reported (Weiergräber et al., 2005 and Kirby et al., 2012).  
Clinical neurologic manifestations were not induced in the TNFf/f and NsTNF-/- mice, 
whereas, severe clinical neurologic manifestations were prominent (p < 0.01) within 16-21 day 
post-infection in TNF-/- mice. The maximum severity of disease was observed at day 21, where 
animals entered the moribund state (Figure 3.1.7A).  Clinical neurologic outcomes correlated 
favourably with survival data.  
In addition, we measured organ weight as a surrogate marker of inflammation.  Brains, 
lungs and spleens were weighed during the course of the infection. The brain weights in NsTNF-
/- mice were not significantly difference when compared to TNFf/f mice, both TNFf/f and NsTNF-/- 
mice showed significantly higher brain weight at week 3 post-infection when compared to earlier 
time points (Figure 3.1.7B). The brain weights of the TNF-/- mice were significantly lower (p < 
0.01) at week 3 post-infection compared to TNFf/f and NsTNF-/- mice.  No significant differences 
in brain weights were observed in TNF-/- mice when relative comparisons are made to earlier 




The lung weights of the TNF-/- mice were significantly lower (p < 0.05) at week 3 post-
infection compared to TNFf/f and NsTNF-/- mice.  No significant differences in lung weights were 
observed in TNF-/- mice when relative comparisons are made to earlier time points (Figure 
3.1.7C). 
No significant difference in spleen weight was observed at NsTNF-/- mice at all time 
points post-infection compared with TNFf/f mice (Figure 3.1.7D). However, TNF-/- mice showed a 
significant increase (p < 0.05) in spleen weight at week 3 post-infection compared with TNFf/f 
and NsTNF-/- mice (Figure 3.1.7D).  
Study has shown that TNF has four main actions during M. tuberculosis infection (Ray et 
al., 2009). TNF plays a key role in (i) activation of macrophages, affecting their phagocytic and 
killing abilities (Hehlgans et al., 2005 and Saunders et al., 2005); (ii) regulating the recruitment 
of many inflammatory cells (Algood et al., 2004 and Roach et al., 2002); (iii) regulating the 
induction of cytokine and chemokine production (Roach et al., 2002 and Algood et al., 2005); 
and (iv) induction of apoptosis of macrophages and T cells (Keane et al., 1997). Its central role 
appears to be in the generation of a structurally effective granulomatous response. Thus, 
granuloma formation requires the activation of Ag-specific T cells, the accumulation of T cells 
and monocytes at the site of infection, and their local organisation into a mature granuloma that 
limits the infection (Bean et al., 1999). We speculate that the increased brain weight observed in 
TNFf/f and  NsTNF-/-  mice may be associated with the pro-inflammatory response. However, we 
suggest that the clinical manifestations observed in the TNF-/- mice at week 3 post-infection 
could be associated with neuronal death, which may be caused by the increased bacterial 
overgrowth, leading to microglia or macrophages lysis and exudates formation occupying the 
subarachnoid spaces or the ventricular pathways. The thick gelatinous exudates block the 
subarachnoid spaces in the base of the brain (notably the interpeduncular and ambient cisterns) 
resulting in hydrocephalus (Dastur et al., 1995). Recently, the underlying mechanism of 
neurotuberculosis susceptibility in both zebrafish and humans were studied (Tobin et al., 2010, 
2012). In the above mentioned studies, individuals with a specific mutation on both alleles of the 
gene LTA4H develop an anti-inflammatory response with little TNF production, whereas 
individuals having two wild-type alleles have a pro-inflammatory phenotype with abundant TNF 
levels. Both phenomena are detrimental to the host leading to bacterial overgrowth and hyper-
inflammation, respectively. Therefore, the unchanged brain weight observed in TNF-/- mice 
indicate the anti-inflammatory response, despite the high phagocytes and T cells influx into the 




crosstalk with signaling pathways of growth factors or other chemokines and cytokines (Perry et 
al., 2002). 
The no effect seen in lung weight of TNF-/- mice could be associated with the delay 
recruitment of immune cells into the lung. Thus, the increase spleen weight observed in TNF-/- 
mice could be attributed to the uncontrolled inflammation, where the increase in leukocytes 
produced in the spleen engulf bacteria, dead tissue, and foreign matter, trying to remove them 
from the blood as blood passes through it; leading to splenomegaly. From these findings, we 
report the critical importance of the cytokine TNF of the host immune response during 
neurotuberculosis, but concluded that neurons derived TNF does not confer any protection 
against experimental M. tuberculosis infection of the CNS. The data also indicate that neuro-















    
                    

























    
 
               




























Figure 3.1.6:  NsTNF
-/-
 mice do not succumb to CNS M. tuberculosis infection. TNFf/f, NsTNF-/- and 
TNF-/- mice were intracerebraly infected with 1x105 cfu/brain of M. tuberculosis. Percentage survival (n= 
10 mice/group) (A), and changes in body weight (B) were monitored subsequent to infection. Change in 
body weight values are expressed as the mean of 10 mice/group. Data shown are representative of one 










                                                                                            




























                  



















                                                                                                                                            
 
 
                                                                                                                                   
























                                          























                      
         
Figure 3.1.7: Clinical course and controlled inflammation in NsTNF
-/-
 mice during acute CNS M. 
tuberculosis infection. TNFf/f, NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis 
at a dose of 1x105 cfu/brain. For clinical signs, the scoring was recorded after intracerebrally infecting 
TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis for 21 days (A). TNFf/f and NsTNF-/- mice did not 
exhibit overt clinical manifestations, while TNF-/- mice induced more clinical manifestations after day 14 
post-infection. **p < 0.01 for TNF-/- vs TNFf/f and NsTNF-/-. Each data point represents the mean ± SD of 
10 animals per group. Organ weights of mice euthanised at week 0 (naïve), 1, 2 and 3 post-infection (B-
D): brain weights (B), lung weights (C), and spleen weights (D) were assessed. The data represent the 







R1.4 Bacillary replication and dissemination in NsTNF-/- mice during 
neurotuberculosis 
 
The importance of TNF for the control of bacillary replication was assessed by 
comparing pathogen burden in the brains, lungs and spleens of M. tuberculosis infected TNFf/f, 
NsTNF-/- and TNF-/- mice during acute (3 weeks post-infection) and chronic (15 weeks post-
infection) infection (Figure 3.1.8A-F). An overall increase in bacterial burden was observed in 
TNFf/f mice over the 3 weeks infection period. The M. tuberculosis bacterial burden in the brain 
was increased in TNFf/f mice at day 21 post-infection compared to the earlier time points post-
infection (p < 0.001) (Figure 3.1.8A). NsTNF-/- mice had a similar bacterial burden trend to TNFf/f 
mice (Figure 3.1.8A) and no significant differences were observed in bacilli burdens of NsTNF-/- 
mice during either acute (Figure 3.1.8A) or chronic infection (Figure 3.1.8B) compared to TNFf/f 
mice. Similarly TNF-/- mice displayed an increasing bacilli burden over 3 weeks; however, TNF-/- 
mice exhibited a significant increased bacilli burden compared to the TNFf/f mice at week 2 (p < 
0.01), and week 3 (p < 0.001) post-infection (Figure 3.1.8A).  
We next assessed the extent of dissemination of bacilli from the brain by measuring the 
levels of bacilli burden in the lung and spleen. Bacilli dissemination occurred in the TNFf/f mice 
over 15 weeks post M. tuberculosis infection and was in agreement with the previously 
published studies using wild type (C57BL/6) mice (van Well et al., 2007 and Lee et al., 2009). 
The complete TNF-/- mice exhibited a significant increase (2-fold) in mycobacterial burden 
compared to TNFf/f mice at week 1 (p < 0.05), week 2 (p < 0.01), and week 3 (p < 0.01) post-
infection in the lung, and in the spleen at week 1 (p < 0.05), week 2 and week 3 (p < 0.01)  
(Figure 3.1.8C and E).  We observed control of bacilli replication in both lung and spleen of 
TNFf/f mice during chronic infection (Figure 3.1.8D and F). However, NsTNF-/- mice showed 
bacterial burden dissemination similar to the TNFf/f mice in both lung and spleen during acute 
and chronic (Figure 3.1.8C-F) infection.  
Differences in bacterial growth in the brain were confirmed histologically by Ziehl-
Neelsen staining with mycobacteria in NsTNF-/- mice largely localised intracellularly as in TNFf/f 
mice (Figure 3.1.9). The control bacterial growth in NsTNF-/- was therefore controlled at all time 
points post-infection. The significant increase of bacilli burdens seen in the brain of TNF-/- mice 
correlated, visual data obtained for acid fast bacilli, most being located extracellular at  week 2 






                                                                                                                                                           





































   
                                                                                      





































                                                                                       


































mice are resistant to CNS M. tuberculosis infection. TNFf/f, NsTNF-/- and TNF-/- 
mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. The number of viable 
bacteria present in the brains (A), lungs (C) and spleens (E) were assessed at week 1, 2, 3 (acute) and 
15 (chronic) post-infection in brains (B), lungs (D) and spleens (F). The results are expressed as the 
mean ± SD of 5 mice/group. Data is representative of one of three independent experiments. *=p < 0.05, 




Thus, the data demonstrate that complete loss of TNF renders mice susceptible to M. 
tuberculosis infection, and that neuronal derived TNF is not required for control of experimental 
cerebral bacterial growth, and the single neuronal derived TNF ablation resulted in a phenotype 




Figure 3.1.9: Control of M. tuberculosis growth in NsTNF
-/-
 mice. TNFf/f, NsTNF-/- and TNF-/- mice 
were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. The cerebral bacilli burden 
was confirmed by Ziehl-Neelsen staining tissue sections at week 1, 2 and 3 post-infection. The results 
represent one of three similar experiments. Arrows indicate the presence of acid fast bacilli (AFB) (n= 5 




R1.5 Lymphocyte-Rich foci formation is controlled in NsTNF-/- mice during 
neurotuberculosis 
Establishment of tuberculous granulomas is required to control mycobacterial growth 
during pulmonary TB (Saunders et al., 1999). These organised structures are one of the main 
features of the immune response against M. tuberculosis (Miranda et al., 2012).  Rich foci are 
considered as tuberculous granulomas in the brain, mainly contain foamy macrophages, 
surrounded by epithelioid histiocytes, infiltrated lymphoid cells, new blood vessels, and variable 
fibrosis of adjacent parenchyma (Zucchi et al., 2012).  The aim of this study was to therefore 
investigate whether neurons derived TNF signalling induced lymphocyte-rich foci formation. 
NsTNF-/- mice were compared with TNFf/f and TNF-/- mice after intracerebral infection with M. 
tuberculosis at a dose of 1x105 cfu/brain at week 1, 2 and 3 post-infection. NsTNF-/- mice 
controlled the perivascular lymphocytic infiltration like TNFf/f mice at week 2 and 3 post-infection 
(Figure 3.1.10b-f). In NsTNF-/- and TNFf/f mice, perivascular lymphocytic foci were limited to one 
site and there was no widespread inflammatory process (Figure 3.1.10c and f), however the 
TNF-/- mice exhibited exuberant perivascular lymphocytic infiltration at week 3 post-infection 
(Figure 3.1.10i).  
All mice strains presented with meningeal lymphocytic infiltration at week 3 post-infection 
(Figure 3.1.11c, f and i), however meningeal lymphocytic infiltration in TNF-/- mice was 
excessive (Figure 3.1.11i).  
Therefore, these findings suggested that neurons derived TNF has a limited role in 
regulating cellular recruitment to rich foci, in contrast the uncontrolled lymphocytic infiltration 
observed in TNF-/- mice at week 3 post-infection may be attributed to the lack of TNF in immune 








 mice present with low perivascular lymphocytic infiltration foci. Low 
magnification (40x) of cerebral perivascular lymphocytic infiltration foci in TNFf/f, NsTNF-/- and TNF-/- mice 
intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Morphology of 2μm brain 
sections was assessed at week 2 and 3 post-infection after haemotoxylin and eosin staining. Arrows 










Figure 3.1.11: Presence of meningeal lymphocytic infiltration in NsTNF
-/-
. Hematoxylin-eosin–stained 
sections of murine brain of TNFf/f, NsTNF-/- and TNF-/- mice intracerebrally infected with M. tuberculosis at 
a dose of 1x105 cfu/brain. Hematoxylin-eosin–stained sections were assessed at week 1, 2 and 3 post-
infection. Presence of meningeal leukocyte infiltration was evident in TNFf/f, NsTNF-/- and TNF-/- mice at 
week 3 post-infection. The results represent one of three similar experiments. Arrows indicate meningeal 












R1.6  iNOS expression in NsTNF-/- mice after intracerebral infection with M. 
tuberculosis  
MacMicking et al., (1997) have convincingly identified iNOS (iNOS or NOS2) as a 
protective immune mediator during M. tuberculosis infection. We therefore investigated the 
expression of iNOS in the brain tissue of TNFf/f, NsTNF-/- and TNF-/- mice intracerebrally infected 
with M. tuberculosis at a dose of 1x105 cfu/brain (Figure 3.1.12). NsTNF-/- mice displayed a 
similar increase in the expression of iNOS protein in the brain compared to TNFf/f mice at day 21 
post-infection. In contrast, TNF-/- mice failed to produce significant levels of iNOS protein.  
The data therefore showed that, neuronal derived TNF is not required for the regulation 





Figure 3.1.12: Normal iNOS expression in brains of NsTNF
-/-
 mice infected with M. tuberculosis. 
Brains of TNFf/f, NsTNF-/- and TNF-/- mice intracerebrally infected with M. tuberculosis at a dose of 1x105 
cfu/brain were sectioned at 2μm, and iNOS expression detected by immunohistochemistry at week 3 
post-infection. The results represent one out of three similar experiments. (n= 5 mice/group and 









R1.7 TNF dependent recruitment of macrophages and dendritic cells, and 
microglia proliferation in the CNS in response to cerebral M. tuberculosis infection  
To address whether neurons derived TNF regulates the influx and proliferation of 
myeloid cell subsets in response to M. tuberculosis, we analysed recruitment of macrophages, 
dendritic cells and resident microglia over a 3 week period.  TNFf/f, NsTNF-/- and TNF-/- mice 
were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain.  
The CD11b+CD45low (microglia) population in TNFf/f mice increased 2-fold at week 3 
compared to week 1 post-infection (Figure 3.1.13). Similarly, NsTNF-/- mice showed a significant 
(1.48% vs 0.063%; p < 0.05) increase in the proliferation of the microglia population at week 3 
post-infection compared to week 1 post-infection. However, there were no significant differences 
in the percentages of microglia in NsTNF-/- compared to TNFf/f mice at any time point. In TNF-/- 
mice, the microglial proliferation was higher compared to that of either TNFf/f or NsTNF-/- mice at 
2 and 3 weeks points post-infection. We further investigated the cerebral infiltrating 
CD11b+CD45high (macrophages) population and found that macrophages infiltration occurred 
subsequent to neurotuberculosis infection. The infiltration profile which peaked at week 2 was 
similar in TNFf/f and NsTNF-/- mice, while in the TNF-/- mice, the level was approximately 2-fold 
higher compared to TNFf/f mice or NsTNF-/- mice at all time points post-infection (Figure 3.1.13). 
Finally we examined the cerebral infiltrating CD11blowCD45high (dendritic cells) population, where 
we found that DCs recruitment into the CNS occurred almost equally when comparing NsTNF-/- 
with TNFf/f mice at week 1, 2 and 3 post-infection. However, significantly higher DCs infiltration 
was observed in TNF-/- mice compared either to NsTNF-/- or TNFf/f mice (Figure 3.1.13). 
Further, we investigated the kinetic response of CD11b+CD45low, CD11b+CD45high and 
CD11c+CD45high populations in the CNS after M. tuberculosis infection challenge. Initial 
assessment of all three mouse strains showed that naïve mice had an average of 3.4x106 
resident-microglia, while the number of macrophages were 1x103, and DCs 0.8x103 in all adult 
naïve mouse strains. This was in agreement with the previously published data in which the 
number of CD11b+CD45low cells in adult naïve mice was reported to be 3.5x106 (Lawson et al., 
1990), the number of CD11b+CD45high was reported to be 1.1x103 (Foley et al., 2009), and the 
number of CD11c+CD45high cells was reported to be ~1x103 (Karman et al., 2004). All three 
strains demonstrated an equivalent increase in microglial proliferation at 1 week post-infection 
(Figure 3.1.14A). Whereas peak values were reached at 2 weeks post-infection for both TNFf/f 
and NsTNF-/- mice, TNF-/- mice exhibited uncontrolled microglial expansion, which was 




mice, and at week 3 (3.8x107 vs 1x107 and 9x106; p < 0.05) post-infection compared to both 
TNFf/f and NsTNF-/- mice (Figure 3.1.14A). We next evaluated the absolute numbers of recruited 
macrophages and found a 5 and 3-fold increase in TNFf/f mice at week 2 and 3 post-infection, 
respectively compared with earlier week 1 post-infection. Similar increases were observed in 
NsTNF-/- mice at week 2 and 3 post-infection. Interestingly, we found that deletion of TNF in 
neurons resulted in a transient but significant (5x106 vs 3x106; p < 0.05) increase in macrophage 
recruitment at week 2 post-infection (Figure 3.1.14B). However, complete deletion of TNF 
resulted in uncontrolled macrophage recruitment, represented by a significant increase in TNF-/- 
mice compared to TNFf/f mice at week 2 (6x106 vs 3x106; p < 0.05) and 3 (1.5x107 vs 3x106; p < 
0.01) post-infection (Figure 3.1.14B). We thereafter assessed the absolute number of recruited 
DCs, and observed equivalent levels of infiltrating CD11c+CD45high cells in the brain at 2 and 3 
weeks in both TNFf/f and NsTNF-/- mice in response to M. tuberculosis infection (Figure 
3.1.15C). TNF-/- mice, however, had a greater absolute number of recruiting DCs at week 2 
(1.7x106 vs 1x104 and 1.5x104; p < 0.05) and 3 (7.5x107 vs 1x105 and 1.6x104; p < 0.01) post-
infection compared to either TNFf/f or NsTNF-/- mice (Figure 3.1.14C). 
Our results clearly demonstrate that, TNF is required to regulate the influx of infiltrating 
macrophages- and DCs as well as the proliferation of resident microglia population. However, 







Figure 3.1.13: Frequency of antigen presenting cells infiltration during neurotuberculosis. 
Phenotypic analyses of myeloid derived APC isolated from TNFf/f, NsTNF-/- and TNF-/- mice intracerebrally 
infected with M. tuberculosis at a dose of 1x105 cfu/brain. Isolated brain cells were labelled and analysed 
at week 1, 2 and 3 post-infection for the expression of CD11b and CD45 by flow cytometry. Dot plots are 
representative of one of two experiments and show labelling of CD11b+CD45low, CD11b+CD45high, and 
CD11blowCD45high cells. The frequency increase cell infiltration was evident as from week 2 post-infection 
in all populations. The values seen in the dot plot are the percentages of the parent gate which are 









                                                                                             












































              




































                                          
        


































Figure 3.1.14: Kinetic profile of APCs during CNS M. tuberculosis infection: TNFf/f, NsTNF-/- and 
TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at 0 (naïve), 1, 2 and 3 weeks post-infection, and single cells were labelled for APC and 
activation markers. Shown are absolute numbers of CD11b+CD45low cells (A), CD11b+CD45high cells (B), 
and CD11c+CD45high cells (C).  Data are one representative of three independent experiments. The 








R1.7.1 TNF dependent activation of microglia during neurotuberculosis  
 
Different population of APCs are involved during the cerebral immune response, 
including microglia. Previously it was reported that glial activity can potentially be influenced by 
the neuronal response (Hansson & Rönnbäck, 2003). In this study, we investigated the role of 
TNF in general and the specific contribution of neuron derived TNF in the proliferation and 
activation microglia. TNFf/f, NsTNF-/- and TNF-/- mice were challenged with M. tuberculosis 
intracerebral infection at a dose of 1x105 cfu/brain. Whole brain's tissues were harvested at 
week 0 (naïve), 1, 2 and 3 post-infection, and single cells were labelled using lineage 
(CD11b:PerCP-Cy5-5 and CD45:APC), co-stimulatory (CD80:FITC and CD86:V450) and cell 
surface (MHCII (I-A/I-E): PE) marker (Figure 3.1.15).  
We investigated the expression of co-stimulation markers (CD80 or B7-1) and (CD86 or 
B7-2) at week 0 (naïve), 1, 2 and 3 post-infection on microglia. We found that in all mouse 
strains, the CD80 expression on microglia were similar (~10%) at week 1 and 2 post-infection 
(Figure 3.1.15A). CD80+ expressing microglia was significantly (p < 0.01) increased in both 
TNFf/f and NsTNF-/- mice at week 3 post-infection when compared to the earlier time point. In 
contrast, the percentage of CD80+ expressing microglia cells remained altered in TNF-/- mice 
(Figure 3.1.15A) and was significantly (p < 0.01) lower compared to either TNFf/f and NsTNF-/- 
mice. Interestingly, microglia expression of CD86 peaked 1 week after infection, and remained 
constant thereafter being equivalent in all three strains over the experimental period (Figure 
3.1.15C). Microglial MHCII+ expression increased significantly in all three mouse strains at 2 
weeks post-infection and was equivalent, however the percentage of MHCII+ expressing 
microglial cells in TNFf/f and NsTNF-/- mice was maintained at 3 weeks post-infection, but 
decreased in TNF-/- mice and was significant (p < 0.05) lower (Figure 3.1.15E). In addition, we 
measured the MFI of CD80, CD86, and MHCII expression on microglia over 3 weeks. We found 
an escalation in CD80+ MFI in TNFf/f and NsTNF-/- mice with maximum values obtained at 3 
weeks post-infection. Although CD80+ MFI values were equivalent in all three strains over the 
first two weeks, it decreased in TNF-/- mice after 3 weeks post-infection and was significantly (p 
< 0.05) lower when comparing to TNFf/f and NsTNF-/- mice (Figure 3.1.15B). Interestingly CD86+ 
MFI expression remained equivalent for all three mouse strains over the 3 week experimental 
period (Figure 3.1.15D). However, a similar MFI profile was observed for MHCII+ expression, 
however peak values were observed in all mouse strains at 2 weeks post-infection and 
sustained for the 3 week period in both TNFf/f and NsTNF-/- mice (Figure 3.1.15F). In contrast, 




0.05) lower compared to either TNFf/f and NsTNF-/- mice. 
These data suggest that TNF is required for the control of microglial activation; however 
the neuronal TNF is not required.   
 
 
R1.7.2 Defective response to antigen by macrophages in TNF-/- but not NsTNF-/- 
mice during experimental neurotuberculosis  
 
To investigate the overall effect of TNF and in particular neuronal derived TNF on 
macrophage activation during neurotuberculosis, we intracerebrally infected TNFf/f, NsTNF-/- and 
TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. At week 0 (naïve), 1, 2 and 3 post-
infection, brains were harvested and isolated single cells were labelled for expression of lineage 
(CD11b:PerCP-Cy5-5 and CD45:APC), co-stimulatory (CD80:FITC and CD86:V450) and cell 
surface (MHCII (I-A/I-E):PE) markers (Figure 3.1.16).  
We noted an equivalent kinetic increase in CD80+ expression in macrophages over the 
first 2 weeks in TNFf/f, NsTNF-/- and TNF-/- mice. The number of CD80+ macrophages was 
sustained at 3 weeks post-infection in NsTNF-/- and TNFf/f mice, the percentage of macrophage 
cells expressing CD80+ were significantly (p < 0.05) reduced in TNF-/- mice at week 3 post-
infection when compared with TNFf/f and NsTNF-/- mice (Figure 3.1.16A). All mouse strains 
exhibited similar levels of macrophage cells expressing the CD86+ marker at week 1, 2 and 3 
post-infection with no difference among strains, although a decreasing trend was observed in 
TNF-/- at week 3 post-infection compared to TNFf/f and NsTNF-/- mice (Figure 3.1.16C). The 
kinetic profile of MHCII+ expressing macrophages generally approximated that observed for 
CD80+ expressing macrophages. TNFf/f, NsTNF-/- and TNF-/- mice displayed an escalation in 
MHCII+ macrophages over the first 2 weeks, which was maintained at 3 weeks post-infection in 
TNFf/f and NsTNF-/- mice. In contrast, the number of MHCII+ expressing macrophages in TNF-/- 
mice was significant (p < 0.05) decreased when compared to either TNFf/f or NsTNF-/- mice 
(Figure 3.1.16E). In addition, we measured the MFI of CD80+, CD86+ and MHCII+ expression on 
macrophages over 3 weeks. We found an equivalent kinetic increase in MFI of CD80+ 
expressing macrophages in all mouse strains over the first two weeks, it decreased in TNF-/- 
mice after 3 weeks post-infection and was significantly lower compared to TNFf/f and NsTNF-/- 
mice where MFI levels were sustained (Figure 3.1.16B). Interestingly, the MFI of CD86+ 
expressing macrophages remained increased and equivalent for TNFf/f, NsTNF-/- and TNF-/- mice 




MHCII+ expression in macrophages at week 1 post-infection, however peak values were 
observed in all mouse strains at 2 weeks post-infection and sustained for the 3 week 
experimental period in both TNFf/f and NsTNF-/- mice. In contrast, the MFI of MHCII+ expressing 
macrophages in TNF-/- mice was significantly (p < 0.05) lower compared to either turn-off/f and 
NsTNF-/- mice (Figure 3.1.16F). 
Our findings indicate that TNF is required to maintain activation of CD80+ and MHCII+ 
expressing macrophages during CNS M. tuberculosis infection. However, neurons derived TNF 





























                                                                       
  


























                                  























     
                                                                       























                                   

























    
                                                                                                                                      
























                                   




















Figure 3.1.15: TNF dependent microglial activation during CNS M. tuberculosis infection. TNFf/f, 
NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
Whole brain tissues were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were 
labelled for specific APC surface markers. From the CD11b+CD45low population were gated for 
percentage of cells expressing CD11b+CD45lowCD80+ (A), CD11b+CD45lowCD86+ (C) and 
CD11b+CD45lowMHCII+ (E) surface markers. Changes in MFIs values of CD80+, CD86+ and MHCII+ 
expressing microglia are shown in B, D and F, respectively. *=p < 0.05 and **=p < 0.01. Data are one 




                                                                             
 


































                     




























                                                                                        























                                       























         
                                                                                                                                                                                           



























                                            



























Figure 3.1.16: Defective response to antigen by macrophages in TNF
-/-
 but not NsTNF
-/-
 mice. 
TNFf/f, NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 
cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were 
labelled for APC and activation. CD11b+CD45highCD80+ (A), CD11b+CD45highCD86+ (C), and 
CD11b+CD45highMHCII+ (E) population were determined. MFI values of CD80+, CD86+ and MHCII+ 
expressing macrophages are shown in B, D and F, respectively. *=p < 0.05. Data are one representative 




R1.7.3 TNF mediates response to antigen in dendritic cells during 
neurotuberculosis  
 
We then investigated whether TNF in general and in particular neuronal derived TNF 
play a critical role in the activation of the DCs population. TNFf/f, NsTNF-/- and TNF-/- mice were 
intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were harvested 
at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were labelled for expression of 
lineage (CD11b:PerCP-Cy5-5, CD11c:Alexa 700 and CD45:APC), co-stimulatory (CD80:FITC 
and CD86:V450) and cell surface (MHCII (I-A/I-E):PE) markers (Figure 3.1.17).  
We found 10% of the DC population in all mouse strains expressed the CD80+ marker at 
week 1 post-infection but decreased to 5% at week 2 post-infection and were equivalent in all 
mouse strains (Figure 3.1.18A). The CD80+ expression in NsTNF-/- mice, then significantly 
increased from 5% to 8% in the DCs comparable to TNFf/f mice at week 3 post-infection. In 
contrast, a continuous significant decrease (3±0.1 vs 8±05 and 8±0.4; p < 0.05) in CD80+ 
expression was observed in the TNF-/- mice compared to TNFf/f and NsTNF-/- mice (Figure 
3.1.18A). Interestingly, DCs expression of CD86+ peaked over the 2 week period after M. 
tuberculosis infection in all mouse strains, and the equivalent continuous increase was found in 
TNFf/f and NsTNF-/- mice at week 3 post-infection. In contrast, the percentage of CD86+ in TNF-/- 
mice was significantly decreased (68±0.2 vs 80±01 and 80±0.2; p < 0.05) at week 3 post-
infection (Figure 3.1.18C). DCs MHCII+ expression increased significantly in all three mouse 
strains over 2 weeks post-infection period and was equivalent. However, where the percentage 
of MHCII+ expressing DCs was continuously increased at 3 weeks post-infection in both NsTNF-
/- and TNFf/f mice, it decreased in TNF-/- mice and was significantly lower (10±00 vs 32±07 and 
30±08; p < 0.05) (Figure 3.1.18E).  
Further, we measured the MFI of CD80+, CD86+ and MHCII+ expressing DCs over 3 
weeks. We observed that the MFI of CD80+ expressing DCs peaked at week 1, and similarly 
decreased at week 2 post M. tuberculosis infection in all three mouse strains; however a 
continuous decrease was found in TNF-/- mice which were significantly lower (250±20 vs 
400±30 and 450±45; p < 0.05) compared to TNFf/f and NsTNF-/- mice at week 3 post-infection 
(Figure 3.1.18B). Interestingly the MFI of CD86+ expressing DCs remained increased and 
equivalent to TNFf/f, NsTNF-/- and TNF-/- mice over the 3 week experimental period. A similar 
DCs MFI profile was observed for MHCII+ expression at week 1, however peak values were 
observed at 2 weeks post-infection in all mouse strains and continuously increased for the 3 




expressing DCs was significantly lower (230±20 vs 550±25 and 575±30 p < 0.05) in TNF-/- mice 
compared to both TNFf/f and NsTNF-/- mice (Figure 3.1.18F). 
Our results indicate that TNF is required for the recruitment of CD80+, CD86+ and 
MHCII+ DCs and regulates surface expression of co-stimulatory and antigen presentation 
markers during neurotuberculosis. However, neuronal derived TNF do not play a critical role in 

































                                                                       




























                          





























                                                                       
  



























                                       






















                                                                                                   
                                                                       





























                                           































Figure 3.1.17: TNF mediates surface markers expression in DC population. TNFf/f, NsTNF-/- and 
TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection, and isolated single cells were labelled for APC and 
surface markers. From the CD11c+CD45high population were gated for percentage of cells expressing 
CD11c+CD45highCD80+ (A), CD11c+CD45highCD86+ (C), and CD11c+CD45highMHCII+ (E) surface markers 
at week 0 (naïve), 1, 2 and 3 post-infection. Changes in MFIs values of CD80+, CD86+ and MHCII+ 
expressing DCs are shown in B, D and F, respectively. Data are one representative of three independent 




R1.8 Infiltrating B-cell mediated immunity during neurotuberculosis  
R1.8.1 TNF dependent recruitment of follicular B cells during neurotuberculosis  
 
B cells enter the CNS as part of normal immune surveillance and also in the pathologic 
state (Alter et al., 2003). B cells capture antigens via cell-surface receptors, thereafter activation 
is initiated. B cells aggregate into lymphoid follicle-like structures in the target organ (Franciotta 
et al., 2008). Previous studies have reported the presence of follicle-like B cells aggregates in 
the lungs of TB patients (Ulrichs et al., 2004; Tsai et al., 2006 and Maglione & Chan, 2009), and 
of ectopic B-cell follicles in the meninges of patients with multiple sclerosis (Serafi et al., 2004). 
The presence of pulmonary follicle-like B cells aggregates in TB patients suggests that B cells 
mediate immunity. B cells were also shown to contribute to host protection against pulmonary 
TB infection, and are believed to shape anti-tuberculous immune responses through various 
mechanisms such as antibody secretion and cytokine production (Maglione et al., 2007 and 
Maglione & Chan, 2009). These include direct effects of antibody upon the pathogen, antigen-
presentation, cytokine production, and influencing intracellular killing mechanisms of leukocytes 
(Maglione & Chan, 2009). The role of the follicular B cells (Fo B cells) subset in host immune 
response against CNS M. tuberculosis infection has not yet been well defined, although a few 
studies have documented its role during pulmonary tuberculosis (Sousa et al., 2000; Ulrichs et 
al., 2004; Tsai et al., 2006 and Maglione & Chan, 2009). Activated Fo B cells responding to T 
cell-dependent antigens can also respond rapidly, forming short-lived IgM-secreting B cells 
(Owens et al., 2006). We asked whether, complete ablation of TNF in general and particularly in 
neurons influences the infiltration of Fo B cells into the CNS during neurotuberculosis. Mice 
were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection from TNFf/f, NsTNF-/- and TNF-/- mice and 
single cells were labelled with specific B-cell markers (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5 
and B200:Horizon V500). We observed no significant difference in the absolute number of 
infiltrating Fo B cells population in NsTNF-/- mice compared to TNFf/f mice at all time points post 
M. tuberculosis infection. However, the absolute number of infiltrating Fo B cells in TNF-/- mice 
were significantly (p < 0.05) higher at week 1, 2 and 3 points post-infection compared to the 
TNFf/f or NsTNF-/- mice (Figure 3.1.18). 
These findings suggest that the ablation of TNF in neurons does not affect the influx of 
Fo B cells into the CNS. The increased infiltrating level of Fo B cells found in TNF-/- mice 




required to control follicular B-cell infiltration into the CNS during neurotuberculosis. 
                                    












































Figure 3.1.18: Fo B cells infiltrating cell number during neurotuberculosis. TNFf/f, NsTNF-/- and TNF-
/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells labelled and analysed using the 
BD LSRFortessa flow cytometer analyzer. In order to identify Fo B cells population, isolated single brain 
cells were labelled with CD1d:PE-A, CD93(AA4.1):PerCP-Cy5-5-A and B220:V500-A markers. *=p <0.05, 




R1.8.1.1 TNF is essential for follicular B cell immunity during neurotuberculosis  
 
TNFf/f, NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a 
dose of 1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and 
single cells were labelled with specific B cells (CD1d:PE, AA4.1:PerCP-Cy5-5 and 
B200:HorizonV500), co-stimulatory (CD86:V450) and surface (IgM:PE-Cy7, and MHCII:Alexa 
700) markers. Preliminary studies have shown variability in CD86 but not CD80 surface 
expression, and therefore CD86 was included in the analysis. Little is known about the 
involvement of plasmablast during neurotuberculosis, we then hypothesis that if plasmablast 
play a role during neurotuberculosis, the antibody IgM may be altered in TNF deficient mice. 
We investigated whether the ablation of TNF in the neurons affected the regulation of 
co-stimulatory markers. We found that the Fo B cells population in NsTNF-/- mice had similar 
percentage and MFI of CD86+ expressing Fo B-cell at all time points post-infection compared to 




marker in the Fo B-cell population in TNF-/- mice were significantly higher week 1 (p < 0.05), and 
lower (p < 0.05) at week 3 post-infection when compared either to TNFf/f or NsTNF-/- mice 
(Figure 3.1.19A and B). We further evaluated the role of neuronal derived TNF in the secretion 
of IgM. We observed a significant (25±0.3 and 20±0.5 vs 10±0.3; p < 0.05) escalating IgM 
secretion in TNFf/f and NsTNF-/- mice over the 3 weeks post-infection period. Although TNF-/- 
mice displayed lower IgM synthesis over the first 2 weeks post-infection, antibody product was 
not sustained and IgM concentration was significantly lower at week 3 post-infection compared 
to TNFf/f and NsTNF-/- mice (Figure 3.1.19C). The IgM percentage expression pattern correlated 
with IgM MFI values (Figure 3.1.19D). To examine the pattern expression of MHCII+ in the Fo B 
cells population, comparative analysis between TNFf/f mice, NsTNF-/- and TNF-/- mice was 
performed. We found that the percentage and MFI of MHCII+ expressing Fo B cells in TNFf/f and 
NsTNF-/- mice were similar, and peaked at week 1 post-infection. On the contrary, the increase 
in the percentage and MFI of TNF-/- mice cells expressing MHCII+ were delayed at week 1 post-
infection, and only peaked at week 2 post-infection, and subsequently decreased at week 3 
post-infection as opposed to being maintained as was evident in TNFf/f and NsTNF-/- mice 
(Figure 3.1.19E and F). 
Although TNF is essential for Fo B-cell immunity during experiment neurotuberculosis, 
our findings once again demonstrate that ablation of TNF in neurons does not affect the pattern 


















                                                                    





































                  































                                                                   
 

























                                  



























                                                                                                                                             

























                                


























          
Figure 3.1.19: TNF mediates Fo B cells surface marker expression. TNFf/f, NsTNF-/-, and TNF-/- mice 
strains were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection, and isolated single cells were labelled for 
CD1d:PE-A, CD93(AA4.1):PerCP-Cy5-5-A and B220:V500-A with surface markers CD86, IgM and 
MHCII. The CD1dlowB220+AA4.1- population were gated for percentage of cells expressing 
CD1dlowB220+AA4.1-CD86+ (A), CD1dlowB220+AA4.1-IgM+ (C) and for the CD1dlowB220+AA4.1-MHCII+ 
(E). MFI values of CD86+, IgM+ and MHCII+ are shown in B, D and F, respectively. *=p <0.05 and **=p < 
0.01. Data are one representative of three independent experiments. Results are represented as mean ± 




           R1.8.2 Plasmablast and plasma cell infiltration during neurotuberculosis 
 
Extrafollicular plasmablasts growth imparts the first antibodies to be secreted after 
exposure to antigen; B cells differentiate into plasmablasts approximately a day after cognate 
interaction with T cells (Toellner et al., 1996 and Luther et al., 1997) or activation by a T cell-
independent antigen (García de Vinuesa et al., 1999). Plasmablasts in extrafollicular responses 
divide rapidly for around 3 days before differentiating further into antibody producing plasma 
cells (Sze et al, 2000). To analyse the infiltrating CD1dhighB220highD138- (plasmablast cells) and 
B220lowD138+ (plasma cells) populations into the CNS during neurotuberculosis, we infected 
TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested at week 0 (naïve), 1, 2 and 3 post-infection and single cells were labelled with specific 
B-cell (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5-A, CD138:APC and B200:Horizon V500) markers. 
Figure 3.1.20A shows the gating strategy used to identify the plasmablast and plasma cell 
populations.  
There was no significant difference in the absolute numbers of the infiltrating 
plasmablast cells in NsTNF-/- mice compared with the TNFf/f mice at all time points post-
infection. The absolute number of the infiltrating plasmablast cells in TNF-/- mice showed no 
significant difference at week 1 post-infection compared to TNFf/f and NsTNF-/- mice. However, a 
significant (p < 0.05) increase was observed in TNF-/- mice at week 2 post-infection compared to 
TNFf/f and NsTNF-/- mice, but was significantly reduced (p < 0.001) at week 3 post-infection 
compared to either TNFf/f or NsTNF-/- mice (Figure 3.1.20A). We next examined the absolute the 
number of plasma cell at week 1, 2 and 3 post-infection. The absolute number of the plasma cell 
in TNFf/f mice was 2-log higher at week 3 post-infection compared to week 1 post-infection. A 
similar trend was observed in NsTNF-/- mice. In this population, we found no significant 
difference in the absolute numbers of infiltrating plasma cells in NsTNF-/- mice compared with 
the TNFf/f mice at all time points post-infection. In contrast, at week 1 and 2 post-infection, the 
absolute number of the infiltrating plasma cells in TNF-/- mice were significantly (p < 0.001 ) 
increased compared to TNFf/f or NsTNF-/- mice. However, a significant (p < 0.001) decrease was 
seen at week 3 post-infection when comparing to TNFf/f or NsTNF-/- mice (Figure 3.1.20B).    
These data demonstrate that ablation of TNF in neurons was not critical for the influx of 







                                                                                                                                                                                   
                              







































          
 
                             
                              


































Figure 3.1.20: Plasmablast and plasma cell and their absolute numbers. Brains were harvested at 
week 0 (naïve), 1, 2 and 3 post-infection, and cells isolated from naïve and the intracerebrally infected 
TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Isolated single cells 
were labelled with CD1d:PE-A, AA4.1:PerCP-Cy5-5-A, CD138:APC-A and CD45R/B220:V500-A. Data 
shows the absolute numbers of CD1dhighB220highCD138- cells (A) and B220lowCD138+ cells (B).  *=p < 
0.05, **=p < 0.01 and ***=p < 0.001.  Data are one representative of three independent experiments. 












R1.8.2.1 TNF influences plasmablast cellular activation patterns during 
neurotuberculosis  
 
We evaluated the surface expression of co-stimulatory (CD86:V450) molecules, 
antibody (IgM:PE-Cy7I) secretion and antigen presenting (MHCII:Alexa 700) markers by multi-
colour flow cytometric analysis of an infiltrating plasmablast population. TNFf/f, NsTNF-/- and 
TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains 
were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were labelled and 
analysed for CD86+, IgM+ and MHCII+ expression. Preliminary studies have shown variability in 
CD86 but not CD80 surface expression, and therefore CD86 was included in the analysis. Little 
is known about the involvement of plasmablasts during neurotuberculosis. However, IgM 
antibody to heparin-binding hemagglutinin was shown to play a role in protection against 
extrapulmonary TB dissemination (Shin et al., 2006). We hypothesised that if plasmablasts play 
a role during neurotuberculosis, the antibody IgM may be altered in TNF deficient mice. 
When examining the percentage expression and MFI of co-stimulatory molecules, we 
found that the percentage of infiltrating plasmablast cells expressing CD86+ was significantly 
increased in all mouse strains at week 1 and 2 post-infection. However, the percentage and MFI 
of plasmablast cells expressing CD86+ in TNFf/f and NsTNF-/- mice were maintained to the same 
level at week 3 post-infection. In contrast, the percentage and MFI of CD86+ expressing 
plasmablast cells was drastic reduced (p < 0.001) at week 3 post-infection in TNF-/- mice 
compared to TNFf/f and NsTNF-/- mice  (Figure 3.1.21A and B). 
We then examined the percentage and MFI of the infiltrating plasmablast population, 
which secreted the IgM antibody. Equivalent recruitment of plasmablast cells expressing IgM+ 
was observed at week 1 and 2 post-infection in all mouse strains. However, the percentage of 
IgM+ secreting plasmablast population was significant (p < 0.01) increased in TNFf/f and NsTNF-
/- mice at week 3 post-infection. In contrast, IgM production level was significant (p < 0.01) 
decreased at week 3 post-infection in TNF-/- mice compared to TNFf/f or NsTNF-/- mice (Figure 
3.1.21C and D). Next, we examined whether the ablation of TNF in general or in neurons in 
particular affected the ability to present antigen in the plasmablast population. We found no 
significant difference, in the percentage, or MFI of MHCII+ expressing plasmablast cells at week 
1 post-infection in all mouse strains. However, a significant (p < 0.05) increase was observed in 
MHCII+ expressing plasmablast cells of the TNF-/- mice compared to TNFf/f and NsTNF-/- mice at 
week 2 post-infection. At week 3 post-infection, the percentage and MFI of MHCII+ expressing 
plasmablast population in NsTNF-/- mice was similar to that of the TNFf/f mice. However, the 




significantly (p < 0.01) decreased when comparing either to TNFf/f or NsTNF-/- mice (Figure 
3.1.21E and F). 
These data demonstrate that complete ablation of TNF is critical, but the ablation of TNF 
in the neurons was not critical for the activation of the plasmablast population.  
 
 
R1.8.2.2 TNF mediates plasma cell antibody secretion during neurotuberculosis 
 
Plasma cells can develop from naïve marginal zone B-cell, follicular B- cell and memory 
B cells. After encountering foreign antigen, marginal zone B cells are the first to differentiate, 
forming short-lived plasma cells that provide a rapid IgM response skewed towards T cell-
independent antigens (Owens et al., 2006). Antibody secreting cells comprise of both terminally 
differentiated plasma cells as well as their plasmablasts precursors, and are integral to both the 
primary and secondary humoral immune response against pathogens (Marques et al., 2011). 
To evaluate the surface expression of co-stimulatory molecules, antibody secretion and 
antigen presenting cell markers in the plasma cells, TNFf/f, NsTNF-/- and TNF-/- mice were 
intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were harvested 
at 0 (naïve), 1, 2 and 3 weeks post-infection, and isolated single cells were labelled and 
analysed. We found that the percentage of plasma cells expressing CD86+ were increased in all 
mouse strains at week 1 and 3 post-infection. At week 2, the percentage of plasma cells 
expressing CD86 in TNF-/- mice showed a significant (p < 0.05) decrease compared to TNFf/f or 
NsTNF-/- mice (Figure 3.1.22A). No significant differences were seen in all mice strains and time 
point when analysing the MFI of CD86 (Figure 3.1.22B). We next asked whether the complete 
ablation of TNF in general and in neurons in particular influenced the antibody secretion. There 
was an increase in the percentage and MFI of plasma cells expressing IgM+ in all mouse strains 
at week 1 and 2 post-infection. However, while the percentage and MFI in this population was 
maintained in TNFf/f and NsTNF-/- mice at week 3 post-infection, there was a significant (p < 
0.05) decrease in this cell population in TNF-/- mice at this time point (Figure 3.1.22C and D). 
We examined whether the ablation of TNF in general or in neurons in particular affected the 
ability to present antigen in the plasma cell population. We found no significant difference, in 
MHCII+ expressing plasma cells in all mice strains at all time points post M. tuberculosis 
infection (Figure 3.1.22E).  
The data suggested that ablation of TNF in the neurons does not alter the plasma cell 




                                                                             
 


































                     




































                                                                           


























                                   


























                                                                                                                                                                                     































                                      
































Figure 3.1.21: TNF mediates plasmablasts surface marker activation pattern during 
neurotuberculosis. TNFf/f, NsTNF-/- and TNF-/- mice were intracerebrally infected at with M. tuberculosis 
at a dose of 1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and 
single cells were labelled for CD1d, AA4.1, CD138 and B220 with surface markers CD86, IgM and MHCII. 
The CD1dhighB220highD138- population was gated for cells expressing CD1dhighB220highCD138-CD86+ (A), 
CD1dhighB220highCD138-IgM+ (C) and CD1dhighB220highCD138-MHCII+ (D).  The bar graphs show the MFI 
values for CD86+ (B), IgM+ (D) and MHCII+ (F). *=p < 0.05, **=p < 0.01 and ***=p < 0.001. Data are one 




                                                                       
 


































                                       
































                                                                                                               
























                                    

























                                                    


























Figure 3.1.22: TNF mediates plasma cell antibody production. TNFf/f, NsTNF-/- and TNF-/- mice were 
intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were harvested at week 0 
(naïve), 1, 2 and 3 post-infection, and single cells were labelled for CD1d, AA4.1, CD138 and B220, with 
surface markers CD86, IgM and MHCII. The B220lowD138- population was gated for plasma cells 
expressing CD86+ (A), IgM+ (B) and MHCII+ (C). *=p < 0.05 for TNFf/f and NsTNF-/- vs TNF-/-. The bar 
graphs show the MFI values for CD86+ (B) and IgM+ (D). Data are one representative of three 




R1.9 TNF mediates infiltration of effectors CD4+ and CD8+ T cells into the CNS  
Several reports have demonstrated the interaction between neurons and T cells, and the 
direct immune-regulatory role of neurons on T cells (Liu et al., 2006; Kioussis & Pachnis, 2009 
and Meuth et al., 2009). We therefore asked whether complete ablation TNF in general and in 
neurons in particular would have an effect on CD4+- and CD8+ T cells. We intracerebrally 
infected TNFf/f, NsTNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Brain 
tissues at week 0 (naïve), 1, 2 and 3 post-infection were harvested, and single cells were 
labelled for analysis of CD4+- and CD8+ T cell populations by flow cytometry.  
We observed that the frequency of effector CD4+ T cell in TNFf/f mice was 10-fold higher 
at week 2, and 30-fold higher at week 3 post-infection compared to week 1 post-infection. 
Similar trends were also observed in TNF-/- and NsTNF-/- mice (Figure 3.1.23). Recruited CD4+ T 
cells in NsTNF-/- mice were similar to TNFf/f mice at week 1 post-infection, in contrast to TNF-/- 
mice, which already displayed 2-fold increase compared to TNFf/f or NsTNF-/- mice. We 
observed an equivalent increase in the frequency of inflammatory CD4+ T cells in both TNFf/f or 
NsTNF-/- mice over the next weeks. However, uncontrolled CD4+ lymphocytic inflammation was 
observed in TNF-/- mice, eventually being 3-fold higher compared to TNFf/f or NsTNF-/- mice 
(Figure 3.1.23). We next examined the frequency of CD8+ T cells in the CNS during 
neurotuberculosis. CD8+ T cells increased 2-fold at week 2 and 3 post-infection in all mouse 
strains compared to week 1. Similar to CD4+ T cells, recruitment of CD8+ T cells to the CNS was 
controlled in the absence of neuron specific TNF, but displayed an exacerbated influx of CD8+ T 
cells in the absence of complete TNF (Figure 3.1.24). We next evaluated the absolute number 
of recruiting lymphocyte T cells to the CNS subsequent to infection. There was no significant 
differences in the absolute number of CD3+CD4+ cells or in CD3+CD8+ cells in NsTNF-/- mice at 
all time points post-infection compared to TNFf/f mice. However, significant (p < 0.05) increase 
was seen at week 1, 2 and 3 post-infection in CD4 T cell subset population as well as at week 1, 
2 and 3 post-infection in CD8 T cell subset population were noted in TNF-/- mice compared to 
TNFf/f or NsTNF-/- mice (Figure 3.1.25A and B).  
Overall the data demonstrated that the TNF derived from neurons is not required for 
controlling the T cell influx into the CNS, however, TNF in general regulates recruitment of CD4+ 






Figure 3.1.23: Frequency of effector CD4
+
 T cells influx into the CNS during neurotuberculosis. 
TNFf/f, NsTNF-/- and TNF-/- mice were intracerebrally infected with M tuberculosis at a dose of 1x105 
cfu/brain. CD4+ T cells analysis was performed at 1, 2 and 3 weeks post-infection where brain tissues 
were harvested, and isolated single cells were labelled for expression CD3 and CD4. The values seen in 
the dot plot are the percentages of the parent gate which are positive. Representative data from one of 







Figure 3.1.24: Frequency of CD8
+
 T cells influx into the CNS during neurotuberculosis. TNFf/f, 
NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
CD8+ T cells analysis was done at 1, 2 and 3 weeks post-infection where brain tissues were harvested, 
and isolated single cells were labelled for CD3 and CD8 expression. The values seen in the dot plot are 
the percentages of the parent gate which are positive. Representative data from one of the three 











                                                                                                     
  








































                













































T cells recruitment during CNS M. tuberculosis 
infection. TNFf/f, NsTNF-/- and TNF-/- mice strains were intracerebrally infected with M. tuberculosis at a 
dose of 1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single 
cells were labelled for CD3 and CD4 or CD8, with activation markers CD44. Shown are CD4+ T cells 
(CD3+CD4+) absolute numbers (A), and also shown are CD8+ T cells (CD3+CD8+) absolute numbers (B). 
*=p < 0.05 and **=p < 0.01. Data (mean ± SD) are representative of at least three independent 




R1.9.1 Activation of cerebral infiltrating effectors CD4+ and CD8+ T cells during 
neurotuberculosis  
 
We further examined the effect of TNF and particularly neuronal derived TNF on the 
level of CD44 expression in CD4+ and CD8+ T cells. We observed no significant differences in 
NsTNF-/- mice effectors CD4+CD44+ cells at all time point post-infection compared to TNFf/f 
mice. Similarly, CD44+ expressing CD8+ cells of NsTNF-/- mice were not significantly different 
compared to TNFf/f mice at any of the time points post-infection (Figure 3.1.26A and B). In 
contrast, the percentage of CD4+ T cells expressing CD44+ were signed (5.5±0.5 vs 1.5±0.5 and 
1.6±00; p < 0.05) higher in TNF-/- mice at week 3 post-infection (Figure 3.1.26A). While CD8+ T 
cells expressing CD44+ were significant increased (1.5±00 vs 0.2±00 and 0.5±00 at week 2, and 
2.2±0.4 vs 0.2±00 and 0.4±01 at week 3; p < 0.05 ) at both week 2 and week 3 post-infection 
compared to TNFf/f or NsTNF-/- mice (Figure 3.1.26B). 
Therefore, while TNF plays an important role in the activation of T cells recruited to the 






                                                                                     
 
       






















                             





















    




T cells during CNS M. tuberculosis infection. 
TNFf/f, NsTNF-/- and TNF-/- mice strains were intracerebrally infected with M. tuberculosis at a dose of 
1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection and, single cells were 
labelled for CD3 and CD4 or CD8, together with the activation markers CD44. The CD3+CD4+ population 
was gated to determine the percentage of cells expressing CD4+CD44+ (A), the CD3+CD8+ population 
were then gated to determine the percentage of cells expressing CD8+CD44+ (B). Data (mean ± SD) are 
representative of at least three independent experiments that yielded similar results (n= 5 mice/group). 




R1.10 Cytokine secretions in NsTNF-/- mice are not compromised following 
cerebral M. tuberculosis infection 
The role of cytokines during pulmonary tuberculosis infection has been documented 
(Flesch & Kaufmann, 1993; Sharma & Bose, 2001 and Cooper & Khader, 2008). However, 
there is insufficient information on gene expression and regulation during neurotuberculosis. 
Thus, we selected genes expressed preferentially by neurons, microglia/macrophages or T 
cells. Several studies have demonstrated the secretion of TNF, IFN-γ, IL-1β, IL-2, IL-6 and IL-
12p70 by infiltrating leukocytes and resident cells of the CNS, including neurons (Saliba & 
Henrot, 2001; Taoufik et al., 2001; Sredni-Kenigsbuch, 2002; Kadhim et al., 2003; Kawanokuchi 
et al., 2006; Miyatake et al., 2006; Jiao et al., 2008 and Xin et al., 2011). We therefore assessed 
whether complete ablation of TNF in general and in neurons, in particular, influences cerebral 




Cytokine concentrations were measured in the supernatants of whole brain homogenates at 
week 0 (naïve), 1, 2 and 3 post M. tuberculosis infection by ELISA. All mouse strains displayed 
cytokine induction subsequent to M. tuberculosis challenge in all three mouse strains. Although 
there was a trend towards a decrease in TNF concentration in NsTNF-/- mice compared to the 
TNFf/f mice, this was not significant. As expected, no TNF production was detected in TNF-/- 
mice at any of post-infection time points (Figure 3.1.27A). We next examined total cerebral IFN-
γ production in response to M. tuberculosis infection. Interestingly, we observed peak 
concentrations early during infection (1 week post-infection) in TNFf/f and NsTNF-/- mice, while it 
decreased progressively during the course of infection with no significant differences present 
between TNFf/f and NsTNF-/- mice. In contrast, escalating IFN-γ concentrations were measured 
over 3 weeks in TNF-/- mice, which was significantly higher at week 2 (p < 0.05) and week 3 (p < 
0.001) post-infection compared to TNFf/f and NsTNF-/- mice (Figure 3.1.27B). Maximum and 
equivalent induction of IL-1β was observed in TNFf/f and NsTNF-/- mice during early infection 
(week 1) and decreased thereafter. Interestingly, although TNF-/- mice induced IL-1β in 
response to M. tuberculosis infection, cerebral concentrations similarly peaked at week 1 post-
infection, but never attained equivalent levels and remained significantly (p < 0.05) lower at 
each of the time points investigated (Figure 3.1.27C). 
Total cerebral IL-2 production was similar at week 1 post-infection when comparing 
TNFf/f with NsTNF-/- mice, and progressively increased at a similar rate during week 2 and 3 
post-infection. The levels of total cerebral IL-2 production in TNF-/- mice were significantly (p < 
0.001) lower and delayed at week 1, and also lower at week 3 post-infection respectively, when 
compared to TNFf/f or NsTNF-/- mice. And no significant difference was observed in all mice 
strains at week 2 post-infection (Figure 3.1.27D). Maximum induction of cerebral IL-6 was 
measured at week 1 post-infection in TNFf/f and NsTNF-/- mice and decreased 2-fold thereafter. 
Interestingly, neuronal TNF deficiency presented with significantly (p < 0.05) reduced IL-6 
concentrations at week 1 post-infection. Synthesis of IL-6 was delayed in the complete absence 
of TNF with significant (p < 0.01) lower concentrations measured in TNF-/- mice compared to 
TNFf/f and NsTNF-/- mice. TNF dependent regulation of IL-6 synthesis was evident as mice 
completely deficient in TNF displayed uncontrolled escalating concentrations at weeks 2 and 3 
post-infection, which was significantly (p < 0.01) higher at week 2 and 3 post-infection compared 
to immune competent and neuron TNF deficient mice (Figure 3.1.27E). Examination of the total 
cerebral IL-12p70 production, found no significant difference in TNFf/f and NsTNF-/- mice at week 
1, 2 and 3 post-infection. In contrast, the total cerebral IL-12p70 production in the TNF-/- mice 




The data thus show that ablation of TNF derived from neuron cells did not affect the 
overall production of cerebral cytokines. However, TNF had a definitive regulatory effect on 
cytokine synthesis, where it displayed roles for both induction and inhibitory control.  
 
R1.11 TNF mediates chemokines production during CNS M. tuberculosis infection 
Multiple CC chemokines are involved in leukocyte recruitment (Lukacs et al., 1997; 
Hesselgesse & Horuk, 1999; Babcock et al., 2003 and Locati et al., 2005). Trafficking of 
peripheral myeloids and lymphoid cells to the inflamed CNS has been attributed to specific 
chemokines (Ransohoff, 2009) which are highly expressed by CNS resident neuronal and glial 
cells (Glabinski et al., 1995; Godiska et al., 1995; Berman et al., 1996; McManus et al., 1998; 
Simpson et al., 1998; Xia et al., 1998; Sorensen et al., 1999; Van Der Voorn et al., 1999; 
Simpson et al., 2000; Che et al., 2001; Flügel et al., 2001; Sorensen et al., 2002; Babcock & 
Owens, 2003 and de Haas et al., 2007). To date, little is known about chemokines production 
during CNS M. tuberculosis infection. Here we investigated the major β-chemokines such as 
MCP-1 (CCL2), MIP-1α (CCL3) and RANTES (CCL5) produced in response to M. tuberculosis 
infection at week 1, 2 and 3 post-infection. MCP-1 is a potent β-chemokine mainly acting on 
monocytes and macrophages (Jiang et al., 1992). Other important β-chemokines are MIP-1α 
and RANTES that induces the activation and proliferation of T cells (Taub et al., 1996) and 
macrophages (Fahey et al., 1992 and Lima et al., 1997), and also MIP-1α is involved in the 
promotion of Th1 cell differentiation (Karpus & Kennedy, 1997 and Karpus et al., 1997). 
The level of MCP-1 in TNFf/f mice was 2-fold higher at week 3 post-infection compared to 
week 1. Similar trends were noticed in NsTNF-/- and TNF-/- mice at week 1 post-infection. No 
significant difference was observed in MCP-1 secretion in the brain of NsTNF-/- mice compared 
to TNFf/f mice at all time points post-infection. The level of MCP-1 in TNF-/- mice was significantly 
(p < 0.001) higher at week 1, 2 and 3 post-infection compared either with TNFf/f or TNF-/- mice 
(Figure 3.1.28A). Assessment of MIP-1α, found 2-fold higher levels at week 3 post-infection 
compared to week 1 in TNFf/f and NsTNF-/- mice. In contrast, a 5-fold increase was noted in 
MIP-1α levels of TNF-/- mice at week 3 post-infection compared to week 1 post-infection. In 
addition, no significant differences in MIP-1α levels were observed at any time points when 
comparing NsTNF-/- to TNFf/f mice (Figure 3.1.28B). However, the level expression of MIP-1α in 
TNF-/- mice were significantly (p < 0.01) higher at week 2 and 3 post-infection when compared 




1 post-infection (Figure 3.1.28B). The level of RANTES in TNFf/f and NsTNF-/- mice was 2-fold 
higher at week 3 post-infection compared to week 1. In contrast, 2- and 3-fold increases were 
noted in TNF-/- mice at week 2 and 3 post-infection respectively, when compared to week 1 post-
infection. We found no significant difference at week 1 post-infection in all mouse groups, and 
no significant difference was observed at week 2 and 3 post-infection when comparing NsTNF-/- 
versus TNFf/f mice. The level of RANTES in TNF-/- mice was significantly (p < 0.01) increased at 
week 2 and 3 post-infection compared to TNFf/f or NsTNF-/- mice (Figure 3.1.28C). 
The deletion of TNF in neuron cells has no effect on the control and immunoregulation of 
MCP-1, MIP-1α and RANTES after experimental CNS infection with M. tuberculosis. However, 
the data convincingly demonstrate TNF dependent control of each of chemokines in the host 


























                                                                                             
 































               






















                                                                                                                                             























                      























                                                
 
                                                                           


























                    




























Figure 3.1.27: Relative expression of total cerebral cytokines during neurotuberculosis. TNFf/f, 
NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain at 
week 1, 2 and 3. Cytokine concentrations were measured at week 0 (naïve), 1, 2 and 3 weeks post-
infection, where the brains of mice were homogenised and TNF (A), IFN-γ (B), IL-1β (C), IL-2 (D), IL-6 (E) 
and IL-12p70 (F) levels were measured in the supernatants by ELISA. Data are representative of at least 
three independent experiments that yielded similar results. Results are mean ± SD of 5 mice/group. *=p < 





                                                                              























































                                              






























Figure 3.1.28: TNF regulates cerebral chemokines production during neurotuberculosis. TNFf/f, 
NsTNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
Chemokines concentration was measured at 1, 2 and 3 weeks post-infection, where the brains of infected 
mice were homogenised and MCP-1 (A), MIP-1α (B) and RANTES (C) levels were assessed in the 
supernatants by ELISA. Data are representative of at least three independent experiments that yielded 




R1.12 General summary  
Taken together, our data suggest that neuronal derived TNF has very limited protection 
against cerebral M. tuberculosis infection. Thus, the resistance to cerebral M. tuberculosis 
infection observed in this mouse strain may be due to compensation from other TNF cellular 
sources such as myeloid TNF derived cell, or to the lack of redundancy of other cytokines such 
as lymphotoxin, which may signal through both TNFR1 and TNFR2 like TNF but cannot 
compensate for TNF. Data also show that complete ablation of TNF is detrimental to host 




The role of microglia-macrophages, neutrophils and T cell subsets 
derived TNF in protective immunity against neurotuberculosis 
 
R2.1 Confirmation of M-TNF-/- and MT-TNF-/- mice genotype by PCR analysis 
To investigate the role of myeloid derived TNF during neurotuberculosis, we used cell-
type specific microglia/macrophages and neutrophils TNF knockout (M-TNF-/-), TNF floxed 
(TNFf/f) and global TNF knockout (TNF-/-) mice. The genotypes of TNFf/f and TNF-/- mice were 
confirmed as described in sections R1.1 and R1.1.1, respectively, (Figure 3.1.1B and Figure 
3.1.4). M-TNF-/- mice were genotyped for the, presence of the Cre gene directed under the Mlys 
Cre promoter in the Mlys1 locus by using Mlys1, Mlys2 and Cre8 primers. The 700bp (primers 
Cre8 and Mlys1) amplification product confirmed the presence of the Cre transgene (lanes 3-6, 
from the left hand) as seen in Figure 3.2.1A. Mlys Cre transgene is constitutively expressed in 
cells of myeloid origin (Park et al., 2002 and Greten et al., 2004) including microglia (Perry et al., 
1985; Zucker-Franklin et al., 1987; Hao et al., 1991; Cho et al., 2008; Solodova et al., 2011 and 
Kallfass et al., 2012). Amplification using primers Mlys1 and Mlys2 yielded the WT allele, 
represented by a 350bp amplification product (lanes 1-8) as shown in Figure 3.2.1A. To confirm 
the presence of the floxed TNF gene, specific flox primers (KO41 and KO42), yielded a 400bp 
amplification product (Figure 3.2.1B: lanes 2-7, from the left hand). The unfloxed TNF gene in 
C57BL/6J mice (lanes 1 and 8) is represented by a 350bp gene product. Thus, all M-TNF-/- mice 
used in this study were confirmed as being of the genotype TNFf/fMlysCre/wt.  
Next, we confirmed the genotype of MT-TNF-/- mice. The Cre gene in the Mlys1 locus 
was identified using primers Mlys1, Mlys2 and Cre8 represented by a 700bp (primers Cre8 and 
Mlys1) amplification product (Figure 3.2.2A: lanes 2-6). The WT allele is represented by an 
amplification product of 350bp (Figure 3.2.2A: lanes 1-6, from the left hand). We also confirmed 
the presence of the Cre gene under control of the CD4 promoter using CD4Cre1, CD4Cre2 and 
CD4Cre3 primers. The Cre gene was confirmed by PCR analysis using primers CD4Cre1 and 
CD4Cre2 which resulted in a 242bp amplification product (Figure 3.2.2B: lanes 2-6), while 
amplification using primers CD4Cre1 and CD4Cre3 generated the 350bp WT allelic 
amplification product (Figure 3.2.2B: lanes 1-6, from the left hand). We further confirmed the 
presence of the TNF gene with two flanking loxP sequences using the flox specific primers 
(KO41 and KO42) represented by a 400bp amplification product (lanes 2-7, from the left hand), 




350 amplification product (Figure 3.2.2C). 
MT-TNF-/- mice used in this study were confirmed as being of the genotype 





                
 
Figure 3.2.1: Genotyping of M-TNF
-/-
 mice. PCR analysis was performed using genomic DNA extracted 
from tail biopsies using Mlys Cre specific primers Mlys 1, Mlys 2 and Cre8 (A). WT (C57BL/6J) and TNFf/f 
mice were used as positive controls and water as a negative control (-).  The presence of the Cre gene in 
M-TNF-/- mice (lanes 3-6, from the left hand) yielded an amplification product of 700bp (primers Cre8 and 
Mlys 1) (A). An amplification product of 350bp (primers Mlys 1 and Mlys2) confirmed the presence of TNF 
gene in the WT mice indicative of C57BL/6J mice. We further used the flox specific primers (KO41 and 
KO42) to confirm the presence of the TNF gene with two flanking loxP sequences, confirming the TNF 













                            
Figure 3.2.2: Genotyping of MT-TNF
-/- 
mice. PCR analysis was performed using genomic DNA 
extracted from tail biopsies using Mlys Cre specific primers: Mlys1, Mlys 2 and Cre8. WT (C57BL/6J) and 
TNFf/f mice were used as positive controls and water as a negative control (-). Amplification product of 
350bp (primers Mlys1 and Mlys2) confirmed the presence TNF gene in WT control C57BL/6J mice, 
however the presence of the Cre gene (lanes 2-5 from the lef hand) yielded an amplification product of 
700bp (primers Cre8 and Mlys1) (A). The same DNA sample was subsequently analysed for the 
presence of CD4 Cre expression using CD4 Cre specific primers: CD4Cre1, CD4Cre2 and CD4Cre3. An 
amplification product of 350bp (primers CD4Cre1 and CD4Cre3) confirmed the presence TNF gene in the 
WT control mice indicative of C57BL/6J background. However, the presence of the Cre gene (lanes 2-5, 
from the left hand) yielded an amplification product of 242bp (primers CD4Cre1 and CD4Cre2) (B). When 
using the flox specific primers (KO41 and KO42), the presence of TNF gene with two flanking loxP 
sequences was confirmed, TNF floxed gene yielded 400bp (lanes 2-7, from the left hand), while the 
unfloxed TNF gene in C57BL/6J mice is represented by a 350bp amplification product as seen in lanes 1 




R2.2 MT-TNF-/- mice but not M-TNF-/- are highly susceptible and induced clinical 
neurologic manifestations during experimental CNS M. tuberculosis infection 
To investigate the cellular origin of protective TNF in experimental neurotuberculosis, we 
intracerebrally infected TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice with 1x105 cfu/brain of M. 
tuberculosis. The survival rate of mice was monitored; body weights and organ weights 




Our data showed that M-TNF-/- mice survived experimental cerebral M. tuberculosis 
infection and subsequently gained weight together with the TNFf/f mice (Figure 3.2.3A-B). In 
contrast, we found that the MT-TNF-/- mice succumbed to experimental cerebral M. tuberculosis 
infection by 21 days post-infection similar to global TNF-/- mice. We also found that the MT-TNF-
/- mice dramatically lost > 20% of their body weight by day 21 post-infection similar to TNF-/- 
mice (Figure 3.2.3A-B).  
As previously reported, no clinical manifestations were induced in TNFf/f mice, and also 
no overt clinical neurologic manifestations were induced in the M-TNF-/- mice (Figure 3.2.4A). In 
contrast, the MT-TNF-/- mice induced severe clinical manifestations (p < 0.01) comparable to 
TNF-/- mice within 16-21 days post-infection (Figure 3.2.4A). The maximum severity of disease 
was observed at day 20, where animals entered moribund state. The severity of the clinical 
neurologic manifestations correlated with tuberculosis susceptibility. 
In addition, we measured organ weights of brains, lungs and spleens during the course 
of the infection. The brain weights in M-TNF-/- mice showed no significant difference when 
compared to TNFf/f mice, both TNFf/f and M-TNF-/- mice showed significantly higher brain weight 
at week 3 post-infection when compared to earlier time points (Figure 3.2.4B). The brain 
weights of the MT-TNF-/- mice was similar to TNF-/- mice and significantly lower (p < 0.01) at 
week 3 post-infection compared to TNFf/f and M-TNF-/- mice.  No significant differences in brain 
weights were observed in either MT-TNF-/- mice or TNF-/- mice when relative comparisons are 
made  to earlier time points (Figure 3.2.4B).  
Lung weights of all mouse strains showed no significant difference at week 1 and 2 post 
M. tuberculosis infection. Similarly, no significant difference was observed in M-TNF-/- mice at 
week 3 post-infection when compared to TNFf/f mice. The lung weights of the MT-TNF-/- mice 
was similar to TNF-/- mice and significantly lower (p < 0.05) at week 3 post-infection compared to 
TNFf/f and M-TNF-/- mice.  No significant differences in lung weights were observed in either MT-
TNF-/- mice or TNF-/- mice when relative comparisons are made  to earlier time points (Figure 
3.2.4C). 
We found no significant difference in spleen weight of M-TNF-/- mice at all time points 
post-infection when compared with TNFf/f mice (Figure 3.2.4D). On the contrary, MT-TNF-/- mice 
showed significant (p < 0.05) increase in spleen weight similar to the TNF-/- mice at week 3 post-
infection when compared with TNFf/f (Figure 3.2.4D). We have previously found that CD4/CD8-
TNF-/- mice (T-TNF-/-) are not susceptible to experimental cerebral M. tuberculosis infection 
(unpublished data).  




the control of cerebral M. tuberculosis infection. Data also suggest strongly that T cell-derived 
TNF in the M-TNF-/- mice is responsible for controlling cerebral TB infection.  
 
 
                  
                     
























                  
                   





























Figure 3.2.3:  MT-TNF
-/-
 mice succumbed to experimental CNS M. tuberculosis infection. TNFf/f, M-
TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with 1x105 cfu/brain of M. tuberculosis. The 
percentage of survival (A) and changes in body weight (B) were monitored for 105 days subsequent to 
infection. Data shown are representative of one of three independent experiments. Results are expressed 







                                                                                                  




































                          



















       
  
 
                                          
                                                                                  
 























                                             






















                                           
 
Figure 3.2.4: Clinical state deterioration and increase inflammation in MT-TNF
-/-
 mice during acute 
CNS M. tuberculosis infection. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected 
with M. tuberculosis at a dose of 1x105 cfu/brain. Clinical neurologic manifestations after intracerebral 
infection were scored and recorded during 21 days (A). #=p < 0.01 for MT-TNF-/- or TNF-/- vs M-TNF-/- 
mice. Each data point represents the mean ± SD of 10 animals per group. Organ weights (B-D): Mice 
were euthanised at week 0 (naïve), 1, 2 and 3 post-infection, brain weights (B), lung weights (C) and 
spleen weights (D) were measured. Data presented here are one of three independent experiments, and 








R2.3 Uncontrolled M. tuberculosis replication in MT-TNF-/- but not in M-TNF-/- mice 
during neurotuberculosis 
To assess the importance of TNF in the control of bacilli replication, we compared 
pathogen burden in the brains, lungs and spleens of M. tuberculosis infected TNFf/f, M-TNF-/-, 
MT-TNF-/- and TNF-/- mice (Figure 3.2.5A-F). Our data showed that the M. tuberculosis bacterial 
burden in the brain was increased in TNFf/f and M-TNF-/- mice over 3 weeks period compared to 
the earlier post-infection time point (Figure 3.2.5A). No significant differences were observed in 
cerebral bacilli burdens of M-TNF-/- mice during either acute or chronic infection compared to 
TNFf/f mice (Figure 3.2.5A and B). MT-TNF-/- and TNF-/- mice exhibited similar significant 
increases in bacilli burdens compared to TNFf/f and M-TNF-/- mice at week 2 (p < 0.01), and 
week 3 (p < 0.001) post-infection (Figure 3.2.5A). We next assessed the extent of dissemination 
of bacilli from the brain by measuring the levels of bacilli burden in the lung and spleen. M-TNF-/- 
mice showed mycobacterial dissemination similar to the TNFf/f mice in both lungs (Figure 
3.2.5C) and spleen (Figure 3.2.5E) during acute infection. We observed a significant (p < 0.05) 
increase in the pulmonary bacilli burden in M-TNF-/- mice during chronic infection compared to 
TNFf/f mice (Figure 3.2.5D). No significant difference was seen between M-TNF-/- and TNFf/f 
splenic bacilli burden during chronic infection (Figure 3.2.5F). MT-TNF-/- and complete TNF-/- 
mice exhibited significant (p < 0.01) increases in mycobacterial dissemination at week 1, 2 and 
3 post-infection in the lung, and at week 2 and 3 (p < 0.01) post-infection in the spleen when 

















                                                                          
 









































     
                                                                                                  










































                                                                          



































 mice are susceptible to CNS M. tuberculosis infection. TNFf/f, M-TNF-/-, MT-
TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. The 
number of viable bacteria present in the brains (A), lungs (B) and spleens (C) was assessed at week 1, 2, 
3 (acute) and 15 (chronic) post-infection. Data is representative of one of three independent experiments. 
Results are expressed as the mean ± SD of 5 mice/group. *=p < 0.05, **=p < 0.01 and ***=p < 0.001. #=p 





Differences in bacterial growth in the brain were confirmed histologically by Ziehl-
Neelsen staining with mycobacteria in M-TNF-/- mice largely localized intracellularly as in TNFf/f 
mice (Figure 3.2.6). The bacterial growth in M-TNF-/- was therefore controlled at all time points 
post-infection. The significant increase of bacilli burdens seen in the brains of MT-TNF-/- mice 
and  in TNF-/- mice correlated with the significantly higher presence of acid fast bacilli, being 
mostly extracellular, at week 2 and 3 post-infection (Figure 3.2.6).  
Thus, these data demonstrate that deletion of T cells derived TNF in M-TNF-/- mice  
renders mice highly susceptible to the infection and that myeloid derived TNF alone is 





Figure 3.2.6: Uncontrolled M. tuberculosis growth in MT-TNF
-/-
 mice. TNFf/f, M-TNF-/-, MT-TNF-/- and 
TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. The cerebral 
bacilli burden was confirmed by Ziehl-Neelsen staining at week 1, 2 and 3 post-infection. The results 





R2.4 Increase of perivascular lymphocyte-rich foci formation in MT-TNF-/- mice 
during neurotuberculosis 
Tuberculomas, also referred to as rich foci are the major characteristic of 
neurotuberculosis (Rich & Mc Cordock, 1933). Rich foci formation starts by the recruitment of 
infiltrating immune cells. Epithelioid cells, giant cells, macrophages, microglia, neutrophils, 
CD4+- and CD8+ T cells are the major constituents of the tuberculoma structure (Miranda et al., 
2012). We assessed whether microglia/macrophages, neutrophils and T cell subset-derived 
TNF signalling induced a lymphocyte-rich inflammatory foci formation (Figure 3.2.7). M-TNF-/- 
and  the MT-TNF-/- mice were compared with TNFf/f and TNF-/- mice after intracerebral infection 
with M. tuberculosis at a dose of 1x105 cfu per brain at week 1, 2 and 3 post-infection. Presence 
of perivascular lymphocytic infiltration in M-TNF-/- mice were evident, but controlled similar to 
that in TNFf/f mice at week 2 and 3 post-infection (Figure 3.2.7b-f). On the contrary, MT-TNF-/- 
mice exhibited exuberant perivascular lymphocytic infiltration similar to TNF-/- mice at week 3 
post-infection (Figure 3.2.7i and l). 
Furthermore, we examined the presence of meningeal lymphocytic infiltration in M-TNF-/- 
and MT-TNF-/- mice compared with TNFf/f and TNF-/- mice.  All mice strains presented meningeal 
lymphocytic infiltration at week 3 post-infection (Figure 3.2.8c, f, i and l), however meningeal 
lymphocytic infiltration was more prominent in MT-TNF-/- than in TNFf/f mice, but in MT-TNF-/- 




















Figure 3.2.7: Increase of perivascular lymphocytic infiltration rich foci in MT-TNF
-/-
 mice. Cerebral 
lymphocytic infiltration rich foci in TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice intracerebrally infected with 
M. tuberculosis at a dose of 1x105 cfu/brain. Morphology of 2μm brain sections was assessed at week 2 
and 3 post-infection after haemotoxylin and eosin staining. Arrows indicate lymphocytic infiltration foci 




















Figure 3.2.8: Exuberant meningeal lymphocytic infiltration in MT-TNF
-/-
. Hematoxylin-eosin-stained 
section of murine brain of TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice intracerebrally infected with M. 
tuberculosis at a dose of 1x105 cfu/brain and analysed at week 1, 2 and 3 post-infection. The results (n= 5 
mice/group) represent one of three similar experiments. Arrows indicate meningeal lymphocytic 











R2.5 Decreased expression of iNOS in MT-TNF-/- mice after CNS M. tuberculosis 
infection  
We asked whether microglia/macrophages, neutrophils, CD4+- and CD8+ T cells-derived 
TNF regulate the expression of iNOS in the brain of  TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice 
intracerebrally infected with M. tuberculosis, at a dose of 1x105 cfu/brain (Figure 3.2.9). The 
iNOS expression pattern in M-TNF-/- mice were similar to TNFf/f mice, and largely distributed 
within the confinement of leukocytes infiltrating rich foci at week 3 post-infection. In contrast, 
both MT-TNF-/- and TNF-/- mice had a lower iNOS expression pattern, dispersed and associated 
with the diffused leukocytes infiltrating rich foci when compared either to TNFf/f or M-TNF-/- mice 
(Figure 3.2.9).  
Our data show microglia/macrophages and neutrophils derived TNF is not required in 
the regulation of iNOS expression. This could be the result of compensation from T cell-derived 
TNF. Data also demonstrate that the ablation of T cells derived TNF in M-TNF-/- mice alter the 
iNOS induction during cerebral M. tuberculosis infection and present a phenotype similarly to 
complete TNF deficient mice. Therefore, the results obtained confirm a critical role of T cell-




Figure 3.2.9: Decreased expression of iNOS in the brain of MT-TNF
-/-
 mice. TNFf/f, M-TNF-/-, MT-TNF-
/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain and brain 
tissue sectioned at 2μm; for analysis of iNOS expression at week 3 post-infection. Data (n= 5 mice/group) 








R2.6 Increased recruitment of myeloid derived cells in MT-TNF-/- mice but not M-
TNF-/- mice during CNS M. tuberculosis infection 
To address whether microglia/macrophages and neutrophils, CD4+- and CD8+ T cells-
derived TNF regulates cellular influx and proliferation in response to cerebral M. tuberculosis 
infection, we analysed macrophages, dendritic cells and resident microglia over a 3 week 
period. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. 
tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues were harvested at week 0 (naïve) 
1, 2 and 3 post-infection, and single cells were generated. Single cells were labelled with 
specific markers (CD11b:PerCP-Cy5-5, CD11c:Alexa 700 and CD45:APC)  and flow cytometric 
analysis was used to identify the different cell populations.  
The CD11b+CD45low (microglia) population in TNFf/f mice increased to 2-fold at week 3 
compared to week 1 post-infection (Figure 3.2.10). Similarly, M-TNF-/- mice showed a significant 
(p < 0.05) increase in the proliferation of the microglia population at week 3 post-infection 
compared to week 1 post-infection. However, the microglia population in the M-TNF-/- mice 
increased to 2-fold at week 1 post-infection compared to TNFf/f, MT-TNF-/- or TNF-/- mice. In MT-
TNF-/- mice, the microglia population was significantly (p < 0.05) increased similar to TNF-/- mice 
at week 3 compared to week 1 post-infection. We also found a 2-fold increase in the microglia 
population of MT-TNF-/- mice at week 2 and 3 post-infection compared either to TNFf/f or M-TNF-
/- mice.  No significant difference was observed between MT-TNF-/- and TNF-/- mice at all time 
points (Figure 3.2.10). We further investigated the cerebral infiltrating CD11b+CD45high 
(macrophages) population, and we found that macrophage population infiltration occurred 
subsequent to neurotuberculosis infection. In M-TNF-/- mice, we found approximately 2-fold 
increase at week 3 post-infection compared to week 1 post-infection. In addition, a 2-fold 
increase was observed in M-TNF-/- mice at week 3 post-infection compared to TNFf/f mice, and 
no significant difference was observed at earlier time points (Figure 3.2.10). We next assessed 
the macrophage population in MT-TNF-/- mice and found that the percentage influx of infiltrating 
macrophage population was increased in both MT-TNF-/- and TNF-/- mice to 4-fold at week 1, 6-
fold at week 2, and 10-fold at week 3 post-infection compared to TNFf/f mice (Figure 3.2.10). In 
addition, a 2-fold increase was also noticed in both MT-TNF-/- and TNF-/- mice at week 2 and 3 
post-infection when comparing with M-TNF-/- mice (Figure 3.2.10). We last examined the 
cerebral infiltrating CD11blowCD45high (dendritic cells) population. In the dendritic cells population 
kinetic, we found a 30-fold increase in TNFf/f mice and 60-fold increase in M-TNF-/- mice at week 




population infiltrated almost equally into the CNS when comparing M-TNF-/- with TNFf/f mice at 
week 1 post-infection. However, a 3-fold increase was observed in M-TNF-/- at week 2 and 3 
post-infection compared to TNFf/f mice (Figure 3.2.10). In contrast, the DCs population in MT-
TNF-/- mice showed 100-fold higher numbers at week 3 post-infection compared to week 1 post-
infection. A similar trend was also seen in TNF-/- mice. We also observed an increase infiltrating 
DCs population in both MT-TNF-/- and TNF-/- mice to 2-fold at week 1, 4-fold at week 2, and 
almost 6-fold at week 3 post-infection when comparing with TNFf/f mice (Figure 3.2.10). 
 We thereafter investigated the absolute numbers of microglia, macrophages and 
dendritic cell population. Assessing the microglia absolute number, we found similar levels of 
absolute cell numbers in all the naïve mouse strains as in previous result section. No significant 
differences in absolute numbers were observed in all mouse strains at week 1 and 2 post-
infection (Figure 3.2.11A). However, the microglia cells in both MT-TNF-/- and TNF-/- mice were 
significantly (p < 0.05) increased at week 3 post-infection when compared to TNFf/f mice (Figure 
3.2.11A). No significant difference was observed between M-TNF-/- and MT-TNF-/- or TNF-/- 
mice.  
We found 5- and 6-fold increases in the infiltrating macrophage population in TNFf/f mice 
at week 2 and 3 post-infection, respectively when compared to week 1 post-infection. Similar 
increases were observed in M-TNF-/-, MT-TNF-/- and TNF-/- mice at week 2 and 3 post-infection. 
We also found that deletion of TNF in the microglia/macrophages and neutrophils resulted in a 
significant (p < 0.05) increase in the macrophage population of M-TNF-/- mice only at week 3 
post-infection when compared with TNFf/f mice (Figure 3.2.11B). Also, a significant (p < 0.01) 
increasein the macrophage population was observed in the MT-TNF-/- and TNF-/- mice compared 
to TNFf/f mice at week 2 and 3 post-infection (Figure 3.2.11B). No significant difference was 
observed between M-TNF-/- and MT-TNF-/- mice or TNF-/- mice. 
Approximately 3- to 4-fold increase of DCs population into the brain was observed at 
week 2 and 3 post-infection in all mouse strains compared to week 1 post-infection (Figure 
3.2.12C). No significant differences in the absolute numbers of the DC population of M-TNF-/- 
mice were observed at all time points post-infection compared to TNFf/f mice. TNF-/- mice had a 
greater (p < 0.05) absolute number of the DC population at week 2 post-infection compared to 
TNFf/f mice. Remarkably, both MT-TNF-/- and TNF-/- mice had significant (p < 0.01) increase in 
absolute numbers at week 3 post-infection compared to TNFf/f mice (Figure 3.2.11C). We did not 
find any significant difference when comparing M-TNF-/- with either MT-TNF-/- or TNF-/- mice. 
Our results clearly demonstrate that TNF derived from microglia/macrophages and 




proliferation of the microglia population. We speculated here that the protection observed in M-
TNF-/- mice may result from the compensation of T cell or other non-imunne cell-type derived 
TNF. Also, data revealed that the deletion of TNF from T cells in the M-TNF-/- mice increases 
the influx infiltration of myeloid cell subsets during cerebral M. tuberculosis infection and argues 

























Figure 3.2.10: Increased myeloid APCs infiltration and proliferation in cell-type specific mice 
during neurotuberculosis. Phenotypic analyses of myeloid derived APC isolated from TNFf/f, M-TNF-/-, 
MT-TNF-/- and TNF-/- mice intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains 
were harvested at week 1, 2 and 3 post-infection, and isolated brain cells were labelled and analysed for 
the expression of CD11b and CD45 by flow cytometry. The values seen in the dot plot are the 
percentages of the parent gate which are positive. Dot plots are representative of one of two experiments 
and show staining of respective CD11b+CD45low, CD11b+CD45high and CD11blowCD45high cells. Data are 













                                                                                  
 
















































                

















































                                            
     






































Figure 3.2.11: Increased cerebral absolute cell numbers in MT-TNF
-/- 
mice. TNFf/f, M-TNF-/-, MT-TNF-
/- and TNF-/- mice were intracerebrally infected at a different time points with M. tuberculosis at a dose of 
1x105 cfu/brain. Whole brain tissues were harvested at week 0 (naïve) 1, 2 and 3 post-infection, and 
isolated single cells were labelled for APC and activation markers. Shown are absolute numbers of 
CD11b+CD45low cells (A), CD11b+CD45high cells (B) and CD11c+CD45high cells (C). Data (n= 5 mice/group) 









R2.6.1 Decreased antigen presentation by microglia of MT-TNF-/- mice during CNS 
M. tuberculosis infection 
 
We investigated the role of TNF derived from microglia/macrophages, neutrophils, and 
CD4+ and CD8+ cells by activating microglia after intracerebrally infecting TNFf/f, M-TNF-/-, MT-
TNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues 
were harvested at week 0 naïve, 1, 2 and 3 post-infection, and generated single cells were 
labelled using lineage (CD11b:PerCP-Cy5-5 and CD45:APC), co-stimulatory (CD80: FITC and 
CD86: V450) and antigen presenting cell marker (MHCII (I-A/I-E): PE) as seen in Figure 3.2.12. 
We found that in all mouse strains, the microglia population expressed a similar 
percentage (~10%) of the CD80 marker at week 1 and 2 post-infection. However, in M-TNF-/- 
mice, a significant (p < 0.01) increase was equivalent to TNFf/f mice, which was observed at 
week 3 post-infection when compared to MT-TNF-/- and TNF-/- mice, whereby the MT-TNF-/- and 
TNF-/- mice maintained their percentage of CD80+ expressing microglia cells (Figure 3.2.12A). 
MFI activation of CD80+ was comparable to the percentage expression of CD80 marker (Figure 
3.2.12B). 
Similar up-regulation of CD86+ expressing microglia cells were found in all mouse strains 
at week 1, 2 and 3 post M. tuberculosis infection (Figure 3.2.12C). However, trend decrease 
was seen in MT-TNF-/- and TNF-/- mice at week 3 post-infection compared to TNFf/f and M-TNF-/- 
mice. Also, we found that MFI activation of CD80+ expressing microglia cells was comparable to 
the percentage expression of CD80 marker (Figure 3.2.12D).  
Examining the MHCII expression, we found similar percentage and MFI expression in all 
mouse strains at week 1 and 2 post-infection. The percentage of MHCII+ expressing microglia 
cells was maintained the same in TNFf/f and M-TNF-/- mice at week 3 post-infection. 
Interestingly, the percentage of microglia cells expressing MHCII+ were significant (p < 0.05) 
lower in MT-TNF-/- mice comparable to TNF-/- mice at week 3 post-infection compared to TNFf/f 
and M-TNF-/- mice (Figure 3.2.12E and F).  
The data suggest that although TNF is required for the control of microglia cell 
activation, the acclaimed microglia/macrophages and neutrophils TNF component is not critical 
for this control. In contrast, the ablation of T cells-derived TNF in the M-TNF-/- mice decreased 






                                                                       




































                     


























             
                                                                      
 























                                      
























                                                                                                                                                       



























                                      



























 expressing microglia in MT-TNF
-/-
 mice. TNFf/f, M-TNF-/-, 
MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
Whole brain tissues were harvested at week 0 (naïve) 1, 2 and 3 post-infection, and single cells labelled 
for APC and surface markers. From the CD11b+CD45low population were gated for percentage of cells 
expressing CD11b+CD45lowCD80+ (A), CD11b+CD45lowCD86+ (C) and CD11b+CD45lowMHCII+ (E) surface 
markers. MFI values of CD80+ (B), CD86+ (D) and MHCII+ (F) are shown. *=p < 0.05, **=p < 0.01, and #=p 
< 0.05 for M-TNF-/- versus MT-TNF-/- and TNF-/- in (A). Data are one representative of three independent 




R2.6.2 Defective response to antigen by macrophages of MT-TNF-/- but not M-TNF-/- 
mice during cerebral M. tuberculosis infection  
To investigate whether microglia/macrophages, neutrophils, and CD4+- and CD8+ T 
cells-derived TNF affects activation of CD11b+CD45high cells, we intracerebrally infected TNFf/f, 
M-TNF-/-, MT-TNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Whole 
brain tissues were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were 
labelled using lineage (CD11b:PerCP-Cy5-5 and CD45:APC), co-stimulatory (CD80: FITC and 
CD86: V450) and cell surface (MHCII (I-A/I-E): PE) markers as seen in Figure 3.2.13. 
We assessed the co-stimulation (CD80 and CD86) and the cell surface markers (MHCII) 
expression in this population. Here we found that more than 60% of the macrophage population 
in TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice highly expressed the CD80 marker by week 2 
post-infection. However, by week 3 post-infection, the macrophages expressing CD80+ in M-
TNF-/- mice had a 3-fold increase when compared to week 1 post-infection, and the increase 
was comparable to TNFf/f mice. In contrast, macrophages expressing CD80+ in MT-TNF-/- and 
TNF-/- mice significantly (p < 0.05) decreased to less than 50% compared to TNFf/f or M-TNF-/- 
mice (Figure 3.2.13A). The MFI activation of CD80+ expressing macrophages was comparable 
with the percentage expression (Figure 3.2.13B). 
Although a delayed up-regulation was observed in MT-TNF-/- and TNF-/- mice at week 1 
post-infection, all mouse strains exhibited high up-regulation (more than 50%) of the 
macrophage cells expressing the CD86+ marker at weeks 1, 2 and 3 post-infection with no 
difference among strains (Figure 3.2.13C and D). However, a trending decrease was observed 
in MT-TNF-/- and TNF-/- mice at week 3 post-infection compared to TNFf/f and M-TNF-/- mice.  
Analysis of percentage and MFI of MHCII+ expression in the macrophage population of 
TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice showed high expression of 40% by week 1, and 80% 
by week 2 post-infection. However, by week 3 post-infection, the level expression of MHCII+ in 
the macrophage population of both MT-TNF-/- and TNF-/- mice significantly decreased to 50% 
when comparing to TNFf/f or M-TNF-/- mice, while TNFf/f and M-TNF-/- mice maintained their 
MHCII+ expression (Figure 3.2.13E and F). 
Our finding suggested that microglia/macrophages and neutrophils derived TNF do not 
play a pivotal role in the control of macrophage activation. The protective effect observed in M-
TNF-/- mice could be the result of compensation from T cell-derived TNF. We speculate that 
during the first 2 weeks post-infection, the activation observed in macrophages could be driven 
by the early inflammatory response. The results also suggest that the regulation of CD80+ and 




inflammation after cerebral M. tuberculosis infection. Data also demonstrate that the ablation of 
T cell-derived TNF in M-TNF-/- mice alter the macrophage activation during cerebral M. 


































                                                                   
 
































                




























     
                                                                      
 























                                 





























                
                                                                                                                                                                                           

























                              




























Figure 3.2.13: TNF dependent activation of macrophages during neurotuberculosis. TNFf/f, M-TNF-/-
, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
Brains were harvested at week 0 (naïve) 1, 2 and 3 post-infection, and single cells were labelled for APC 
and surface markers. From the CD11b+CD45high population was gated for cells expressing 
CD11b+CD45highCD80+ (A), CD11b+CD45highCD86+ (C) and CD11b+CD45highMHCII+ (E) surface markers. 
MFIs of CD80+ (B), CD86+ (D) and MHCII+ (F) are shown. *=p < 0.05, and #=p < 0.05 for M-TNF-/- versus 
MT-TNF-/- and TNF-/- in (A and E). Data (mean ± SD of 5 mice/group) are one representative of three 




R2.6.3 Modulation of dendritic cells surface marker expression in MT-TNF-/- mice  
 
We investigated whether myeloid and lymphoid T cell subset derived TNF plays a critical 
role in the activation of the CD11c+CD45high population. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- 
mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
collected, harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were labelled 
using lineage (CD11b:PerCP-Cy5-5, CD11c:Alexa 700 and CD45:APC), co-stimulatory (CD80: 
FITC and CD86: V450) and cell surface marker (MHCII (I-A/I-E): PE) as is seen in Figure 
3.2.14A-F and analysed using flow cytometry. We investigated the contribution of 
microglia/macrophages, neutrophils, and CD4+- and CD8+ T cells-derived TNF to DCs activation 
by analysing the percentage expression and MFI of co-stimulatory (CD80+ and CD86+) and 
antigen presenting cell (MHCII+) markers. Interestingly, less than 10% of the DCs population in 
all mouse strains expressed the CD80+ marker at week 1 post-infection, and the expression 
level was decreased to 5% in all mouse strains at week 2 post-infection. The CD80+ expressing 
DCs in TNFf/f and M-TNF-/- mice significantly (p < 0.05) increased from 5% to 8% at week 3 post-
infection compared to TNF-/- or MT-TNF-/- mice (Figure 3.2.14A). In contrast, a continuous 
decrease CD80+ expression was noticed in MT-TNF-/- and TNF-/- mice at week 3 post-infection 
(Figure 3.2.14A and B). Assessing the percentage and MFI of CD86+ expression on DCs, we 
found that ~75% of the DCs population in all mouse strains expressed CD86+ at week 1 and 2 
post-infection, however a significant (p < 0.05) up-regulation was seen in M-TNF-/- mice 
compared to TNFf/f mice at week 3 post-infection when compared MT-TNF-/- and TNF-/- mice. 
The percentage and MFI of CD86+ expressing DCs was maintained at equivalent levels in both 
MT-TNF-/- and TNF-/- mice (Figure 3.2.14C and D). The expression of MHCII+ in the DCs 
population was significant (p < 0.05) increased in M-TNF-/- mice at week 2 post-infection 
compared to TNFf/f, MT-TNF-/- and TNF-/- mice. The MHCII+ expressing DCs population in MT-
TNF-/- had a significant (p < 0.05) reduction at week 3 post-infection compared to TNFf/f mice 
(Figure 3.2.14E and F). A Similar significant increase (p < 0.05) was found in TNF-/- mice at this 
time point.  
Our finding suggested that microglia/macrophages and neutrophils derived TNF do not 
play a pivotal role in the control of dendritic cell activation, although TNF is required in the 
control of CD80+ and MHCII+ expression during CNS M. tuberculosis infection. The data also 
indicate that the ablation of T cell-derived TNF in M-TNF-/- mice has a critical effect on the 




                                                                      
 

































                  






























                                                                        
  




























                                       




























                                                                                                                                             


































                                        

































Figure 3.2.14: TNF mediated DCs surface marker expression. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- 
mice were intracerebrally infected at a different time points with M. tuberculosis at a dose of 1x105 
cfu/brain. Brains were harvested at week 0 (naïve) 1, 2 and 3 post-infection, and single cells were 
labelled for APC and surface markers. From the CD11c+CD45low population was gated for percentage of 
cells expressing CD11c+CD45highCD80+ (A), CD11c+CD45highCD86+ (C) and CD11c+CD45highMHCII+ (E) 
surface markers. MFI of CD80+ (B), CD86+ (D) and MHCII+ (F) are shown *=p < 0.05, and #=p < 0.05 for 
M-TNF-/- versus MT-TNF-/- and TNF-/- in (A, C and E). Data are one representative of three independent 




 R2.7 TNF mediates cerebral B-cell subsets infiltration during neurotuberculosis  
            R2.7.1. Increase influx of follicular B cells in MT-TNF-/- but not M-TNF-/- mice            
 
To address the question of whether the ablation of TNF in microglia/macrophages, 
neutrophils, and CD4+- and CD8+ T cells impaired the CD1dlowB220+AA4.1- (Fo B cells) 
population during cerebral M. tuberculosis infection; TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice 
were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Whole brain 
tissues were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were 
labelled with specific B cells markers (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5, and 
B200:HorizonV500), and the gating strategy used to identify the CD1dlowB220+AA4.1- population 
is shown again in Figure 3.2.15A. 
We observed no significant difference in the absolute number of infiltrating Fo B cells in 
M-TNF-/- mice compared to TNFf/f mice at all time points post M. tuberculosis infection. However, 
the absolute number of infiltrating Fo B cells in MT-TNF-/- and TNF-/- were significantly (p < 0.01) 
higher at week 1, 2 and 3 post-infection compared to the TNFf/f mice at all time points post-























                                    














































Figure 3.2.15: Absolute cell number during neurotuberculosis. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- 
mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. In order to identify Fo 
B cells population, whole brain tissues were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and 
single cells were labelled with CD1d:PE-A, CD93(AA4.1):PerCP-Cy5-5-A and CD45R/B220:V500-A.  





R2.7.1.1 Down-regulation of follicular B-cell antibody production in MT-TNF-/- mice 
but not in M-TNF-/- mice during neurotuberculosis  
 
We evaluated the activation of Fo B cells in TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice. 
Mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. Brains were 
harvested and single cells were labelled at week 0 (naïve), 1, 2 and 3 post-infection with specific 
B cells (CD1d:PE, CD93(AA4.1):PerCP-Cy5-5 and B200:Horizon V500), co-stimulatory 
(CD86:V450) and surface (IgM:PE-Cy7 and MHCII:Alexa 700) markers. We next investigated 
whether the ablation of TNF in microglia/macrophages, neutrophils, CD4+- and CD8+ T cells 
affected the regulation of co-stimulatory marker. We found no significant difference in the 
percentage and MFI of Fo B cells expressing CD86 in M-TNF-/- mice compared to TNFf/f mice 
(Figure 3.2.16A and B). In contrast, the percentage and MFI of cells expressing the CD86+ 
marker in the Fo B cells population of MT-TNF-/- and TNF-/- mice were significantly (p < 0.05) 
higher at week 1 and lower at week 3 post-infection compared either to TNFf/f or M-TNF-/- mice 
(Figure 3.2.16A and B). We further assessed the role of microglia/macrophages, neutrophils, 




show that the Fo B cells of TNFf/f and M-TNF-/- mice secreted similar levels at week 3 post-
infection, which was significant (p < 0.05) higher compared to week 1 post-infection. In contrast, 
the MT-TNF-/- and TNF-/- mice secreted significant (p < 0.05) lower levels of IgM+ at week 3 post-
infection compared either to TNFf/f or M-TNF-/- mice (Figure 3.2.6C and D). We examine the 
expression pattern of MHCII+ in the Fo B-cell population, and found that the percentage 
expression and MFI values of MHCII+ on Fo B cells in TNFf/f and M-TNF-/- mice were similar and 
peaked at week 1 post-infection. In contrast, the increase in the percentage and MFI of Fo B 
cells expressing MHCII+ in both MT-TNF-/- and TNF-/- mice were significantly (p < 0.05) delayed 
at week 1 post-infection and only peaked at week 2 post-infection and subsequently dropped at 
week 3 post-infection as opposed to being maintained as was evident in TNFf/f and M-TNF-/- 
mice (Figure 3.2.16E and F).  
Our findings demonstrate that ablation of TNF in microglia/macrophages and neutrophils 
cells does not affect the expression pattern of Fo B-cell surface marker and antibody secretion 
during neurotuberculosis. The immune effects observed in M-TNF-/- mice could be associated 
with the compensation of T cell-derived TNF or other cerebral TNF cellular sources. Our results 
also indicate that the ablation of TNF in T cells of M-TNF-/- mice results in the incapacity of Fo B 




















                                                                    
 




































                      



































                                                                     
 
























                               
































                                                                                                           




























                                



























Figure 3.2.16: Impairment in antibody secretion and antigenic response by Fo B cells in MT-TNF
-/-
 
but not M-TNF mice: TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. 
tuberculosis at a dose of 1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-
infection, and single cells were labelled for CD1d, AA4.1, and B220, with surface markers CD86, IgM and 
MHCII. The CD1dlowB220+AA4.1- population were gated for percentage of cells expressing 
CD1dlowB220+AA4.1-CD86+ (A), CD1dlowB220+AA4.1-IgM+, (C) and CD1dlowB220+AA4.1-MHCII+ (E). MFI 
values of CD86+ (B), IgM+ (D) and MHCII+ (F) are shown. *=p < 0.05, and #=p < 0.05 for M-TNF-/- versus 
MT-TNF-/- and TNF-/- in (A), (C) and (E). Data are one representative of three independent experiments. 




R2.7.2 Modulation of plasmablast and plasma cells absolute numbers during 
experimental neurotuberculosis 
 
To analyse the infiltrating CD1dhighB220highD138- (plasmablasts) population into the CNS 
during neurotuberculosis, we intracerebrally infected TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice 
with M. tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues were harvested at week 0 
(naïve), 1, 2 and 3 post-infection and single cells were labelled with specific B-cell (CD1d:PE, 
CD93(AA4.1):PerCP-Cy5-5, CD138:APCPerCP-Cy5-5 and B200:Horizon V500) markers.  
No significant difference was found in the absolute cell numbers of the infiltrating 
plasmablast population in the M-TNF-/- mice compared with the TNFf/f mice, at all time points 
post-infection. However, the absolute cell numbers of the infiltrating plasmablast population in 
MT-TNF-/- and TNF-/- mice were increased (non-significant) at week 1 post-infection compared 
either to TNFf/f or M-TNF-/- mice. Significant (p < 0.05) increases were found in  MT-TNF-/- and 
TNF-/- at week 2 post-infection, and also a significant (p < 0.01) decrease was observed at week 
3 post-infection compared to either TNFf/f or M-TNF-/- mice (Figure 3.2.17A). Next, we examine 
the absolute  numbers of plasma cells in TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice, and found 
that the absolute number of the plasma cell population in TNFf/f mice was 2-log higher at week 3 
post-infection compared to week 1 post-infection. A similar trend was observed in M-TNF-/- 
mice. In this population, we found no significant difference in plasma cell absolute numbers of 
M-TNF-/- mice compared with the TNFf/f mice at all time points post-infection. Interestingly, the 
absolute number of the plasma cells in both MT-TNF-/- and TNF-/- mice was significantly (p < 
0.001) increased when compared to TNFf/f or M-TNF-/- mice at week 1 and 2 post-infection, and 
was followed by a significant (p < 0.001) decrease in both MT-TNF-/- and TNF-/- mice at week 3 
post-infection when compared to TNFf/f or M-TNF-/- mice (Figure 3.2.17B). 
These data demonstrate that ablation of TNF in the microglia/macrophages and 
neutrophils were not critical to the influx of the plasmablast and plasma cell populations, 
suggesting that there is  is better control of the influx of plasmablasts and plasma cells into the 









                                                                        




















































           





































Figure 3.2.17: TNF modulates the plasmablasts and plasma cells absolute number during 
neurotuberculosis. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. 
tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues were harvested at week 0 (naïve), 1, 2 and 
3 post-infection, and isolated single cells were labeled for CD1d, AA4.1, CD138 and B220. Shown are 
absolute numbers of CD1dhighB220highD138- cells (A), also shown are absolute numbers of B220lowCD138+ 
cells (B). *=p < 0.05, **=p < 0.01 and ***=p < 0.001. Data are one representative of three independent 
experiments. Results are represented as mean ± SD of 5 mice/group. 
 
 
R2.7.2.1 Reduced humoral immunity and antigenic response by plasmablast cell 
in  MT-TNF-/- but not M-TNF-/- mice  
 
To examine the activation of the plasmablast population into the CNS during 
neurotuberculosis, we infected TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice with M. tuberculosis 
at a dose of 1x105 cfu/brain. Whole brain tissues were harvested at week 0 (naïve), 1, 2 and 3 
post-infection, and single cells were labelled with specific B cells (CD1d:PE, 
CD93(AA4.1):PerCP-Cy5-5, CD138:APC and B200:Horizon V500) and surface (CD86 and 
MHCII) and  antibody (IgM) markers. 
Analysing the surface expression of co-stimulatory molecules, we found that the 
percentage and MFI of infiltrating plasmablast cells expressing CD86+ was increased in all 
mouse strains at week 1 and 2 post-infection. However, the percentage and MFI of plasmablast 
cells expressing CD86+ in TNFf/f and M-TNF-/- mice were maintained the same level at week 3 




MFI of plasmablast cells expressing CD86+ in both MT-TNF-/- and TNF-/- mice were significantly 
(p < 0.05) lower compared to TNFf/f and M-TNF-/- mice (Figure 3.2.18A and B). We thereafter 
examined the percentage and MFI of the infiltrating plasmablasts which secreted the antibody 
IgM. A similar up-regulation of cells expressing IgM+ was observed at week 1 and 2 post-
infection in all mouse strains. However, the percentage of the IgM secreting plasmablast 
population was significant (p < 0.05) increased in TNFf/f and M-TNF-/- mice at week 3 post-
infection. On the contrary, both MT-TNF-/- and TNF-/- mice had significantly (p < 0.05) decreased 
percentage and MFI of plasmablasts expressing IgM+ at week 3 post-infection compared to 
TNFf/f or M-TNF-/- mice (Figure 3.2.18C and D). Next, we assessed whether the ablation of TNF 
in the microglia/macrophages, neutrophils, and CD4+- and CD8+ T cells affected the antigen 
presentation ability in the plasmablast population. We found no significant difference in 
percentage and MFI of MHCII+ expressing plasmablast cells at week 1 post-infection in all 
mouse strains. However, a significant (p < 0.05) difference was observed in the MHCII+ 
expressing plasmablasts of the MT-TNF-/- and TNF-/- mice at week 2 post-infection compared to 
TNFf/f mice. Following the kinetic at week 3 post-infection, no significant difference was 
observed in the percentage and MFI of the MHCII+ expressing plasmablasts in M-TNF-/- mice 
compared to TNFf/f mice. Interestingly, the percentage of the MHCII+ expressing plasmablasts in 
MT-TNF-/- and TNF-/- mice was significantly (p < 0.05) decreased when comparing to either turn-
off/f or M-TNF-/- mice (Figure 3.2.18E and F). 
These data demonstrate that ablation of TNF in the microglia/macrophages and 
neutrophils is not critical for the activation of the plasmablasts. The resistance observed in M-
TNF-/- mice may derive from the compensation of T cell-derived TNF. In addition, the results 
clearly demonstrate that the ablation of T cell-derived TNF in M-TNF-/- mice leads to the 
deregulation of surface markers. 
 
 
R2.7.3 Impaired humoral immunity by plasma cells in MT-TNF-/- but not M-TNF-/- 
mice  
 
To evaluate the absolute number and examine the surface expression of co-stimulatory 
molecules, and antibody secretion of plasma cells, we intracerebrally infected TNFf/f, M-TNF-/-, 
MT-TNF-/- and TNF-/- mice with M. tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues 
were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and single cells were labelled with 




surface markers and analysed for  CD86, IgM and MHCII expression.  
Examining the percentage and MFI of CD86+ expressed on the plasma cells, we found 
that the percentage and MFI of plasma cells expressing this co-stimulatory marker was 
increased in all mouse strains at week 1 and 3 post-infection. At week 2 post-infection, the 
percentage and MFI of plasma cells expressing CD86+ in MT-TNF-/- and TNF-/- mice showed a 
significant (p < 0.05) decrease compared to TNFf/f and M-TNF-/- mice (Figure 3.2.19A and B). 
We next asked whether the microglia/macrophages, neutrophils, and CD4+- and CD8+ T cells-
derived TNF influenced antibody secretion. There was an increase in the percentage and MFI of 
plasma cells expressing IgM+ in all mouse strains at week 1 and 2 post-infection. However, this 
expression was maintained at week 3 post-infection in TNFf/f and M-TNF-/- mice. In contrast, 
there was a significant (p < 0.05) decrease in IgM of both MT-TNF-/- and TNF-/- mice at week 3 
post-infection (Figure 3.2.19C and D). Assessing the expression of MHCII+, we found very low 
and no significant difference in all mice strains and time points post-infection (Figure 3.2.19E). 
The data show that ablation of TNF in the microglia/macrophages and neutrophils does 
not alter the plasma cell activation, suggesting that the no effect observed in M-TNF-/- mice may 
derived from the T cells-derived TNF. Also data show that T cells-derived TNF deletion in M-




















                                                                      
 
































            







































                                                                      
 





























                                




























                                                                                                                                                  






























                                  

































Figure 3.2.18: Defective humoral immunity and antigenic response by plasmablast cells in MT-
TNF
-/-
 but not M-TNF
-/-
 mice. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected 
with M. tuberculosis at a dose of 1x105 cfu/brain. Brains single cells were labelled at week 0 (naïve) 1, 2 
and 3 post-infection for CD1d, AA4.1, CD138 and B220 with surface markers CD86, IgM and MHCII. The 
CD1dhighB220+D138- population were gated for cells expressing CD1dhighB220+D138-CD86+ (A), 
CD1dhighB220+D138-IgM+ (C) and CD1dhighB220+D138- MHCII+ (E). Also shown are bar graphs of MFI 
values of CD86+ (B), IgM+ (D) and MHCII+ (F). *=p < 0.05 and **=p < 0.01 and #=p < 0.01 for M-TNF-/- 
versus MT-TNF-/- and TNF-/- in A, C and E. Data are one representative of three independent 




                                                                      





































                        

































                                                                                         
 

























                                   





























                                                    























Figure 3.2.19: Reduced antibody production in MT-TNF
-/- 
mice but not M-TNF
-/-
 mice. TNFf/f, M-TNF-/-
, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 cfu/brain. 
Brain single cells were labelled at week 0 (naïve) 1, 2 and 3 post-infection for CD1d, AA4.1, CD138 and 
B220, with surface markers CD86, IgM and MHCII. Shown are the B220lowD138+ population was gated for 
cells expressing B220lowD138+CD86+ (A), B220lowD138+IgM+ (C) and B220lowD138+MHCII+ (E). *=p < 
0.05, and #=p < 0.05 for M-TNF-/- versus MT-TNF-/- and TNF-/- in (C). MFI values of CD86+ (B), IgM+ (D) 
and MHCII+ (F) are shown. Data (mean ± SD of 5 mice/group) are one representative of three 




R2.8 Increased influx of infiltrating of CD4+- and CD8+ T cells in MT-TNF-/- mice 
during neurotuberculosis 
To explore whether the microglia/macrophages, neutrophils, and CD4+- and CD8+ T 
cells-derived TNF alter the influx of infiltrating CD4+- and CD8+ T cells into the brain during 
experimental neurotuberculosis, TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally 
infected with M. tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues were harvested at 
week 1, 2 and 3 post-infection, and single cells were analysed for expression of CD3, CD4, and 
CD8 using flow cytometry.  
We observed an overall increase in the frequency of effector CD4+ T cells in TNFf/f mice, 
which was almost ~8-fold higher at week 2 and ~35-fold higher at week 3 post-infection 
compared to week 1 post-infection. In M-TNF-/- the frequency of effector CD4+ T cells was ~14-
fold higher at week 2 and 35-fold higher at week 3 post-infection compared to week 1 post-
infection, the effector CD4+ T cells in MT-TNF-/- was ~10-fold higher at week 2 and ~33-fold 
higher at week 3 post-infection compared to week 1 post-infection and while overall in the 
frequency of effector CD4+ T cells in TNF-/- mice was ~10-fold higher at week 2 and ~35-fold 
higher at week 3 post-infection compared to week 1 post-infection (Figure 3.2.20). The 
frequency of infiltrating CD4+ T cells in the M-TNF-/- mice have approximated that of TNFf/f mice 
at week 1 post-infection. The frequency of MT-TNF-/- and TNF-/- mice had 2-fold higher at week 2 
and 4-fold higher at week 3 post-infection compared to TNFf/f mice (Figure 3.2.20). We similarly 
examined the influx of CD8+ T cells into the brain during experimental neurotuberculosis. The 
effectors CD8+ T cell population increased 2-fold at week 2 and 3 post-infection in all mouse 
strains compared to week 1 post-infection. A significantly (p < 0.05) higher frequency of CD8+ T 
cells was observed in M-TNF-/- mice at week 3 post-infection compared with TNFf/f mice,  while 
the MT-TNF-/- and TNF-/- mice exhibited a higher influx of CD8+ T cells at week 2 and 3 post-
infection (Figure 3.2.21). When assessing the absolute cell numbers of infiltrating cells, we 
found equivalent numbers of CD3+CD4+ cells in the M-TNF-/- mice at week 1 and 2 post-infection 
compared to TNFf/f mice. In contrast, when assessing the CD3+CD4+ T cell influx in MT-TNF-/- 
and TNF-/- mice, we found a significant (p < 0.05) increase at week 1, 2 and 3 post-infection 
compared to TNFf/f mice (Figure 3.2.22A), suggesting that the absence T cell-derived TNF 
induced susceptibility in MT-TNF-/- mice. This phenotype was not evident in M-TNF-/- mice. 
Further, we examined the absolute number of CD3+CD8+ cellular influx. We observed no 
significant differences between M-TNF-/- and TNFf/f mice or in any of the time points post-




post-infection compared with TNFf/f mice. No significant difference was observed in absolute 
number of CD3+CD8+ T cells in all mouse strains at week 1 post-infection,  and in MT-TNF-/- 
mice at week 2 post-infection compared with TNF-/- mice. In contrast, only TNF-/- mice had a 
significant (p < 0.05) increase at week 2 post-infection compared with TNFf/f mice (Figure 
3.2.22B), while, both MT-TNF-/- and TNF-/- had a significant (p < 0.05) increase in absolute 
number of CD3+CD8+ T cells at week 3 post-infection compared to TNFf/f mice (Figure 3.2.22B).  
Seeing that an intermediary increase in CD4+ and CD8+ T cells were observed in M-TNF-
/- versus TNFf/f mice, data indicated that TNF derived from myeloid and T cells is required in 




Figure 3.2.20: Increased infiltration of CD4
+





/-, MT-TNF-/- and TNF-/- mice strains were intracerebrally infected with M. tuberculosis at a dose of 1x105 
cfu/brain. Whole brain tissues were harvested at week 1, 2 and 3 post-infection, and single cells were 
labelled for CD3 and CD4 expression. The flow cytometry dot plots show prominent infiltration of cerebral 
CD4+ T cells. The values seen in the dot plot are the percentages of the parent gate which are positive. 





Figure 3.2.21: Increase influx of cerebral CD8
+ 
T cells in MT-TNF
-/-
 but not M-TNF
-/- 
mice. TNFf/f, M-
TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 1x105 
cfu/brain. Whole brain tissues were harvested at week 1, 2 and 3 post-infection, and single cells were 
labelled and data analysed for CD3 and CD8 expression. The flow cytometry dot plots show prominent 
infiltration of cerebral CD8+ T cells. The values seen in the dot plot are the percentages of the parent gate 













                                                                         
  










































              














































 T cells in cell-specific TNF
 
mice. 
TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 
1x105 cfu/brain. Whole brain tissues were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and 
isolated single cells were labelled and data analysed for CD3, CD4 and CD8 markers. Shown are CD4+ T 
cells (CD3+CD4+) absolute numbers (A), and also shown are CD8+ T cells (CD3+CD8+) absolute numbers 
(B). *=p < 0.05, **=p < 0.01 and ***=p < 0.001. Data are one representative of three independent 
experiments. Results are represented as mean ± SD of 5 mice/group. 
 
 
R2.8.1 TNF influences activation of effector CD4+ and CD8+ T cells during 
neurotuberculosis  
 
We further evaluated the CD44 expression of cerebral infiltrating CD4+ and CD8+ T cells 
in TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice by flow cytometer. The data showed no significant 
differences in CD44+ expressing CD4+ or CD8+ T cells in M-TNF-/-, MT-TNF-/- or TNF-/- mice at 
week 1 and 2 post-infection compared with TNFf/f mice (Figure 3.2.23A and B). However, a 
significant (p < 0.05) increase in the percentage of CD4+ and CD8+ T cells expressing CD44+ 
was observed in M-TNF-/- mice at week 3 post-infection compared to TNFf/f mice. The 
percentage of CD4+ and CD8+ T cells expressing CD44+ in both MT-TNF-/- and TNF-/- mice were 
significantly (p < 0.05) higher than in TNFf/f and M-TNF-/- mice at week 3 post-infection (Figure 
3.2.23A and B). 
These data suggest that TNF derived from myeloid or T cells play a critical role in the T 





                                                                                      
           

























                        































 T cell percentage in cell-specific TNF mice. 
TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice strains were intracerebrally infected with M. tuberculosis at a 
dose of 1x105 cfu/brain. Brains were harvested at week 0 (naïve), 1, 2 and 3 post-infection, and isolated 
brain single cells were labelled and analysed for CD3, CD4, CD8 and CD44 expression. Shown are the 
CD4+ T cells expressing CD44+ (A), and the CD8+ population cells expressing CD44+ (B).  *=p < 0.05, 
and #=p < 0.05 for M-TNF-/- versus MT-TNF-/- and TNF-/-. In this study, week 0 refers to naïve. Data are 




R2.9 TNF mediates proinflammatory Th1-type cytokines production in MT-TNF-/- 
but not in M-TNF-/- mice.  
We examined whether TNF derived from microglia/macrophages, neutrophils, CD4+- 
and CD8+ T cells modulate the production of proinflammatory Th1-type cytokines such as TNF, 
IFN-γ, IL-1β, IL-2, IL-6 and IL-12p70 during experimental cerebral M. tuberculosis infection. 
TNFf/f, M-TNF-/-, MT-TNF-/-and TNF-/- mouse strains were intracerebrally infected with M. 
tuberculosis at a dose of 1x105 cfu/brain. Whole brain tissues were homogenised at week 0 
(naïve), 1, 2 and 3 post-infection, and supernatants were collected and assayed for TNF, IFN-γ, 
IL-1β, IL-2, IL-6 and IL-12p70 by ELISA.  
TNF production in TNFf/f mice remained relatively constant for the duration of the 
experiment within a narrow margin of between 300pg/m - 400pg/ml during acute M. tuberculosis 
infection (Figure 3.2.24A), suggesting that peak concentration were established early prior to 




although the data in M-TNF-/- mice showed an overall decreasing trend, this was not significant. 
The TNF level in MT-TNF-/- mice were significantly (p < 0.01) lower at all time points post-
infection when compared either to TNFf/f or M-TNF-/- mice. As expected TNF levels in the 
complete TNF-/- mice were not detectable (Figure 3.2.24A).  
We next measured the IFN-γ production levels, where we found that all mouse strains 
had a similar production level at week 1 post-infection, and it remained constant in TNFf/f and M-
TNF-/- mice at week 2 post-infection. IFN-γ production levels were significantly (p < 0.001) 
lowered in TNFf/f and M-TNF-/- mice at week 3 post-infection compared to MT-TNF-/- and TNF-/- 
mice. In contrast, significantly (p < 0.001) higher concentrations were measured in MT-TNF-/- 
comparable to TNF-/- mice at week 2 and 3 post-infection compared either to TNFf/f and M-TNF-/- 
mice (Figure 3.2.24B).  
The IL-1β concentration was significantly (p < 0.05) higher in TNFf/f at week 1 post-
infection compared to MT-TNF-/- and TNF-/- mice, however, not significant difference was 
observed at this time point when compared with M-TNF-/- mice. The IL-1β concentration 
remained similar and relatively constant in both TNFf/f and M-TNF-/- mice at week 2 and week 3 
post-infection. However, continuous significant (p < 0.05) reduction in IL-1β concentrations were 
observed in both MT-TNF-/- and TNF-/- mice at 2 and 3 week post-infection compared to TNFf/f 
and M-TNF-/- mice (Figure 3.2.24C).  
IL-2 production levels in M-TNF-/-, MT-TNF-/- and TNF-/- mice were significantly (p < 0.01) 
lower compared to TNFf/f mice at week 1 post-infection. IL-2 production levels in all mouse 
strains increased relatively constant at week 2 post-infection. Interestingly, IL-2 production 
levels in TNFf/f and M-TNF-/- mice continue to increase at week 3 post-infection. Moreover, a 
transient increase was noticed in IL-2 production at week 2 post-infection. Concentrations of IL-
2 in MT-TNF-/- and TNF-/- mice were significantly (p < 0.01) lowered at week 3 post-infection 
compared either to TNFf/f or M-TNF-/- mice (Figure 3.2.24D).  
We found similar production of IL-6 expression in TNFf/f, M-TNF-/- and MT-TNF-/- mice at 
week 1 post-infection, while in TNF-/- mice, a significantly lower level was found at week 1 post-
infection compared to TNFf/f mice. We found lower IL-6 production in TNFf/f and M-TNF-/- mice at 
week 2 and 3 post-infection compared to the earlier time point. IL-6 production was significantly 
(p < 0.05) higher in MT-TNF-/- and TNF-/- mice at week 2 post-infection compared to TNFf/f mice. 
Significantly (p < 0.01) higher IL-6 production was also observed in MT-TNF-/- and TNF-/- mice at 
week 3 when compared to TNFf/f and M-TNF-/- mice (Figure 3.2.24E).  
No significant differences were detected in IL-12p70 production levels between M-TNF-/- 




0.05) lower IL-12p70 production at week 1 post-infection compared to TNFf/f mice. The IL-12p70 
levels in MT-TNF-/- and TNF-/- mice at week 2 post-infection were similar to TNFf/f and M-TNF-/- 
mice, but significantly (p < 0.05) lower production was found in MT-TNF-/- and TNF-/- mice at 
week 3 post-infection compared to TNFf/f mice (Figure 3.2.24F). 
The overproduction observed at the site of disease in TNF, IL1β, IL-2 and IL-12p70 
concentrations suggest that early regulation of immune responses was present in TNFf/f and M-
TNF-/- mice but not in MT-TNF-/- or TNF-/- mice. Furthermore, the uncontrolled IL-6 and IFN-γ 
production observed in MT-TNF-/- or TNF-/- mice, but not in TNFf/f and M-TNF-/- mice point 
towards compensation of either source of TNF during inflammatory regulation.  
Therefore, data showed that microglia/macrophages and neutrophils derived TNF have 
differential effects on proinflammatory Th1-type cytokines during CNS M. tuberculosis infection. 
These results also illustrated that the deletion of TNF from microglia/macrophages, neutrophils, 
and CD4+- and CD8+ T cells resulted in an uncontrolled increase of IL-6 and IFN-γ protein and 























                                                                      

































           































   
 
                                                                      





















                    































                                                                         
























                     
























      
                                                                            
Figure 3.2.24: Modulation of proinflammatory Th1-type cerebral cytokines in cell-specific TNF
 
mice. TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a 
dose of 1x105 cfu/brain. The brains of mice were homogenised at week 0 (naïve), 1, 2 and 3 post-
infection, and TNF (A), IFN-γ (B), IL-1β (C), IL-2 (D), IL-6 (E) and IL-12p70 (F) concentrations were 
measured in the supernatants by ELISA. Data are representative of at least three independent 
experiments that yielded similar results. Data are mean ± SD of 5 mice/group. *=p < 0.05, **=p < 0.01 and 




R2.10 Cerebral chemokine production following CNS M. tuberculosis infection 
To further understand the factors associated with an increased leukocyte influx into the 
brain leading to susceptibility, we postulated that increased pathology was driven by an 
increased in leukocyte chemoattractants. We therefore measured cerebral MCP-1, MIP-1α and 
RANTES concentration in M. tuberculosis infected TNFf/f, M-TNF-/-, MT-TNF-/-and TNF-/- mice at 
week 1, 2 and 3 post-infection. Several studies have supported the association of MCP-1 with 
TB (Flores-Villanueva et al., 2005; Buijtels et al., 2008; Hasan et al., 2005; Thye et al., 2009 and 
Ben-Selma et al., 2011). Also MIP-1α has been found to be implicated in M. tuberculosis 
infection (Jussi et al., 2002). The association has also been found between RANTES and M. 
tuberculosis infection (Chu et al., 2007; Sanchez-Castanon et al., 2009 and Ben-Selma et al., 
2011).  
We found that the MCP-1 concentration in both TNFf/f and M-TNF-/- mice were equivalent 
at week 1, 2 and 3 post-infection. In contrast, MCP-1 production was significantly higher 
(400±55 and 390±280 vs p < 0.05) in MT-TNF-/- and complete TNF-/- mice at week 1 post-
infection compared to TNFf/f (Figure 3.2.25A). No significant difference was found between MT-
TNF-/- and TNFf/f mice at week 2 post-infection, however, MCP-1 production was significantly (p 
< 0.05) higher in TNF-/- mice at this time point post-infection. In addition, significant (p < 0.05) 
increases in the MCP-1 production levels were observed in both MT-TNF-/- and TNF-/- mice at 
week 3 post-infection when comparing with either TNFf/f or M-TNF-/- mice (Figure 3.2.25A). 
Equivalent MIP-1α production was measured in all mouse strains at week 1 post-infection. A 
significant difference was found in MIP-1α production of TNF-/- mice at week 2 post-infection 
when compared either with TNFf/f or M-TNF-/- mice (Figure 3.2.25B). No significant difference 
was detected in the MIP-1a production of MT-TNF-/- mice at week 2 post-infection compared 
either to TNFf/f, M-TNF-/- or TNF-/- mice. Interestingly, MIP-1α production levels were significantly 
(p < 0.01) higher in MT-TNF-/- and TNF-/- mice at week 3 post-infection compared either with 
TNFf/f or M-TNF-/- mice (Figure 3.2.25B). Similar to MIP-1α production, no significant (p < 0.01) 
difference was detected in RANTES production in all mice at week 1 post-infection. A significant 
difference was found in RANTES production of TNF-/- mice at week 2 post-infection compared 
either with TNFf/f mice (Figure 3.2.25C). No significant difference was detected in RANTES 
production of MT-TNF-/- mice at week 2 post-infection compared either to TNFf/f, M-TNF-/- or 
TNF-/- mice. RANTES production levels were significantly (p < 0.01) higher in MT-TNF-/- and 





Our results clearly demonstrated that deficiency of TNF in microglia/macrophages and 
neutrophils does not impair the chemoattractant response during cerebral M. tuberculosis 
infection. In contrast, ablation of TNF in microglia/macrophages, neutrophils, and CD4+- and 
CD8+ T cells increases the expression of chemokines during cerebral M. tuberculosis infection, 
suggesting that TNF is required for chemokines regulation. 
 
 




























































         
 
 
                                          



































Figure 3.2.25: Total cerebral chemokines expressions during experimental neurotuberculosis. 
TNFf/f, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally infected with M. tuberculosis at a dose of 
1x105 cfu/brain. Brains of infected mice were homogenised at week 1, 2 and 3 post-infection, and MCP-1 
(A), MIP-1α (B) and RANTES (C) levels in supernatants were assessed by ELISA. Data are 
representative of at least three independent experiments that yielded similar results. Results are mean ± 
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Previous studies with both rabbits (Tsenova et al., 2005) and mice (van Well et al., 2007 
and Zucchi et al., 2012) demonstrated formation of meningitis after intracerebral M. tuberculosis 
injection. These models enabled investigation of therapeutic strategies and understanding of 
immune regulation during neurotuberculosis, despite the limitation in the route of pathogen entry 
to the CNS. In humans, neurotuberculosis occurs by lympho-hematogenous dissemination after 
primary lung infection, whereas in the experimental models, bacteria were directly inoculated 
into the cerebellum. To exclude that the intracerebral injection procedure induced substantial 
infiltration of peripheral immune cells by damaging the BBB; it was established that saline 
injected mice exhibited neither clinical manifestations nor pathology (appendix H). We 
investigated the role of cell specific TNF in mediating immune protection, focusing mainly on the 
contribution of neurons, microglia, macrophages, neutrophils, and CD4 and CD8 T cells-derived 
TNF in host immunity against M. tuberculosis. Importantly, M. tuberculosis infected animals 
showed characteristics of TB meningitis and tuberculomas similar to the studies described by 
Tsenova et al., (2005); van Well et al., (2007) and Zucchi et al., (2012). Therefore, there is a 
need for neuro-immunopathology investigation, as susceptibility to TB infection has been 
historically ascribed, to an inadequate immune response that fails to control infected 
mycobacteria pathogen (Tobin et al., 2012) with limited understanding of neuro-immunology. 
Genetic deficiencies of immune effectors such as TNF, IFN-γ and iNOS have confirmed its 
importance as critical for immune protection against tuberculosis (Fortin et al., 2007). Also, non 
genetic immunosuppression, such as TNF-neutralisation and biological immunosuppressors 
such as HIV infection increase susceptibility of TB (Kwan & Ernst, 2011 and Lawn & Zumla, 
2011). Studies using animals and humans have found that the mutation of the leukotriene A4 
hydrolase (LTA4H) locus, which controls the balance of pro- and anti-inflammatory eicosanoids, 
showed two distinct molecular routes to mycobacterial susceptibility converging on dysregulated 
levels of TNF (Tobin et al., 2010 and Tobin et al., 2012). These studies demonstrated two 
different baseline response levels of TNF, one where insufficient levels lead to mycobacterial 
overgrowth, while high levels result in uncontrolled inflammation being detrimental to the host. 
These two baseline response levels of TNF indicate that individuals are susceptible to M. 
tuberculosis infection for two fundamentally different reasons.  
In the brain, the BBB separates the CNS from the regular systemic blood circulation. 
Unlike other organs, the CNS lacks a draining lymph node system where immune cells, such as 
APC and T-cells may interact (El-Kebir et al., 2013). For these reasons, the CNS was previously 
thought to be an immunologically privileged area. Research findings have demonstrated that 




immune responses in the CNS (Rock et al., 2004; Carson et al., 2006 and Galea et al., 2007), 
which upon activation may secrete cytokines including TNF. 
Several immunomodulatory drugs have been used to downregulate the production of 
TNF such as etanercept, which is a fusion protein consisting of 2 soluble TNFR2 receptors 
linked to a human immunoglobulin Fc fragment. Etanercept therapy was implicated in TB 
reactivation (Mohan et al., 2004). Dexamethasone is another drug that was found to cause 
latent TB reactivation in non-human primates (Lin et al., 2010). Although this drug proved to be 
detrimental by influencing the matrix metalloproteinases, which play a role in collagen 
breakdown and cerebral tissue damage (Green et al., 2009); in TBM patients, the co-
administration of dexamethasone with tuberculostatic drugs has shown to be effective in early 
stages of TBM (Thwaites et al., 2004; Prasad & Singh, 2009 and Török et al., 2011). A study by 
Tsenova et al., (1998) proved that combining the TNF targeting immunomodulatory drug such 
as thalidomide (Peterson et al., 1995), with antibiotics results in a reduction of TNF levels and 
higher survival rate in rabbits. However, its clinical use showed less effect in children with TBM 
(Schoeman et al., 2004). In addition, infliximab a monoclonal antibody that completely inhibits 
TNF is used for treatment of inflammatory diseases such as rheumatic and bowel disease. 
Previous studies have shown that patients on infliximab therapy reactivate with pulmonary 
tuberculosis (Fallahi-Sichani et al., 2012), and may potentially have similar contributory effects 
in the development of TBM.  
In humans, primates and mice, TNF has been shown to be essential for the 
maintenance of granuloma structures and for effective control of pulmonary mycobacterial 
infection (Kindler et al., 1989; Tracey et al., 1993; Flynn et al., 1995; Rock et al., 2004; Tsai et 
al., 2006 and El-Kebir et al., 2013). In the brain, TNF is synthesised by both immune (including 
infiltrating cells) and non-immune cells (including neurons). Therefore, identifying the cellular 
sources of TNF that contribute to the pathology is of significant interest. We have recently found 
that M. tuberculosis can infect neurons in vitro and in vivo (Randall & Hsu et al., 2014). Many 
studies have suggested the existence of an extensive crosstalk between the CNS and immune 
system, whereby immune cells protect neurons from degeneration (Kerschensteiner et al., 
1999; Moalem et al., 1999 and Medana et al., 2001), and neurons can mediate the generation 
of T regulatory cells during inflammation (Liu et al., 2006). With this understanding, we opted to 
investigate independently the role of neuronal derived TNF during neurotuberculosis. Because 
neurons are the basic functional unit of the CNS, we then thought to first generate mice that are 
deficient specifically for neuronal TNF synthesis and investigate its contribution to immune 




findings from TNFf/f mice confirmed the expression of TNF in neurons as previously reported 
(Liu et al., 1994; Gahring et al., 1996 and Tchelingerian et al., 1996). TNF expression in 
neurons has also been reported against other pathogens (Cowan et al., 1997 and Zhang et al., 
2010). We found that NsTNF-/- mice are not susceptible to M. tuberculosis infection compared to 
TNFf/f mice. An inflammatory response was observed in TNFf/f mice as was described in 
previous published studies in rabbits (Tsenova et al., 2005) and mice (van Well et al., 2007 and 
Zuchi et al., 2012). As the disease progressed, NsTNF-/- mice showed lymphocytic rich foci, and 
extracerebral dissemination with no clinical manifestations similar to TNFf/f mice. In contrast, 
TNF-/- mice developed severe clinical manifestations which correlated with high bacterial burden, 
uncontrolled leukocyte infiltration, severe lymphocytic rich foci, high extracerebral dissemination 
and subsequently these mice succumbed to infection. The failure of TNF-/- mice to control 
infection verifies the absolute requirement of TNF for immune protection against 
neurotuberculosis. 
Both NsTNF-/- and TNFf/f mice survived M. tuberculosis infection, indicating that neuronal 
derived TNF is not required for neuroimmune protection. Immune cells from the periphery 
migrate into the brain during inflammation response of CNS, where these cells may produce 
antimycobacterial molecules such as iNOS (Dogan et al., 2008). Here we have shown that in 
the absence of TNF of neurons, the expression of iNOS was not altered and expression level 
was equivalent to TNFf/f mice, indicating that neuronal derived TNF is not involved in the overall 
synthesis of iNOS. Induction of iNOS mediates the production of nitric oxide, which is an 
effector molecule for bacterial inhibition (Barnes & Belvisi, 1993). In TNF-/- mice where 
uncontrolled bacterial growth was observed, the production level of iNOS was lower compared 
to TNFf/f mice. Although iNOS synthesis is regulated by several cytokines, we found that 
complete ablation of TNF leads to impaired production of iNOS in the brain, while others have 
shown iNOS detection in TNF-/- mice after pulmonary M. tuberculosis infection (Flynn et al., 
1995 and Bean et al., 1999), and also in the brains of TNF-/- mice with experimental allergic 
encephalitis (Korner et al., 1997 and Riminton et al., 1998); we and other pulmonary 
tuberculosis studies (Jacobs et al., 2000; Botha et al., 2003 and Allie et al., 2008) have shown 
opposite findings,  suggesting that, the regulation of iNOS is TNF independent. Our findings 
support the Olin et al., (2008) study where the authors elegantly illustrated that iNOS−/− mice 
infected with M. tuberculosis developed serious clinical manifestations and exuberant 
lymphocyte meningeal infiltration. Mice with ablation of TNF from the neurons had a moderate 
percentage of infiltrating myeloid and T cells equivalent to TNFf/f mice, whereas mice with 




pulmonary TB study has demonstrated that effector T cells are rapidly recruited to the existing 
granulomas and are retained within this structure with edged egress from the lesions (Egen et 
al., 2008). Indeed, during neurotuberculosis infection, recruited myeloid and T cells were fully 
mature effector cells, expressing CD45 and activation marker CD44, respectively. Taken 
together, the data suggest that infiltration of leukocytes is regulated by TNF. We also found that 
the absence of TNF in the neurons had no regulatory effect on the expression of cell surface 
markers such as CD80+, CD86+ and MHCII+ especially in microglia, macrophages and DCs, and 
was comparable to TNFf/f mice. The increased co-stimulation expression observed in CD86 may 
be explained by the fact that corresponding receptors for CD80 and CD86 are CD28 and CTLA-
4, and their receptors are expressed on both T and B cells; with CD80 having a higher affinity 
for CTLA-4 whereas CD86 binds more effectively to CD28 (Collins et al., 2002). However, both 
CD80 and CD86 are able to initiate both costimulatory and coinhibitory signals upon binding to 
their receptors. The cells continuously interaction with stimuli led to high expression of CD86 
which interact with CD28, and resulted in the initiation of a costimulatory signal. While, in other 
hand, these cells started also to express the CD80 which interacts with CTLA-4 to induce a 
coinhibitory signal that counteracts costimulatory signals (Collins et al., 2005). However, our 
data are in agreement with the studies using recombinant TNF and TNF neutralisation in which 
they have shown that the presence or absence of TNF does not affect the CD86 expression 
(Salgado et al., 1999 and Miyazawa et al., 2008). 
The high MHCII expression observed in APCs of both TNFf/f and NsTNF-/- mice may 
contribute to a protective mechanism to regulate immune activation in the CNS during later 
stages of disease, while complete ablation of TNF resulted in low antigenic responses by APCs. 
Decreased expression of MHCII+ observed in TNF-/- mice, which was associated with decreased 
co-stimulatory markers expression may suggest the impediment of antigen presentation 
processes and a failure to induce M. tuberculosis specific immunity leading to an increase in 
mycobacterial intra-macrophage growth and mycobacterial susceptibility. TNF has been 
implicated in the regulation of MHCII, CD80 and CD86 expression on APCs (Pessara et al., 
1990; Ranheim et al., 1995; Pechhold et al., 1997; Ishikawa et al., 2002; Kim et al., 2002; Iijima 
et al., 2003; Baldwin et al., 2010 and Keller et al., 2011). We found that complete ablation of 
TNF led to decreased expression of CD80+ and MHCII+ observed in TNF-/- mice. Our data is 
consistent with previously published results where cells in the granulomas of TNF-LT-α-/- mice 
expressed low levels of MHCII during pulmonary Mycobacterium bovis BCG infection (Jacobs et 
al., 2000), also our data is consistent with the CD86 expression pattern reported in other 




Our data showed the presence of infiltrating B-cell subsets in the brain at the onset of 
disease. The presence of Fo B cells, plasmablast and plasma cells observed here suggest that 
B cells may contribute to the host immune response and intervene during CNS infection, as the 
role for B cells during early immune responses to pulmonary M. tuberculosis infection was 
reported to be associated with the delay of in dissemination, development of lung pathology and 
alteration of cellular infiltrate in the lungs in B-cell knockout mice (Bosio et al., 2000). Studies 
using other types of infection have shown that B- and T cell responses function complementary 
to repel infection, and both cell-types are able to contribute to long-lived protection (Amanna et 
al., 2006 and Doherty et al., 2006). B cells as professional antigen presenting cells, express 
various cell surface markers to promote the maturation and activation of T cells (Sharpe et al., 
2002). Notably, B cells can modulate this maturation process through the production of 
antibodies and cytokines, by either enhancing or suppressing immune responses (Kalergis et 
al., 2002; Rafiq et al., 2002; Mauri et al., 2003; Dhodapkar et al., 2005; Mizoguchi et al., 2007 
and Sugimoto et al., 2007). Also B cells have been reported to polarize T cell responses through 
the production of cytokines (Harris et al., 2000). Furthermore, B cells mediate adaptive immunity 
that evolves both humoral and cellular component (Maglione & Chan, 2009), and most 
importantly, B cells produce antibodies that neutralize invasion and further target infectious 
agents for destruction (Moore et al., 2001). Our data showed low level production of antibody in 
Fo B cells compared to plasmabast and plasma cells, but had the highest antigen-presenting 
cell marker expression. B-cell subsets in NsTNF-/- mice showed high percentage levels of co-
stimulatory, antibody and antigen presenting cell markers resembling that of TNFf/f mice. On the 
contrary, B-cell populations in TNF-/- mice resulted in decreased co-stimulatory, antibody and 
antigen presenting cell marker expression. Furthermore, plasma cells expressing MHCII+ found 
in all mouse strains confirmed the phenotype of mature plasma cell (Arko-Mensah et al., 2009). 
B cells interaction with naïve CD4+ helper T cells stimulates cytokine synthesis that reciprocally 
regulates the antibody responses of B cells (Vascotto et al., 2007). Amongst the cytokines 
produced by T cells, TNF has been reported to play a major role in B-cell activation to produce 
immunoglobulin antibody (Higuchi et al., 1997). Deficiency in B-cell responses in TNF−/− has 
been well-documented (Pasparakis et al., 1996; Pasparakis et al., 1997; Grivennikov et al., 
2005 and Kuprash et al., 2005). Our data are consistent with the previously published studies 
where others have shown that B cells play a role in shaping the immune response against M. 
tuberculosis infection (Phuah et al., 2012) and in other neurodegenerative disease (Serafini et 




may be attributed to the absence of stimulation of T cell-derived TNF, therefore suggesting that 
T cell TNF may be critical in mediating B cells immunity during neurotuberculosis.  
Early Th1-type cytokine response was found where comparable up-regulation of the 
proinflammatory cytokines TNF, IL-1β, IL-6 and IL-12p70 was measured in NsTNF-/- and TNFf/f 
mice. Thereafter, NsTNF-/- mice had moderate cytokine and chemokines expression throughout 
the experimental period resembling TNFf/f mice, which coincided with control of mycobacterial 
burden. The expression levels of cytokines (IL-6, TNF, and IFN-γ) and chemokine expression 
observed in TNFf/f mice were in line with previously published data (van Well et al., 2007). Our 
findings are in agreement with the previous report by Arko-Mensaha et al., (2009) where they 
reported the protection in C57BL/6J and BALB/c mice was directly associated early increase in 
immunological events such as increases in IL-12 and TNF. On the contrary, TNF-/- mice had 
uncontrolled up-regulation of proinflammatory IL-6 and IFN-γ, and chemokines (MCP-1, MIP-1α 
and RANTES) compared to the TNFf/f and NsTNF-/- mice. The over expression of cerebral IL-6 
and IFN-γ as well as chemokines observed in TNF-/- mice correlated with the higher influx of 
leukocytes, ultimately inducing an inflammatory signature which was probably sustained by the 
high infection burden. Proinflammatory Th1-type cytokines and chemokines are crucial to the 
brain’s immune function serving to maintain immune surveillance, facilitate leukocyte traffic, and 
recruit other inflammatory factors (Takeshita & Ransohoff, 2012). However, uncontrolled 
proinflammatory cytokine and chemokine production may lead to excessive neurodegenerative 
pathology, microcirculatory dysfunction or uncontrolled host’s tissue damage (Beutler et al., 
1985; Björkbacka et al., 2004 and Ramesh et al., 2013). IL-2  promotes selective expansion of 
effector T cells after antigen activation, was found to be induced in NsTNF-/- mice at 
concentration levels equivalent to TNFf/f mice. In contrast, significant lower IL-2 production was 
found in TNF-/- mice despite a higher percentage of infiltrating T cells compared to TNFf/f and 
NsTNF-/- mice suggesting that T cell proliferation is TNF independent. Our data are consistent 
with human pulmonary tuberculosis results with those of Toossi et al., (1986) and Khanna et al., 
(2003) where the authors reported significant lower IL-2 in patients compared to normal 
controls. However, impaired production and responses of IL-2 are critical factors in the defective 
cellular immune response during pulmonary M. tuberculosis infection (Toossi et al., 1986); 
where TNF plays a critical role in the regulation of IL-2 synthesis. 
Uncontrolled cellular influx and protein expression of cytokines and chemokines 
observed in TNF-/- mice are characteristic of TB meningitis in humans, and have been reported 
to cause perivascular inflammation and occlusion of small vessels, which leads to infarcts and 




meningitis other than TB meningitis, the levels of cytokines in CSF correlate with the clinical 
course of meningitis (Mustafa et al., 1989; Saez-Llorens et al., 1990 and Ceyhan et al., 1997). 
Both, TNFf/f and NsTNF-/- mice exhibited similar phenotypes, and indicated that neuronal derived 
TNF is redundant and does not contribute to cytokine mediated immunity against CNS M. 
tuberculosis infection. TNF produced by other immune and non-immune cellular sources can 
partially compensate neuronal derived TNF to control of infection, and leading to some 
redundant functions. Research demonstrated that during inflammation, resident and infiltrating 
myeloid cells are found to be the main cellular sources of TNF in the CNS, following by the T 
cells and other non-immune cells. TNF produced by myeloid cells has been shown to accelerate 
the onset of disease by regulation of chemokine expression in the CNS, driving the recruitment 
of inflammatory cells into the CNS, while TNF produced by lymphoid T cells exacerbated the 
damage to the CNS inflammation, by regulating infiltration of inflammatory myeloid cells into the 
CNS (Kruglov et al., 2011). 
We hypothesised that TNF derived from myeloid phagocytic cells, including microglia 
and macrophages, could affect the resistance to mycobacteria infection. Relevant to this study 
is the widely accepted view that microglia and infiltrating macrophages are significant sources of 
TNF as contributory to host immune responses during bacterial infection (Hirsch et al., 1994; 
Renno et al., 1995; Britton et al., 1998 and Welser-Alves et al., 2013). We then investigated 
host immune function against CNS M. tuberculosis in M-TNF-/- mice, where 
microglia/macrophages and neutrophils were incapable of synthesising TNF (Grivennikov et al., 
2004). We speculated that the ablation of TNF from myeloid origin, especially from microglia 
and macrophages, could result in high susceptibility, defective activation and increase intra-
microglia/macrophages bacterial growth. Interestingly, we found that M-TNF-/- mice did not 
succumb to CNS M. tuberculosis infection, did not exhibit overt clinical manifestations and had 
pathology resembling TNFf/f mice. The histopathological data demonstrated meningeal 
lymphocytic infiltration similar to TNFf/f mice. Furthermore, similar iNOS protein expression was 
observed in M-TNF-/- mice compared to TNFf/f mice, suggesting that myeloid derived TNF do not 
impair iNOS synthesis. This iNOS expression level observed in M-TNF-/- mice could be the 
result of compensation from T cell-derived TNF. Unlike human macrophages, murine 
macrophages induce expression of iNOS which generate nitric oxide that is capable of reacting 
with oxygen and reactive oxygen intermediates to form a nitrite anion (NO2-), nitrate anion (NO3-
), dinitrogen trioxide N2O3, and the highly mycobactericidal peroxynitrite anion (ONOO-) 
(McMicking et al., 1997 and Schneemann & Schoeden, 2007). The influx of myeloid cells into 




recruited myeloid cells were fully functional and mature effector cells, expressing CD45 
markers. Immunity against M. tuberculosis is multifactorial, involving a network of innate and 
adaptive immune responses (Mihret, 2012). In CNS, microglia, and infiltrating macrophages, 
neutrophils and DCs are crucial cells in the immune response to M. tuberculosis by presenting 
antigens to T cells in the context of both MHC class I and II (Rock et al., 2005 and Mihret, 
2012). Also, microglia, and infiltrating macrophages and DCs plays an important role in 
recruitment of cells to the site of infection through secretion of proinflammatory cytokines 
(Giacomini et al., 2001 and Saijo & Glass. 2011). We have found that, in general, infiltrating 
DCs in the brain had low expression levels of the co-stimulatory and MHCII markers compared 
with macrophages. DCs are not resident cells of the brain, therefore they are required to 
transport M. tuberculosis from the site of infection to the local lymph node, but because the 
brain lacks specific lymph nodes; the antigenic response may be impaired therefore resulting in 
lower expression of co-stimulatory and MHC markers as observed in the DCs population. This 
phenomenon has been previously reported in the lung during M. tuberculosis infection (Wolf et 
al., 2007 and Wolf et al., 2008). 
Little evidence exists to indicate that macrophages interact with B cells during M. 
tuberculosis infection. However, exchange of antigen between B cells and other APC has been 
indirectly demonstrated by Townsend & Goodnow, (1998) based on their finding that HEL/ I-Ak-
specific T cells were activated in vivo following adoptive transfer of in vitro Ag-pulsed IgHEL B 
cells. The interaction between macrophages and B cells has also been reported to be an 
important feature of B cells activation for the response to polysaccharide (Boswell et al., 1980). 
The ablation of TNF from the myeloid cell subsets did not alter the influx or the activation of B 
cells. The influx and expression of B-cell subsets surface markers and antibody secretion in M-
TNF-/- mice was similar to that of TNFf/f mice. B-cell humoral and antigenic responses observed 
in both M-TNF-/- and TNFf/f mice is subjective to protection against M. tuberculosis infection. Our 
data is consistent with the non-human primate pulmonary TB study, where Phuah et al., (2012) 
have found that B cells are present and actively secrete antibodies specific for M. tuberculosis 
antigens. Thus, our data indicate that the ablation of TNF in myeloid cells does not impair B 
cells immunity against M. tuberculosis infection. 
We showed in this study that deletion of TNF from microglia/macrophages and 
neutrophils had a transient and significant influence in the recruitment and activation of CD4+- 
and CD8+ cells, which were also fully mature effector cells and expressing CD44 activation 
marker, suggesting that TNF derived from microglia/macrophages and neutrophils had a 




shown that the ablation of TNF from microglia/macrophages and neutrophils do not affect the 
inflammatory response. Levels of IL-1β, IL-2, IL-6, IL-12p70, TNF and IFN-γ in M-TNF-/- mice 
were comparable to TNFf/f mice. Cytokines and chemokines are potential modulators of immune 
responses during acute neurotuberculosis. Chemokines produced by local CNS cells mediate 
leukocytes trafficking into the CNS (Cardona et al, 2003 and Glass et al., 2005), which 
thereafter produce cytokines including TNF. A higher inflammatory response was documented 
in respect to chemokine production, but do not appear to be significantly different compared to 
TNFf/f mice. The data correlate with the phenotype profile of M-TNF-/- mice, and are indicative of 
the limited role of myeloid derived TNF in proinflammatory response against CNS M. 
tuberculosis infection. 
Although TNF plays a critical role in granuloma formation and containment of 
mycobacterial infection (Folgueira et al., 1994 and Flynn et al., 1995), studies have also found 
that local CNS production of TNF in experimental bacterial meningitis lead to, alteration of BBB 
permeability and increased leukocyte infiltration in cerebro-spinal fluid (Ramilo et al., 1990; 
Saez-Llorens et al., 1990 and Saukkonen et al., 1990), and enhances of CNS-TB (Tsenova et 
al., 1999). In contrast, decreased TNF level has been shown to increase intra-macrophages 
bacterial growth leading to necrotic cells (Flynn et al., 1995; Bean et al., 1999; Botha et al., 
2003; Allie et al., 2008 and Tobin et al., 2012). Although widely acclaimed as the main cellular 
sources of TNF, microglia/macrophages and neutrophils derived TNF have limited role in 
restricting mycobacterial replication through TNF dependent synthesis during CNS M. 
tuberculosis infection. Our finding is consistent with the Allie et al., (2013) results where they 
found similar phenotypic outcomes in M-TNF-/- mice during pulmonary TB. We show here that 
resident and infiltrating macrophages as well as neutrophils derived TNF is redundant during 
host immunity against CNS M. tuberculosis infection. How can these observations be 
explained? Given the similarities between M-TNF-/- and TNFf/f mice in phenotype, it is 
conceivable that the protective immunity observed in M-TNF-/- mice may be due to 
compensatory effects of T cell or other non-immune cell-derived TNF, generating sufficient TNF 
concentration levels for containment of M. tuberculosis infection. However, since data of T-TNF-
/- mice are not shown it is difficult to conclude with 100% of certainty that T cell-derived TNF is a 
compensatory source. 
We have also found that mice lacking TNF in CD4 and CD8 T cells (T-TNF-/-) are not 
susceptible to cerebral M. tuberculosis infection (Unpublished data). We speculate here that the 
protective immunity observed in T-TNF-/- mice may derive from the TNF compensated by the 




produced by other non-immune cells. In a pulmonary model, Allie et al., (2013) showed that T-
TNF-/- mice had a similar phenotype as TNFf/f mice during acute M. tuberculosis, and is in line 
with the observation we found in CNS-TB. 
To determine whether TNF derived from myeloid and lymphoid T cell origins have a 
synergistic requirement for protection against neurotuberculosis, we characterised the host 
immune responses in MT-TNF-/- mice. In this model, microglia/macrophages, neutrophils, and T 
cells (CD4+- and CD8+) in MT-TNF-/- mice were unable to synthesise TNF. Myeloid cells as 
APCs, present antigens in association with MHC II molecules to stimulate lymphoid CD4+ T 
cells, and this process is essential to contain M. tuberculosis infection (Harding & Boom, 2010). 
We hypothesised that deleting TNF from CD4+- and CD8+ T cell subsets in M-TNF-/- mice would 
lead to CNS host M. tuberculosis susceptibility. The finding that MT-TNF-/- mice were highly 
susceptible to CNS infection provide important and new evidence that synergistic activity of TNF 
derived from myeloid cells and T cells is required for optimum protection; its absence resulting 
in high susceptibility with exacerbated disease progression comparable to TNF-/- mice. The 
phenotype displayed by MT-TNF-/- mice were characterised by pronounced clinical 
manifestations with uncontrolled cerebral bacterial growth mainly extracellular, severe 
lymphocytic rich foci and meningeal lymphocytic infiltration. The overall lymphocytic rich foci 
architecture was similar in MT-TNF-/- mice to that seen in complete TNF-/- mice. A spectrum of 
extra-cerebral dissemination was noted in MT-TNF-/- mice that resembled to TNF-/- mice, which 
was higher compared to TNFf/f and M-TNF-/- mice. Although the infection route applied in this 
study does not reflect the course of natural infection in humans, clinical and pathological 
findings observed in this study are consistent with neurotuberculosis in humans (Rich & 
McCordock, 1933 and Donald et al., 2005). MT-TNF-/- and TNF-/- mice strains exhibited a low 
expression of iNOS compared to TNFf/f mice which have been associated with susceptibility to 
M. tuberculosis infection (McMicking et al 1997). Interestingly, ablation of TNF from 
microglia/macrophages, neutrophils, and T cells (CD4+- and CD8+ cells) lead to high peripheral 
leukocyte subsets migration and infiltration into the parenchyma. In MT-TNF-/- mice, the overall 
APCs antigenic responsiveness with respect to M. tuberculosis infection was lower, while their 
effector T cell percentage was higher resembling to TNF-/- mice, suggesting that TNF is critical in 
mediating the adaptive immune response. 
The overall B cells humoral and antigenic response in MT-TNF-/- mice resembled that of 
TNF-/- mice; where the ablation of TNF from myeloid and lymphoid cells decreased the 
activation of B-cell population. Humoral and antigenic responses in MT-TNF-/- mice were 




required during humoral immunity. Our data are consistent with the previously published study, 
where authors demonstrated that TNF and LTα deficient mice habour B cells defect 
responsiveness during L. monocytogenes challenges and immunisation (Pasparakis et al., 1996 
and Alexopoulou et al., 1998). 
Like in TNF-/- mice, cytokine expression levels in MT-TNF-/- mice were characterised by 
increased production of IL-6 and IFN-γ comparable to TNF-/- mice. The kinetic profile for IL-6 
production appears to be delayed in MT-TNF-/- mice and TNF-/- mice, indicating that TNF is 
required to induce an early response. IFN-γ is mainly produced by T cells (Abbas et al., 1996, 
Romagnani, 1996 and Wenner et al., 1996) and natural killer cells in response to dying 
bacterial-infected macrophages (Kubota, 2009); the uncontrolled increase IFN-γ concentrations 
observed in the respective mouse strains correlated with the increase infiltrating of effector 
CD4+ and CD8+ T cells. A study by Flynn et al., (1993) using IFN-γ-/- mice clearly demonstrated 
the important role of IFN-γ in the protective immune response to M. tuberculosis infection, while 
other studies using transgenic mice have shown that IFN-γ overexpression in the CNS 
increases disease progression (Corbin et al., 1996 and Renno et al., 1998). Our studies which 
show a correlation between high IFN-γ expression and advanced TB disease support these 
findings. We speculate that the over production of IL-6 and IFN-γ observed in MT-TNF-/- mice 
could be due to the ablation of TNF in T cells as myeloid derived TNF alone resulted in 
controlled production of IL-6 and IFN-γ. Beside increase production levels of IL-6 and IFN-γ, 
cytokines IL-2 was found to be lower in MT-TNF-/- and once again in TNF-/- mice compared to 
TNFf/f and M-TNF-/- mice. As previously addressed, here we speculate that the dysregulation of 
IL-2 observed in MT-TNF-/- mice may be a direct result of TNF ablation in T cells of this mouse 
strain; because M-TNF-/- mice have not demonstrated any dysregulation in IL-2 production. Data 
once again suggest that TNF is pivotal in regulating IL-2 expression. The increase in chemokine 
production observed in MT-TNF-/- mice were comparable to TNF-/- mice, and correlated with 
increased recruitment of infiltrating leukocytes into the brain of these strains.  
The fact that TNF is produced by microglia/macrophages and neutrophils, as well as by 
T-cells, raises the possibility of partial compensation to control infection, and may lead to some 
redundant functions which may be provided by either source of TNF. The similarity in phenotype 
between TNFf/f and M-TNF-/- mice, and with high disparate phenotypes between TNFf/f and MT-
TNF-/- mice, and also with M-TNF-/- and MT-TNF-/- mice during CNS M. tuberculosis infection 
suggests that the absence of T cell-derived TNF exacerbate the susceptibility phenotype. From 
this outcome we conclude that T cell-derived TNF is required for downregulation of 




increase disease severity with overt clinical manifestations, severe pathology, uncontrolled 
mycobacterial growth in the brain, impaired antigenic response and mortality; clearly confirming 
the essential function of TNF from these distinct and important cellular sources of TNF. 
Although, there are differences in organ-specific make-up between the brain and lungs, 
the overall results in neurotuberculosis are consistent with those seen in pulmonary TB (Allie et 
al., 2013), indicating that the underlying immune protection mechanisms in both pulmonary and 
CNS-TB model are similar. Since the protective immunity to tuberculosis depends on CD4+ T 
cells in mice and humans (Perlman et al., 1997 and Mogues et al., 2001), we speculate here 
that the ablation of TNF in myeloid and lymphoid lineage may impede the adaptive immune 
response, which is required for effective control of M. tuberculosis infection. TNF plays a major 
role in the initial and long-term control of tuberculosis (Lin et al., 2007). TNF is important in 
myeloid cells activation as well as cell recruitment to the site of infection. It is the primary 
important signal in granuloma formation, as neutralisation leads to lack of control of initial or 
chronic infection, and loss of granuloma structure. The overall protective immunity  observed in 
M-TNF-/- mice is suggestive that TNF from myeloid cells is not required to control acute infection 
although TNF plays a major role in the initial and long-term control of tuberculosis (Lin et al., 
2007).  
Our data showed that the expression level of TNF in this mouse strain was comparable 
to that of TNFf/f mice, suggesting that TNF from non-myeloid cells in M-TNF-/- mice may be 
responsible in driving the innate and adaptive immune response. In the CNS, TNF is produced 
by immune and non-immune cells, however the mechanisms by which TNF acts to control 
neurotuberculosis, as well as recruitment of cells to the site of infection leading to latency are 
not clearly defined. Reactivation of latent infection can be triggered by several factors which can 
lead to the development of active disease (Ahmad, 2011). From a clinical point of view, HIV 
infection is the most single risk factor for progression to active disease,  since HIV infection 
causes depletion of CD4+ T cells and functional abnormalities of lymphoid T cells, and which 
play an important role in providing protection against active TB disease (Wells et al., 2007 and 
WHO, 2009). The hallmark of M. tuberculosis infection in humans is the inability of an effective 
immune response to completely repel the pathogen (Ahmad, 2011). Host responses which are 
important in controlling the latent infection may include macrophage activation, maintenance of 
granuloma structure, T cells, IFN-γ and TNF (Flynn & Chan, 2001). Studies in mice have shown 
that without TNF, effective granuloma formation is diminished and mycobacterial numbers 
rapidly increase, resulting in susceptibility (Bean et al., 1995 and Bean et al., 1999). 




is crucial to worldwide control of this disease. In approximately, 5 to 10% of latently infected 
persons reactivation will occur and cause active tuberculosis (Flynn & Ernst, 2000). Cytokine 
TNF has been shown to play a major role in the initial and long-term control of tuberculosis (Lin 
et al., 2007). Tuberculous granuloma is typically composed of macrophages, multinucleated 
giant cells, lymphocytes (both CD4+- and CD8+ T cells, and B cells), neutrophils, and sometimes 
fibroblasts (Lin et al., 2007). However, the granuloma formation and also its maintenance 
require TNF. In this study we convincingly demonstrated that MT-TNF-/- and TNF-/- mice are 
highly susceptible to cerebral M. tuberculosis infection. Our data are in agreement with the 
previously reported data where mice with complete deficient in TNF are completely unable to 
control pulmonary M. tuberculosis infection (Flynn et al., 1995 and Bean et al., 1999). Studies in 
both human and mice have also demonstrated the critical role that TNF produced by 
macrophages, dendritic cells, and T cells play in protective role against pulmonary M. 
tuberculosis infection (Bean et al., 1999 and Keane, 2005). A study by Algood et al., (2003) has 
reported that TNF produced by the infected macrophages induces the expression of 
chemokines, such as IL-8, MCP-1, and RANTES which provide signals for migration of immune 
cells to the sites of M. tuberculosis infection. It has also been demonstrated that both 
macrophage and T cell-derived TNF are required for sufficient and long-term protection 
against M. tuberculosis infection (Saunders et al., 2005).  
It has been demonstrated that high levels of TNF are associated with TB meningitis. 
More recently data from human and zebrafish obtained with a persistent CNS M. tuberculosis 
infection indicate that a relative deficiency of TNF results in destructive immunopathology (Tobin 
et al., 2012). Our study has shown that TNF is absolutely required for protective host immune 
responses during neurotuberculosis and is in agreement with the previous mentioned study. 
Further, we established that TNF derived from both myeloid and lymphoid T cellular origins are 
required to generate complete protection during CNS M. tuberculosis infection. Based on the 
susceptibility observed in MT-TNF-/- mice and the resistance of M-TNF-/- mice we propose that T 
cells in particular forms a critical source of TNF to generate protective immunity. CD4+ T cells 
perform several functions that are important to control infection in the granuloma. These include 
production of cytokines (such as TNF), apoptosis of infected macrophages through Fas/Fas 
ligand interaction, induction of other immune cells (macrophages or dendritic cells) to produce 
immunoregulatory cytokines, such as IL-10, IL-12, and IL-15, and activation of macrophages 
through direct contact via CD40 ligand (Cella et al., 1996; Oddo et al., 1998; Chan & Flynn, 
2004 and Cooper, 2009). In addition, CD4+ T cells can control the intracellular growth of M. 




(Cowley & Elkins, 2003 and Cooper, 2009); as previously shown, the mycobacteriocidal effect of 
TNF is associated with iNOS-mediated production of NO (Bekker et al., 2001). TNF is involved 
in both immune and immunomodulatory responses and acts in synergy with T cell-derived IFN-
γ to enhance the macrophages antimycobactericidal activity of nitric oxide and other RNI by 
iNOS (Scanga et al., 2001 and Chan et al., 2004). 
We have recently shown that neurons are the host cells for M. tuberculosis, and that 
neuron cells upon infection by M. tuberculosis can express cytokines including TNF (Randall & 
Hsu et al., 2014). Our evidence presented in this study shows that neuronal derived TNF has a 
very limited protective response during cerebral M. tuberculosis infection, with a phenotype 
resembling to wild type mice. However, the phenotype observed in NsTNF-/- mice which 
resembles wild type control mice could be due to the compensatory mechanisms from other 
TNF cellular sources. In contrast, mice with complete ablation of TNF were highly susceptible to 
cerebral M. tuberculosis infection. M-TNF-/- mice exhibited a protective response during cerebral 
M. tuberculosis infection. We speculated that during cerebral M. tuberculosis infection, NsTNF-/- 
and M-TNF-/- mice may acquire protective responses by the compensatory mechanism of other 
cellular sources including T cells derived TNF, as it has been previously shown that T cells play 
an important role in the defence against M. tuberculosis (Caruso et al., 1999). Deletion of TNF 
in T cells of M-TNF-/- mice lead to high susceptibility during cerebral M. tuberculosis infection 
with a phenotype comparable to complete TNF deficient mice, confirming that T cells derived 
TNF is crucial for host immunity.  Moreover, T cells derived TNF has recently been shown to be 
non-redundant in pulmonary TB (Allie et al., 2013). 
Taken together, our data demonstrate that mice with ablation in a single cell-type or 
lineage derived TNF, produce an optimal baseline response level of TNF similar to wild type, 
and confer protection to immune response against neurotuberculosis. The protection observed 
in these mice may be related to the compensation of TNF from other cellular sources. However, 
dual ablation of TNF in myeloid and lymphoid T cells, produces low baseline response levels of 
TNF comparable to complete TNF-/- mice, and is detrimental, leading to host death. Myeloid and 
T cells participate in TB adaptive immune response (Wolf et al., 2008). During this process, TNF 
is required in the recruitment of cells that participate in adaptive immune response, and also, 
TNF is capable of enhancing the activation of these cells (Brighenti & Lerm, 2012 and Allie et 
al., 2013). However, we have here demonstrated that neuronal and microglia/macrophages and 
neutrophil derived TNF is not required during acute M. tuberculosis infection. We also 
demonstrated that ablation of TNF in neurons as well as in microglia/macrophages and 




control of bacterial growth, and the functional integrity of the lymphocytic rich foci response. In 
contrast, deletion of CD4+- and CD8+ T cell-derived TNF in M-TNF-/- mice resulted in 
exacerbated disease progression with uncontrolled bacterial growth and severe cerebral 
pathology and mortality. Therefore, the deletion of TNF in both lineages is crucial as it renders 















        CHAPTER  V  


















Several studies have investigated neurotuberculosis using animal models that employed 
different mycobacterium species (Peterson et al., 1995; Mazzolla et al., 2002; Tsenova et al., 
2005; Be et al., 2008 and Lee et al., 2009). The significance of murine TB models has been 
demonstrated by its similarity with human models, characterised by both its genetics and the 
severity of its effects on the CNS (Apt, 2011). We were able to develop a reproducible in vivo 
model to study the inflammatory response of cell type-specific TNF in neurotuberculosis. 
However, we acknowledge the limitations of the model, specifically the infection route which 
does not approximate the natural way neurotuberculosis is acquired in humans. Nonetheless, 
the model reflects many of the clinical, pathological and immune responses observed in 
humans.  
The neurotuberculosis experimental murine model used herein highlights the important 
cellular sources of TNF, and its modulation of host immune response. This study, using the cell 
type-specific TNF and complete deficient TNF mice has produced a novel and significant 
outcomes, with respect to the cellular requirement, organ pathology, cytokine and chemokine 
induction during host immunity against CNS M. tuberculosis infection. Overall, the role of 
neurons derived TNF appeared to be redundant for protective host immunity against 
neurotuberculosis. The widely acclaimed view that myeloid cells act as a primary source for 
TNF induced protection are contradicted and had a limited role in the control of CNS M. 
tuberculosis infection. The comparable wild type phenotype observed in NsTNF-/- and M-TNF-/- 
mice could be due to the compensation from T cell-derived TNF or from other TNF cellular 
sources. We found that the ablation of TNF in T cells of M-TNF-/- mice and mice with complete 
TNF ablation showed clinical manifestations of disease and pathology resembling that in 
humans. Data indicate that TNF mediated protective immunity against CNS M. tuberculosis 
infection requires T cell-derived TNF. However, future studies involving synergistic ablation of 
other cell-type combinations such as deletion of TNF in neurons and T cells or in neurons and 
myeloid cells are needed to substantiate our claim that T-cells derived TNF, is a key cellular 
source in driving neurotuberculosis susceptibility. Characterising cellular TNF sources during 
CNS M. tuberculosis infection has contributed substantially to understanding host-mycobacterial 
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APPENDIX  A 
 
Polymerase Chain Reaction (PCR) reagents  
1. 1000 mM Tris-HCl (Stock solution): 
15.76g was dissolved in 100ml of distilled H2O (pH 8) and then autoclaved at 121°C for 30 
minutes. The solution was thereafter filtered through a 0.45μm filter (Millipore Corporation, 
Bedford, USA) and stored at room temperature. 
 
2. 500 mM EDTA (Stock solution): 
18.612g was dissolved in 100ml of distilled H2O (pH8) and then autoclaved at 121°C for 30 
minutes. The solution was thereafter filtered through a 0.45μm filter (Millipore Corporation, 
Bedford, USA) and stored at room temperature. 
 
3. 6000 mM NaCl (Stock solution): 
35.064g was dissolved in 100ml of distilled H2O and then autoclaved at 121°C for 30 minutes. 
The solution was thereafter filtered through a 0.45μm filter (Millipore Corporation, Bedford, USA) 
and stored at room temperature. 
 
4. 10% SDS (Stock solution): 
10g was dissolved in 100ml of distilled H2O and then autoclaved at 121°C for 30 minutes. The 
solution was thereafter filtered through a 0.45μm filter (Millipore Corporation, Bedford, USA) and 
stored at room temperature. 
 
5. 10x TBE (Running buffer): 
108g Tris Base  
55g Boric acid 
40 ml of 500mM EDTA was dissolved in 1 liter distilled H2O and autoclaved for 30 minutes at 





6. Tissue (Tail biopsies) lysis buffer:  
 
50mM Tris-HCl, pH8 
100mM EDTA, pH 8 
100mM NaCl, 
1% SDS and 
0.5mg/ml Proteinase K (Roche, Germany) was made up to the required volume with distilled 
H2O. 
 
7. 6x Gel Loading Buffer: 
0.25% Bromophenol blue  
0.25% Xylene cyanol and 
50% Glucose was dissolved in 100 ml distilled H2O and autoclaved for 30 minutes at 121°C. 
The solution was stored at room temperature. 
 
8. 6x Agarose Gel: 
 
1.5g Agarose (1.5%) and 
100ml 0.5 x TBE was boiled in microwave then cooled slightly and 450ng/ml ethidium bromide 










1. Difco Middlebrook 7H10 Agar (M7H10): 
 
19g M7H10 agar 
5ml glycerol was made up to 900ml with distilled H2O and autoclaved at 121°C for 10 minutes. 
The solution was allowed to cool to 55°C and 100ml of oleic acid albumin dextrose catalase 
(OADC) was added. An agar solution of 7ml was pipetted and poured per side in sterile 
duplicate petridishes (Sterilin). And allowed to set, the plates were sealed with a platic bag and 








2. 0.9% Saline solution: 
 
0.9g NaCl was dissolved in 100ml of distilled H2O and then autoclaved at 121°C for 30 minutes. 
The solution was stored at room temperature. The solution was thereafter filtered through a 
0.45μm filter (Millipore Corporation, Bedford, USA) and stored at room temperature. 
 
 




1. Lethal anaesthetic: 
 
500μl Xylazine and 2ml Ketamine were added to 9 ml of 0.9% of saline solution. The solution 




2. General anaesthetic: 
 
0.66 ml of Ketamine (100 mg/ml) (Bayer Pty Ltd, Germany) and 0.22 ml of Xylazine (20mg/ml) 
(Intervet, Zurich, Switzerland) were added in 9.13 ml of sterile isotonic saline (0.9%). The 









1. Mayers haemotoxylin: 
 
1g Haemotoxylin 50g,  
Ammonium alum (Aluminium ammonium sulphate) 
or potassium alum (Aluminium potassium sulphate) were first dissolved, then after 
0.2g Sodium iodate 
1g Citric acid 
50g Chloral hydrate we added in H2O. Filter through Whatmann filter paper no 1 and the 







150ml of 1% Eosin in distilled H2O (2 parts) 
75ml of 1% Phloxine in distilled H2O (1 part) in  
225ml distilled H2O. One drop formalin or thymol was added to the 1% eosin for preservation. 
Filter through Whatmann filter paper no. 1 and the solution was stored at room temperature. 
 
3. Carbol fuchsin: 
 
10ml of 6% Basic fuchsin in absolute alcohol and 90ml of 5% carbolic acid, the solution was 
filtered through Whatmann filter paper no.1 and stored at room temperature. 
 
 
4. Buffered formalin (Tissues fixative): 
 
100ml formaldehyde (40% w/v formaldehyde solution) in 900ml 1x PBS (pH 7.4). The solution 
was stored at room temperature. 
 
 
5. Loeffers’ Methylene blue: 
 
1ml of 1% KOH was added to 
99ml distilled H2O and 
3ml of 0.8% Methylene blue (in absolute alcohol) was thereafter added. The solution was 





APPENDIX  E 
 
Fluorescent activated cell sorting (FACS) reagents 
 
1. 10% NaN3 (Sodium Azide): 
 
10g NaN3 was dissolved in 100ml of distilled H2O. The solution was filtered through a 0.45μm 
millipore filter (Millipore Corporation, Bedford,USA) and stored at 4°C. 
 
2. FACS buffer: 
 
0.1% BSA and 0.01% NaN3 were added in 1 x PBS (pH 7.4). The solution was sterilised with a 






3. FACS blocking solution: 
 
0.9375μl αFcyRIII (CD32/CD16c) 
3.75μl Normal rat serum (heat inactivated) 
3.75μl Normal mouse serum (heat inactivated) were diluted in  
141.56μl of FACS buffer. 
 
4. Fixation buffer: 
 
2% paraformaldehyde (PFA) in 1 x PBS 
4g NaOH was dissolved in 100ml distilled H2O. 
20g PFA and 600ml 1 x PBS was then added. The pH was adjusted to pH 7.2 with concentrated 
HCl and the volume adjusted to 1000ml. The solution was sterilised through a 0.45μm millipore 
filter (Millipore Corporation, Bedford, USA). The bottle was covered with aluminum foil and 
stored at 4°C. 
 
 




1mM MgSO4 and 
10mM HEPES were dissolved in 1x PBS containing 0.05% NaN3 and 0.1% BSA. The solution 









1. 10 x Phosphate-Buffered Saline (PBS): 
 
80g NaCl (1.37 M), 
2.4g KH2PO4 
2g KCl (0.03M) and 
14.4g Na2HPO4 2H2O were dissolved in 900ml distilled H2O. The pH adjusted to 7.4 and the 
solution made up to 1 liter with distilled H2O. The solution was sterilised through a 0.45μm 









2. Homogenising buffer: 
 
0.9% NaCl 
0.04% Tween 80 was dissolved in distilled H2O and autoclaved for 30 minutes at 121°C. The 
solution was stored at room temperature. 
 
 
3. Saline solution (0.9%): 
 
0.9g of NaCl was dissolved in 100ml of distilled H2O. The solution was autoclaved for 30 





APPENDIX  G 
 




1. Coating buffer: 
 
0.2g NaN3 was dissolved in 800ml 1 x PBS. The pH was adjusted to 7.4 and the solution made 
up to 1 liter. The solution was sterilised through a 0.45μm millipore filter and stored at 4°C. 
 
 
2. Sodium azide (NaN3) 10%:  
 
10g NaN3 was dissolved in 100ml of distilled H2O. The solution was sterilised through a 0.45μm 
millipore filter and stored at 4°C. 
 
 
3. Dilution buffer: 
 
10g (1%) BSA (Roche, Germany)was dissolved in 1 x PBS (pH 7.4) and made up to 1 liter, The 
solution was sterilised through a 0.45μm millipore filter (Millipore Corporation, Bedford, USA) 
and stored at 4°C. 
 
 
4. Blocking buffer: 
 
1% BSA (Roche, Germany) 
5% Sucrose and  




1 liter. The solution was sterilised through a 0.45μm millipore filter (Millipore Corporation, 
Bedford, USA) and stored at 4°C. 
 
 
5. 10 x Washing buffer: 
 
0.5% Tween 20 in 10x PBS, pH 7.4 
 
 
6. Substrate buffer: 
 
0.2g NaN3, 
97ml Di-ethanolamine (liquefy in 37°C water-bath), and 0.8g MgCl26H2O were dissolved in 
700ml distilled H2O. The pH was adjusted to 9.8 and the volume was made up to 1 liter with 
distilled H2O. The solution was sterilised through a 0.45μm millipore filter (Millipore Corporation, 










Figure A1: Representative of hematoxylin-eosin-stained section of murine brain after 3 weeks post 
saline injection. TNFf/f, NsTNF-/-, M-TNF-/-, MT-TNF-/- and TNF-/- mice were intracerebrally injected with 
3µl of saline at each time point of experimental infection. The results (n= 5 mice/group) represent one of 
three similar experiments. Morphology of 2μm brain sections (magnification= 40x) (A), and meningeal 













Figure A2: Representative of TNF expression in naïve neurons following intracerebal stimulation 
with LPS: Representative FACS plots of Beta III Tubulin/IgG-PE versus TNF-Alexa Fluor 647; numbers 
represent the percentage of gated cells. The data represent one of at least three experiments with similar 
results (n= 5 mice/group). Unstained (top) and naïve (bottom). Naïve = unifected mice. 
 
 
